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1
1. HEmatoPoIESIS anD HEmatoPoIEtIC StEm CELLS 
Hematopoiesis (from Greek: αἷμα/aíma is “blood” and ποιεῖν/poieín means “to make”) is 
defi ned as the production of all types of blood cells, including formation, development 
and diff erentiation of those cells. This process starts prenatally, where it progresses in 
wave-like stages (fi gure 1). The fi rst and second wave take place in the yolk sac (day 16 
and day 19). During the third wave, hematopoietic stem cells (HSC) originate in the dorsal 
aorta (aorta-gonad-mesonephros region, AGM) at approximately 4 weeks of gestation 
[1]. Subsequently, HSC home to the placenta (and are present in the umbilical cord blood 
(UCB) as  well [2]) and the fetal liver, which is the primary source of erythrocytes from 
the 9th week of gestation. From there, HSC further expand and eventually seed the bone 
marrow, which becomes the predominant site of hematopoiesis at the end of the second 
trimester. At birth, HSC can still be detected in the umbilical cord blood. After birth, 
hematopoietic activity in the liver ceases and the bone marrow becomes the only site 
for hematopoiesis [3, 4]. 
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figure 1.  Hematopoietic development and migration during human embryogenesis
A. Migration of hematopoiesis 
B. Hematopoietic development in the human embryo in time. 
Adapted from [5] and [6]
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In adults, all mature blood cells are derived from a small population of HSC that reside 
in the bone marrow. HSC are self-renewing and have the ability to differentiate into pro-
genitors of all different hematopoietic lineages and eventually generate mature blood 
cells, including erythrocytes, platelets, and leukocytes. Within the bone marrow, HSC 
reside in anatomically defined regions, the so-called niche. The bone marrow niche con-
sists of niche cells (e.g. osteoblasts, adipocytes and mesenchymal stromal cells), extracel-
lular matrix and soluble factors such as cytokines, chemokines and signaling molecules 
derived from the extracellular matrix [7]. Fate decisions of HSC, balancing self-renewal, 
proliferation and differentiation, are controlled in the bone marrow niche by signaling 
molecules, such as bone morphogenetic proteins and hematopoietic cytokines, direct 
cell-cell contact of HSC with the niche cells and interaction with the extracellular matrix 
[8, 9]. In addition, other factors like the circadian rhythm and oxygen level regulate HSC 
maintenance by influencing the niche cells and the production of cytokines [10, 11]. It is 
hypothesized that the bone marrow comprises two distinct niches: an endosteal niche 
housing the quiescent HSC with self-renewing capacity and a perivascular niche where 
more actively proliferating HSC reside [12-14]. 
In contrast to more mature blood cells, HSC are morphologically indistinguishable from 
immature hematopoietic progenitor cells. In order to identify HSC flow cytometry, gene 
expression profiling, in vitro functional assays and (re)transplantation into immunodefi-
cient mice have been used. HSC are characterized by the expression of a number of cell 
surface markers which can be used to purify and quantitate HSC. In humans, the marker 
profile that leads to the highest enrichment of HSC is: CD34+, CD38-, CD45RA-, CD90+ and 
CD49f+ [15]. In mice, HSC are highly purified within the LSK (Lin-, c-Kit+, Sca-1+), CD34-, 
CD150+, CD48-, CD41-, flt3- and CD49blo population [16].
Transcription factors are able to modulate expression levels of their target genes and 
are thereby able to influence cell fate decisions. Several genes have been identified that 
appear to be active in HSC, including Scl1, Gata1, Gata2 and Runx1 [17] as well as associ-
ated transcription factors forming the gene regulatory network of HSC [18]. However, the 
ability of HSC to both self-renew and differentiate complicates capturing HSC function 
in one gene regulatory network. It is beyond the scope of this thesis to describe these 
proposed gene regulatory networks in further detail.
Multipotency, a key feature of HSC, can be demonstrated by colony forming unit (CFU) 
assays. Upon culture of human bone marrow in semisolid methylcellulose medium, 
colonies containing granulocytes, erythrocytes, monocytes and megakaryocytes (CFU-
GEMM) are formed, indicating the presence of pluripotent hematopoietic progenitors 
[19]. Another technique identifying cells with HSC features is the long-term culture initi-
ating cell (LTC-IC) assay. This assay, where cells are cultured for 5 to 8 weeks on a suitable 
feeder cell layer followed by replating in methylcellulose to score colonies,  identifies 
primitive hematopoietic cells, based on their capacity to produce progenitors for at least 
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5 weeks [20].  However, the essential property of the ability of HSC to reconstitute long-
term hematopoiesis cannot be measured by these assays. Despite these limitations, in 
vitro assays are still used in order to identify the presence of highly immature hematopoi-
etic cells, which might be an indication of the presence of HSC. 
An in vivo transplantation assay is required to address the essential feature of the HSC: 
being able to reconstitute long-term hematopoiesis. To demonstrate the presence of HSC, 
human cell populations comprising HSC are transplanted into immunodeficient mice, af-
ter which human engraftment can be observed in the murine bone marrow [21, 22]. The 
progeny of HSC contribute to long-term hematopoietic recovery, which can be observed 
after 3 to 4 months upon transplantation. Repopulation before that time point is derived 
from committed progenitors and multipotent short term repopulating HSC present in 
the graft. Additionally, bone marrow from engrafted mice can be retransplanted into 
secondary recipient mice, thereby showing the presence of the true self-renewing long 
term repopulating HSC [23]. Currently, these SCID repopulating cells (SRC) represent the 
cell population that is the closest to HSC. 
2. HEmatoPoIEtIC StEm CELL tranSPLantatIon
2.1 Introduction
Following the observation that irradiation is especially harmful for bone marrow [24], 
research was initiated to explore whether transplanted bone marrow would protect 
individuals from otherwise lethal effects of irradiation, given at a toxic bone marrow 
dose. Injection of homologous bone marrow rescued mice [25], rats [26], hamsters [27] 
and rabbits [28] from lethal irradiation.  The first successful bone marrow transplantation 
in humans was reported in 1957 by Thomas et al., who reported the clinical course of a 
patient with leukemia receiving bone marrow of its identical twin via intravenous infu-
sion upon treatment with chemotherapy and radiation [29]. It took more than 10 years, 
until the first successful true-allogeneic, non-twin transplantations were performed, with 
the donors being siblings of the patients [30, 31].  Currently, allogeneic hematopoietic 
stem cell transplantation (allo-SCT) is the treatment of choice for many patients. In total, 
more than 400,000 allo-SCT have been performed worldwide [32]. Primarily, allo-SCT is 
performed in patients suffering from severe hematological diseases such as leukemia, 
myelodysplastic syndrome, lymphoma and aplastic anemia, but is used for many other 
disorders as well (table 1) [33]. The therapeutic effect depends on both intensive che-
motherapy and irradiation and on eradication of residual leukemia cells of the recipient 
by donor immune cells present in the graft, an immune-mediated effect known as ‘graft 
versus leukemia’ (GVL).
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2.2  Immunological principles of allogeneic hematopoietic stem cell 
transplantation
Two types of allogeneic immune reactivity should be distinguished. First, the so-called 
host versus graft (HVG) reaction, mediated by recipient T cells, which may result in 
rejection of the graft and thereby in graft failure. Rejection is primarily determined by 
differences in highly polymorphic human leukocyte antigens (HLA) between donor and 
recipient [34]. HLA antigens are essentially involved in the afferent and efferent phases 
of a T cell dependent immune response and therefore abundantly expressed on hema-
topoietic cells (both class I and II), but also on every nucleated cell (class I) [35, 36]. Major 
HLA-antigens continuously present foreign and autologous peptides to CD4+ T cells (class 
II) or to CD8+ T cells (class I) in order to direct an immune response towards infectious 
micro-organisms, but not to recipient tissues [37]. In addition to major HLA antigens, mi-
nor antigens have been identified, which refer to peptides derived from human proteins 
and tissues, that may differ between donor and recipient and may also be involved in 
alloreactivity after transplantation [38]. Furthermore, the degree of immune suppression 
given to the recipient also strongly affects the probability of rejection and whether or 
not the donor graft is depleted from T cells [39]. Apart from host versus graft reactions, 
a reverse type of alloreactivity can occur, exerted by donor T cells present in the donor 
graft recognizing recipient tissues (graft versus host), again due to differences in HLA 
major and HLA minor antigens. Clinically, such alloreactivity is termed graft versus host 
disease (GVHD) with acute and chronic variants based upon the time of onset and clinical 
manifestations [40]. Acute GVHD may present itself as a maculopapular rash, persistent 
nausea and/or emesis, abdominal cramps with diarrhea and liver function abnormalities 
consistent with hepatitis [41, 42]. In contrast, patients with chronic GVHD demonstrate 
skin involvement resembling lichen planus or the cutaneous manifestations of sclero-
derma, dry oral mucosa with ulcerations and sclerosis of the gastrointestinal tract and 
liver function abnormalities consistent with chronic hepatitis [43]. Chronic GVHD can be 
table 1. Indications for allo-SCT [33]
malignancies other diseases
Acute myeloid leukemia Aplastic anemia
Acute lymphoblastic leukemia Paroxysmal nocturnal hemoglobinuria
Chronic myeloid leukemia Fanconi’s anemia
Myelodysplastic syndrome Blackfan-Diamond anemia
Non-Hodgkin’s lymphoma Thalassemia major
Hodgkin’s disease Sickle cell anemia
Chronic lymphocytic leukemia Severe combined immunodeficiency
Multiple myeloma Wiskott-Aldrich syndrome
Juvenile chronic myeloid leukemia Inborn errors of metabolism
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preceded by acute GVHD, either direct or after a disease-free interval, or it may occur 
de novo without clinically evident acute GVHD preceding. Although GVHD is a severe 
complication of allo-HSCT, that needs immunosuppressive treatment, the alloreactive 
T cells may also recognize and eradicate the underlying leukemia, an effect known as 
the GVL effect. This GVL effect plays a major role in reducing the risk of relapse following 
allo-HSCT [44]. Both GVHD and GVL are the result of graft cells recognizing recipient cells, 
based on differences in HLA antigens. However, it is still unclear whether the specificity of 
T cells responsible for GVHD differ from that of T cells mediating the GVL effect. There are 
several strategies to prevent GVH alloreactivity, including T cell depletion of the graft and 
the use of immunosuppressive agents such as cyclosporine, tacrolimus, sirolimus, myco-
phenolate and corticosteroids. However, these strategies also suppress GVL effects  and 
may therefore be associated with an enhanced frequency of relapse [45]. Prevention of 
host versus graft alloreactivity is primarily based on matching for HLA-antigens between 
donor and recipient in conjunction with immunosuppressive therapy prior to transplan-
tation, aimed at inhibition of the recipients immune response. In contrast to solid organ 
transplantation, allo-HSCT is generally followed by tolerance for donor hematopoietic 
cells by the recipient, resulting in a durable engrafted and functional hematopoietic 
system [46]. Tolerance results from both central and peripheral mechanisms, including 
central (thymic) deletion of newly developed, donor derived auto-reactive T cells and 
peripheral tolerance by the functional inhibition of auto(recipient)reactive donor T cells 
by regulatory T cells and inhibitory cytokines such as IL-10 [47]. In general, tolerance is 
established by 6 months after transplantation allowing then to stop further immunosup-
pressive therapy, provided that no graft versus host disease is present.
2.3 Conditioning regimens prior to hematopoietic stem cell transplantation
The aim of condition therapy prior to allo-SCT is threefold: reducing the disease burden, 
deterging the bone marrow and thereby making room for the donor cells and suppress-
ing the recipients immune system and thereby allowing engraftment of the HSC [48]. 
However, the latter aim is most probably the most important, as the high rates of engraft-
ment following non-myeloablative conditioning has shown that intensive immunosup-
pressive therapy is sufficient[49]. Several regimens are defined based on their intensity 
and toxicity. Three types of conditioning were defined by Bacigalupo et al. [50], namely, 
myeloablative (MA) conditioning, reduced intensity conditioning (RIC) and nonmyeloab-
lative (NMA) conditioning. MA conditioning is defined as a combination of agents ex-
pected to produce profound pancytopenia and myeloablation within 1 to 3 weeks from 
administration; pancytopenia is long lasting, usually irreversible, and in most instances 
fatal, unless hematopoiesis is restored by hematopoietic stem cell infusion. MA regimens 
that are frequently applied include total body irradiation (TBI, 10-12 Gy) in combination 
with cyclophosphamide and the combination of busulfan and cyclophosphamide. NMA 
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regimens are those that will cause minimal cytopenia, do not require stem cell support, 
and mainly consist of immunosuppressive agents. A well-known example of the latter 
is the fludarabine plus TBI (2 Gy) schedule, as was developed by Storb et al. in Seattle 
[51], which results in engraftment and appears to be associated with a low rate of early 
mortality.  RIC regimens are an intermediate category of regimens that fit neither the 
MA nor NMA definition. RIC regimens cause cytopenia, which may be prolonged and 
may require stem cell support, but it is possible that autologous recovery would occur 
eventually. An array of RIC regimen were developed the last decades, including disease 
specific regimens and more generally applicable regimens, but randomized comparative 
studies are lacking, leaving the question which regimen is to be preferred unanswered. 
2.4  Hematologic and immunologic reconstitution following hematopoietic 
stem cell transplantation
Hematopoietic recovery following allo-SCT depends on many variables, but the quality 
of the donor graft in terms of stem cell numbers and whether the graft was manipu-
lated prior to transplantation are the main denominators of hematopoietic recovery. In 
general, following allo-SCT from an HLA-identical sibling donor, neutrophil recovery and 
platelet recovery usually take, respectively, approximately 14 and 25 days [52]. Alterna-
tive donor stem cell grafts usually are associated with a more protracted recovery, which 
is most pronounced following umbilical cord blood stem cell transplantation (UCBT), 
which may take 3 to 4 weeks for neutrophil recovery and up to 3 months for platelet 
recovery, which is due to the low  number of stem cells and the multiple HLA-mismatches 
between donor and recipient [53, 54]. Lymphoid recovery may take much longer than 
myeloid recovery, which is mainly due to insufficient thymopoiesis after allo-SCT in adult 
patients. While NK cells may rapidly recover, B cells usually take up to several months and 
T cell recovery may even be extended up to 12 months [55]. Full immune reconstitution 
requires the restoration of both non-hematopoietic and hematopoietic components. The 
non-hematopoietic components of the immune system (the skin and mucosa surfaces) 
are part of the innate (natural) immunity, which is present from birth and which is not 
adapted or developed during infections such as the adaptive part of the immune system, 
including B cells and T cells. Especially, CD4+ T cell counts may be insufficient beyond 
one year post-transplantation, indicating the slow and retarded recovery of adaptive 
immune function [56]. For T cell recovery, both peripheral expansion of transplanted T 
cells and formation of newly developed T cell in the thymus (thymopoiesis) are pivotal. 
Impaired recovery of thymopoiesis is a major risk factor for retarded T cell recovery and 
subsequent susceptibility for opportunistic infections and treatment related mortality 
[57]. Thymopoiesis can be monitored by measuring the frequency of signal joint T cell 
receptor rearrangement excision circles (sjTRECs). SjTREC positive CD3+ cells are T cells 
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newly formed by thymopoiesis. Measuring sjTREC positive T cells is however not routinely 
applied in clinical care. 
Many variables may affect the timing of reconstitution, including the occurrence of 
GVHD, conditioning regimen, type of donor, source of hematopoietic progenitor cells, 
number of HLA-mismatches and immune suppressive therapy applied post-transplan-
tation[55]. Several therapeutic strategies have been proposed to enhance immune 
reconstitution following allo-SCT, however, most of these strategies have only been 
tested in preclinical settings [58, 59]. One of these approaches is the administration of 
the cytokine interleukine-7 (Il-7). In animal models and in humans, administration of 
Il-7 resulted in strong expansion of newly developed naïve T cells [60, 61]. In a phase 
I trial, administration of recombinant Il-7 enhanced T cell recovery, without increasing 
the incidence of GVHD [62]. Other approaches include adoptive T cell therapy by using 
either unselected donor lymphoid cells or donor T cells selected on the basis of antigen 
specificity, such as anti-cytomegalovirus (CMV) specificity [63, 64].  
2.5 Donors and stem cell sources
Outcome after allo-SCT depends on many variables, including type and stage of underly-
ing disease, patient co-morbidities, timing of the transplant and choice of donor. The 
potential benefit of allo-SCT and potential risks of  the procedure are usually taken into 
account in the decision making whether or not allo-SCT is the preferred treatment in 
a particular patient or whether chemotherapy or autologous transplantation is to be 
preferred [65]. As mentioned earlier, matching of HLA-haplotypes between donor and 
patient is a key part of successful allo-SCT [66, 67]. An HLA-matched sibling of the patient 
is the preferred donor of choice, but 75% of the patients lack such a matched sibling 
donor. As a second option, HLA-matched unrelated donors can be identified using a 
worldwide donor database containing more than 20 million HLA-typed volunteers. 
For up to 50-60% of  Caucasian patients a suitable matched unrelated donor may be 
identified, but for patients without such a donor, alternative donors can be considered, 
including haplo-identical donors and umbilical cord blood [68]. 
3. UmBILICaL CorD BLooD StEm CELL tranSPLantatIon
3.1 Umbilical cord blood as a source for hematopoietic stem cells
During fetal development, Hematopoiesis takes place in the yolk sac, the fetal liver and 
finally, in the bone marrow upon settling of HSCin their bone marrow niches. Hemato-
poietic stem and progenitor cells (HSPC) can be found in fetal blood [69] and especially 
in umbilical cord blood (UCB) around birth [2]. These UCB-derived HSPCappeared to be 
an alternative source of HSPC for allo-SCT [70], In 1988, the first transplantation with 
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HSPC from UCB was performed in a patient with Fanconi’s anemia using the cord blood 
from his HLA-identical sibling [71]. The patient obtained full engraftment of the donor 
cells and has maintained hematological remission for more than 20 years. In this first 
patient, there were no signs of GVHD. Subsequent studies, using unrelated mismatched 
cord blood, showed encouraging results, with similar survival to HLA-identical sibling 
cord blood transplantation and less acute and chronic GVHD [72-74]. The Netcord group, 
an international cord blood bank network, was established in 1998 [75] and more than 
700,000 cord blood units are currently stored in quality controlled public cord blood 
banks worldwide [76]. Currently, the number and broad availability of cord blood grafts 
as well as the organization of cord blood banks have resulted in a relative rapid and easy 
procedure of search and acquisition of cord blood grafts, which may even be faster than 
the search and acquisition for adult bone marrow and blood grafts [74]. In addition, less 
stringent HLA-matching was required compared to other donor sources [77], implying 
cord blood a suitable source of stem cells for many patients lacking a HLA-matched 
sibling or unrelated donor. By 2015, approximately 35,000 UCB  transplantations (UCBT) 
have been performed [76].
Initial studies assessing cord blood transplantations in small groups of pediatric 
patients suffering from hematological malignancies, showed that the procedure was 
feasible and a potential therapeutic option [78]. These positive results were confirmed in 
several prospective multicenter studies, showing similar survival rates after cord blood 
transplantation compared to other donor sources used [79, 80]. In addition, GVHD rates 
were generally lower [79, 80]. These promising survival results, combined with a reduced 
risk of GVHD and the less stringent matching criteria made cord blood transplantation 
an attractive treatment modality for pediatric patients with hematological malignancies 
lacking a sibling or matched unrelated donor. These results in pediatric patients set the 
stage for a large study of cord blood transplantation in adults with hematologic malig-
nancies receiving MA conditioning, showing cord blood transplantation is feasible and 
safe in adults as well [81]. When compared to matched unrelated stem cell transplanta-
tion after MA conditioning in patients with acute leukemia, cord blood transplantation 
displayed similar leukemia-free survival, chronic GVHD rates, transplant-related mortal-
ity and relapse rate[82]. Furthermore, acute GVHD rates were lower upon cord blood 
transplantation, but neutrophil recovery was delayed. Subsequently, several other 
studies showed similar rates of treatment-related mortality, treatment failure, overall 
mortality and leukemia-free survival for cord blood transplants (1 or 2 HLA-mismatches), 
mismatched related and unrelated donors [52, 83]. 
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3.2  Umbilical cord blood stem cell transplantation: challenges and 
recommendations
Prolonged hematopoietic recovery and a higher incidence of graft failure were observed 
after cord blood transplantation, which appeared to be associated with the number 
of HSPC present in the graft and the degree of HLA mismatch] [54, 84, 85]. As a result, 
a higher risk for non-relapse mortality became apparent [79]. To avoid his, guidelines 
advocate the use of UCB grafts with at least 3.0 x 107/kg nucleated cells (NC) for single 
unit transplantations [79], and even higher cell numbers in the case of HLA-mismatches. 
However, these thresholds, combined with the criteria for HLA matching, severely limit 
the number of grafts suitable for transplantation. To improve the outcome of UCBT,  the 
field has come up with various alternative strategies.  We will discuss the most promising 
strategies, some of which are currently used in clinical practice. 
4. DoUBLE UmBILICaL CorD BLooD StEm CELL tranSPLantatIonS
4.1  rationale and history of double umbilical cord blood stem cell 
transplantation
Co-infusing two cord blood units, the so-called double UCBT (dUCBT), was used as a 
strategy to increase the cell dose in order to improve engraftment and recovery, while 
using the same criteria for HLA histocompatibility. The first dUCBTs were performed in 
1999 in two adult patients suffering from acute lymphoid and chronic myeloid leukemia, 
respectively. Donor engraftment was observed in both patients, who however both died 
three months post-transplant (due to relapse and hemorrhage, respectively) [86].  Barker 
et al. reported the first case of dual donor chimerism after dUCBT using two partially HLA-
matched unrelated umbilical cord blood grafts [87]. In the years thereafter, it was shown 
that dUCBT was safe and feasible after both MA [88] and RIC regimens [89]. Following 
these studies, Eurocord advised to perform dUCBT if cell dose criteria could not be met 
using a single cord blood unit and since 2005, according to Eurocord reports, the number 
of dUCBT performed in adult patients has surpassed the number of single UCBT [86].
4.2  Graft predominance after double umbilical cord blood stem cell 
transplantation
In the majority of patients receiving a dUCBT, initial combined engraftment of both units 
is rapidly followed by single-unit-dominance in favor of one of the two grafts [88-91]. 
By day 21 post-transplantation, single-unit-dominance can be detected in more than 
80% of the patients [92-94]. Although the exact mechanisms determining predominance 
are still largely unknown, an important hypothesis is that predominance is based on 
an immune interaction between the cord blood units [95, 96]. According to a study in 
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mice, mixed chimerism was established upon infusing of two CD34+-selected units, 
whereas addition of the corresponding CD34- cells restored single-unit-dominance [96]. 
Furthermore, some studies showed that CD3+ cell dose might be a predictor for cord 
blood predominance following both MA and RIC dUCBT [53, 95]. Early T cell chimerism 
of the predominating unit (day 7 and day 11 post-transplantation, respectively) predicts 
the long-term engrafting unit [93, 97] and in addition, administration of anti-thymocyte 
globulin  shortly before infusion of the grafts, resulted in a higher incidence of mixed 
double chimerism [98], suggesting  that an immunological mechanism involving T cells 
accounts for single-unit-dominance. Detailed engraftment kinetics studies showed that 
CD4+ lymphocytes expand early after SCT, suggesting that CD4+ T cells may play a pivotal 
role in the underlying graft-versus-graft response [93]. In addition, CD4+ T cells of the pre-
dominating graft reactive against a non-matched HLA-class II antigen expressed by the 
disappearing unit were detectable in blood of most patients after dUCBT [99], suggest-
ing a pivotal role for alloreactive CD4+ T cells in immediate rejection. However, prediction 
of the winning unit prior to transplantation is still not feasible. Another factor may be the 
CD34+ cell viability, which presumably reflects the quality of the overall graft, with grafts 
with a CD34+ viability exceeding 75% showing a higher rate of engraftment compared to 
grafts with a lower CD34+ viability [53, 100]. In addition, the number of ALDH-bright cells, 
as a reflection of viable progenitor cells, might influence donor chimerism, engraftment 
and recovery [101]. Order of UCB infusion or level of HLA matching with the patient did 
not appear to influence engraftment kinetics [95]. 
4.3  Clinical outcome following double umbilical cord blood stem cell 
transplantation
Sustained engraftment is usually observed in 85% to 100% of patients after dUCBT, both 
after MA and NMA conditioning [88, 91, 102, 103]. Median time to neutrophil recovery 
upon dUCBT varies from 12 days [91] to 36 days [94], depending on the conditioning regi-
men used and administration of granulocyte colony-stimulating factor (G-CSF) following 
transplantation. Conflicting results are reported on relapse and progression after dUCBT 
compared to other graft sources. Several studies report a lower incidence of relapse or 
progression upon dUCBT compared to single UCBT [104] and transplantation with grafts 
obtained from either matched-related or –unrelated donors [105]. Strikingly, there was 
no association with an increased risk of severe GVHD. However, others have reported 
no advantage in progression-free-survival following dUCBT [106-108]. It is important to 
emphasize that transplantation outcome is affected by many variables, including donor 
source, conditioning regimen used, characteristics of the underlying disease, post-
transplant treatment and overall patient health. Therefore, conflicting results might be 
due to different treatment protocols and selected patient populations. In current clinical 
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practice, dUCBT is considered an appropriate alternative for patients lacking a single 
adequately dosed cord blood unit. 
5. In vItro ExPanSIon of UCB-DErIVED HEmatoPoIEtIC StEm CELLS 
Because UCB grafts contain a relatively low number of HSPC and the dose of HSPC infused 
is related to patient survival and time required for engraftment [84, 105], it was hypoth-
esized that expansion of HSPC in vitro prior to transplantation may result in improved 
engraftment and recovery compared to transplantation with non-expanded cord blood 
HSPC. Robust expansion of long-term repopulating HSC ex vivo, however, remains a chal-
lenge. Culturing HSPC with different combinations of hematopoietic cytokines such as 
stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), thrombopoietin (TPO) 
and granulocyte-macrophage colony-stimulating factor (GM –CSF) resulted in massive 
expansion of committed HPC which is accompanied by a loss or at best maintenance of 
primitive HSC with long-term repopulation ability [109-112]. In addition to these prolif-
eration- and differentiation-inducing cytokines, ex vivo expansion of HSC may require 
additional signals that inhibit differentiation of HSC during culture. Expansion of HSC 
requires symmetric self-renewal cell divisions in which both daughter cells retain all HSC 
characteristics (figure 2). Asymmetric cell divisions in which one daughter cell is still a 
HSC and the other daughter cell is a more differentiated progenitor cell leads to main-
tenance of HSC number in culture, whereas symmetric differentiation cell divisions in 
which both daughter cells lost HSC characteristics results in a loss of HSC during culture. 
Decades of research has resulted in the identification of many developmental regulators 
and chemical modulators that have been implicated  to be involved in the regulation of 
self-renewal, proliferation, differentiation and survival of HSC and that may increase the 
frequency of HSC symmetrical self-renewal cell divisions in culture [113]. Several of these 
factors have been evaluated for their potential to expand HSC in culture. Ex vivo HSC 
expansion protocols using some of these factors are currently evaluated in clinical trials. 
Several of these early phase clinical trials have reported promising results [7]. However, 
the search for the most optimal expansion protocol continues.
5.1 nicotinamide
Nicotinamide (NAM) is a form of vitamin-B3, which inhibits several classes of ribosylase 
enzymes and sirtuin1 (SIRT1), a class III NAD+-dependent-histone-deacetylase, and is 
implicated to play an role in the regulation of cell adhesion, polarity, migration, prolifera-
tion and differentiation [114]. In addition, NAM modulates the fate of embryonic stem 
cells [115]. In primary growth factor-driven expansion cultures with UCB-derived CD34+ 
cells, addition of NAM resulted in a higher number of immature CD34+CD38- cells, a 
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lower number of diff erentiated cells and delayed cell cycling of CD34+ cells. Furthermore, 
both in vitro and in vivo studies showed enhanced migration, homing and engraftment 
of the NAM-expanded CD34+ cells compared to CD34+ cells expanded in control condi-
tion (culture medium supplemented with fetal bovine serum (FBS), SCF, Flt3L, TPO and 
interleukin-6 (IL-6) [116]. In a phase I study, 11 patients received a NAM-expanded graft 
(consisting of both the expanded CD133+ fraction and the non-expanded CD133- frac-
tion) in a dUCBT setting, together with an unmanipulated graft. No adverse events were 
reported that were attributable to the infusion of the expanded product. In 8/11 patients, 
the expanded graft engrafted as the dominant graft, with stable engraftment upon 
a median follow-up of 21 months. In addition, patients engrafted with the expanded 
graft achieved a median neutrophil recovery of 13 days versus 25 days in the patients 
engrafted with the unmanipulated graft [117]. Currently, a phase I/II study investigating 
engraftment and recovery after transplantation with a single NAM-expanded graft is 
ongoing (ClinicalTrials.gov Identifi er: NCT01816230).
5.2 Copper chelator tetraethylenepentamine 
Copper has been implicated to be involved in the modulation of self-renewal and dif-
ferentiation of HSPC. Defi ciency of copper in patients mimics refractory anemia, which 
is manifested by an excess of immature cells and a reduction of diff erentiated cells in 
Symmetric self-renewal Asymmetric self-renewal Symmetric differentiation
figure 2. Symmetric and asymmetric cell division of a hematopoietic stem cells. Purple cells are HSC; green 
cells lost HSC characteristics.
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the bone marrow [118]. In vitro, copper defi ciency results in delayed diff erentiation and 
prolonged proliferation of HSPC, while increased cellular copper levels result in acceler-
ated diff erentiation [119]. It appeared that reduction of the cellular chelatable copper 
content, rather than the overall copper content, resulted in the observed eff ects of cop-
per defi ciency [120].  Copper chelator tetraethylenepentamine (TEPA) can be used to 
modulate the level of cellular chelatable copper. Addition of TEPA to expansion cultures 
(containing FBS, SCF, Flt3L, TPO and IL-6) results in robust expansion of HSPC. These 
HSPC show both high levels of engraftment and multi-lineage diff erentiation potential 
upon transplantation in NOD/SCID mice [121]. In a phase I/II study, co-transplantation of 
TEPA-expanded CD133+ CB-derived HSPC and unmanipulated HSPC from the same graft 
appeared to be safe and feasible [122]. Nine out of 10 patients engrafted with a median 
time to neutrophil and platelet recovery of 30 and 48 days respectively which is similar 
compared to recipients of unmanipulated single UCB grafts. 
5.3 notch ligands
Notch and its ligands (Jagged-1, Jagged-2, Delta-1) are expressed in the bone marrow 
micro-environment and by HSC, which may suggest that Notch is an important regulator 
in hematopoiesis [123]. The immobilized form of Delta-1 has been shown to promote 
expansion of murine and human HSPC in culture and to increase the number of SRC 
with secondary transplantation ability. The eff ects of Notch ligand appeared to be dose-
dependent and HSPC expansion was only observed using lower Delta-1 concentrations 
[124, 125]. In a clinical phase I study, upon co-transplantation of a Notch ligand-expanded 
graft and an unmanipulated graft, patients engrafted with an accelerated time to neutro-
phil recovery of 16 days. In the fi rst week after transplantation, hematopoietic recovery 
was mainly derived from the expanded graft, but upon day 80 all hematopoietic cells in 
blood and marrow were derived from the unmanipulated graft [126]. These data suggest 
that either long term HSC were lost during expansion or that the expanded graft, lacking 
T cells, was rejected by the unmanipulated graft. 
5.4 Wingless-related integration site proteins
Wingless-related integration site (Wnt) signaling has been implicated to play a role in the 
regulation HSPC fate decisions in vivo and might promote HSPC self-renewal by inhibit-
ing diff erentiation. However, the eff ects of Wnt on the ex vivo expansion of HSPC remain 
controversial. In primary cultures of  Bcl2-mouse Lin-Sca-c-Kit+ cells (LSK cells, enriched 
for HSPC in mice) supplemented with cytokines and serum, Willert et al. and Reya et al. 
showed induction of proliferation and inhibition of diff erentiation upon the addition 
of purifi ed Wnt3a [127, 128]. However, other studies observed a decrease in mouse LSK 
cells upon addition of Wnt3a to the culture medium [129], which is also described in this 
thesis. In addition, we describe the eff ect of the addition of Wnt3a to expansion cultures 
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with human UCB-derived HSPC. To date, no clinical trials with Wnt protein expanded 
HSPC have been initiated. 
5.5 aryl hydrocarbon receptor antagonist Stemregenin1 
The Aryl hydrocarbon Receptor (AhR) pathway is involved in HSC self-renewal and inhibi-
tion of differentiation. AhR-KO mice have an increased number of hyperproliferative LSK 
cells [130], while treatment of donor mice with AhR agonist TCDD results in impaired 
competitive engraftment [131]. Using high throughput screening of a library of small 
molecules,  purine derivative StemRegenin1 (SR1), an AhR antagonist, was identified  pro-
moting the ex vivo expansion of CD34+ cells [132].  Addition of SR1 to expansion cultures 
supplemented with SCF, Flt3L, TPO and IL-6 resulted in a 50-fold increase in the number 
of CD34+ cells and a 17-fold increase in SRC, the cells that are capable of hematopoi-
etic reconstitution in sublethally irradiated mice [132]. Transplantation of SR1-expanded 
CD34+ cells in a double cord blood setting appeared safe and feasible and resulted in 
engraftment in all 17 transplanted patients. The median time to neutrophil and platelet 
recovery was 15 and 49 days, respectively, which was faster compared to an historical 
control group receiving unmanipulated dUCBT. In 11/17 patients, hematopoiesis was 
primarily derived from the expanded unit and in those patients, neutrophil recovery was 
even more rapid with a median of 11 days versus 23 days in the 6/17 patients engrafting 
with the unmanipulated unit [133]. These results set the stage for clinical studies in a 
single UCBT setting (ClinicalTrials.gov Identifier: NCT01930162). 
5.6 Um729 and Um171
In a recent study, a library-screen of more than 5000 low-molecular-weight compounds 
identified UM729 as an AhR-independent compound capable of expansion of human 
CD34+CD45RA- cells [134]. Further characterization and optimization resulted in the 
synthesis of the analog UM171, which appeared to be 10 to 20 times more potent 
than UM729. When compared to SR1, UM171 resulted in similar CD34+ and higher 
CD34+CD45RA-  cell frequencies and absolute numbers after 12 days of in vitro culture 
in the presence of SCF, Flt3L and TPO. Transplantation of UM171-expanded cells into 
NSG mice resulted in higher levels of human chimerism compared to transplantation of 
SR1-expanded cells. In addition, transplantation of the input equivalent of only 50-100 
UM171-expanded cells resulted in long-term multilineage engraftment, which was not 
the case upon transplantation of the same amount of SR1-expanded cells. These data 
indicate that UM171 enables robust ex vivo expansion of human CB cells with long-term 
in vivo repopulating capacity. Currently, a phase I/II trial exploring the safety and feasibil-
ity of transplantation of UM171-expanded CD34+ cells in a single graft setting is ongoing 
(ClinicalTrials.gov Identifier: NCT02668315). 
General introduction and outline of the thesis 23
1
5.7 Co-culture with mesenchymal stem cells
Most expansion protocols use selected CD34+ or CD133+ HSPC and subsequent culture 
with the addition of exogenous growth factors and differentiation-inhibiting factors. An-
other approach is to co-culture cord blood cells with cells that are present in the micro-
environment of HSC in bone marrow, such as mesenchymal stem cells (MSC). Mimicking 
the in vivo ‘niche’ of the HSC is thought to provide the complex molecular signals that are 
important for HSC self-renewal, proliferation and differentiation. Co-culturing CB cells 
for 14 days on primary MSC cells in the presence of FBS, SCF, TPO and G-CSF resulted in a 
significant increase of CD34+ cells and CFU [135]. Transplantation of MSC-expanded cells 
in a dUCBT setting together with a unmanipulated graft appeared to be safe and feasible 
[136]. Compared to historical controls that had received an unmanipulated dUCBT, the 
cumulative incidence of neutrophil engraftment at day 26 and platelet engraftment at 
day 60 was significantly increased. Although about half of the patients had hematopoi-
esis derived from both units in the first month after transplantation, long-term engraft-
ment was produced primarily by the unit of the unmanipulated cord blood in all patients, 
suggesting either loss of self-renewing HSC in the expanded graft or rejection of the 
manipulated graft by T cells present in the unmanipulated graft. 
The quest to the most optimal expansion protocol is still ongoing. An optimized pro-
tocol might involve a combination of several factors that act synergistically in order to 
induce cell proliferation while maintaining self-renewal capacities and inhibit differentia-
tion [137]. 
6. aImS anD oUtLInE of tHE tHESIS
UCB has emerged as an important donor source in patients lacking a suitable sibling 
or matched unrelated donor. However, the lower number of HSPC in UCB and their 
relative primitivity combined with a higher degree of HLA-mismatches results in 
prolonged hematopoietic recovery and retracted immune reconstitution upon UCBT, 
which may predispose for infections and non-relapse mortality. To improve outcome 
following UCBT, various strategies have been developed including ex vivo expansion of 
UCB-derived HSPC. In the last decade, several factors have been reported to affect HSC 
fate decisions promoting self-renewal and inhibiting differentiation.  The general aim 
of this thesis was to improve and optimize the ex vivo expansion and subsequent in 
vivo engraftment of HSPC. It was hypothesized that the combination of growth factors 
stimulating proliferation with promising factors that reportedly inhibit differentiation 
and enhance self-renewal of HSC (figure 3) would result in robust ex vivo HSC expansion. 
The thesis starts with a study of recovery of thymopoiesis, immune reconstitution, 
the incidence of infections and clinical outcome in our own population of patients with 
24 Chapter 1
high-risk hematological malignancies who underwent dUCBT preceded by a RIC regimen 
without in vivo T cell depletion as described in chapter 2. Furthermore, as it is known 
that retracted thymopoiesis predicts for severe infections in patients receiving allo-SCT 
from a sibling or matched unrelated donor following MA condition, we evaluated the 
impact of recovery of thymopoiesis on clinical outcome in this dUCBT cohort. 
In chapter 3 we investigated the effect of Wnt3a on the proliferation and differentiation 
of mouse LSK cells in combination with early acting cytokines in stroma-free, serum-free 
cultures, as the Wnt signaling pathway has been implicated to play a role in the regula-
tion of mouse HSC fate decisions between self-renewal and differentiation. Exogenous 
Wnt3a was found to decrease the number of LSK cells in expansion cultures. This was 
due to binding of Wnt3a to its receptor and subsequent activation of the canonical Wnt 
pathway and not due to an increase in apoptosis of LSK cells. 
Next, we set out to evaluate the effects of exogenous Wnt3a in combination with 
hematopoietic growth factors on the ex vivo expansion of UCB-derived HSPC. The 
results of these studies are described in chapter 4. It was shown that exogenous 
Wnt3a protein suppresses rather than promotes the expansion of UCB-derived CD34+ 
cells in serum free expansion cultures. In addition, we analyzed the effect of Wnt3a on 
Lin-CD34+CD38lowCD45RA-CD90+ cells which are highly enriched in HSC, and we observed 
the same effect. These data where further confirmed by in vivo transplantation assays in 
immunodeficient (NSG) mice. 
In chapter 5 we investigate the effects of the combination of hematopoietic growth 
factors and AhR antagonist SR1 on the ex vivo expansion of UCB-derived HSPC. We 
confirm that SR1 enables robust ex vivo expansion of UCB-derived HSPC retaining 
multilineage and long-term repopulation potential in NSG mice. Unexpectedly, we 
found human chimerism levels after transplantation of expanded cells to be lower than 
after transplantation of non-expanded cells which might be due to a combination of a 
Promotion of self-renewal Inhibition of differentiation
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B cell-prone NSG mouse model and a reduced number of lymphoid progenitors in the 
expanded cell population. 
To non-invasively monitor and quantify homing of transplanted HSPC in the bone mar-
row, we developed a 19F-labeling protocol for HSPC as described in chapter 6. Our results 
show sufficient intracellular labeling of UCB-derived CD34+ cells using 19F-containing 
Poly(Lactic-co-Glycolic Acid) (PLGA) nanoparticles. These labeled cells were detectable 
with both flow cytometry and magnetic resonance spectroscopy (MRS), while maintain-
ing their ability to proliferate and differentiate. 
In chapter 7, the development of a Good Manufacturing Practice (GMP)-compliant 
expansion protocol for clinical application, based on the results presented in chapter 
5, is described. In addition, the protocol for a clinical study addressing the safety and 
feasibility of the transplantation of SR1-expanded HSPC in a single UCB unit setting is 
presented.
Finally, in chapter 8, the results, implications and future perspectives of the experi-
mental chapters are discussed in a broader perspective.
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aBStraCt
Background
Double umbilical cord blood transplantation is an important treatment option in patients 
in need of an allogeneic hematopoietic stem cell transplantation but lacking a matched 
related or unrelated adult donor. Hematopoietic recovery and immune reconstitution, 
in particular recovery of thymopoiesis, however, are retarded, which may predispose for 
infections and non-relapse mortality. Earlier, we reported that retarded thymic recovery 
strongly predicts for subsequent opportunistic infections in recipients of matched re-
lated and unrelated transplants. Here, we set out to assess whether impaired recovery of 
thymopoiesis also predicts for opportunistic infections in recipients of double umbilical 
cord blood transplantation and whether it is associated with infection-related mortality, 
non-relapse mortality, relapse-free survival and overall survival. 
Patients and methods
Fifty-five patients with high-risk hematological malignancies receiving a double um-
bilical cord blood transplantation preceded by a reduced intensity conditioning regimen 
without in vivo T cell depletion were included. Recovery of B cells, NK cells, and T cells 
(including CD4+ and CD8+ subsets) was assessed at baseline and at 1, 2, 3, 6, 12 and 24 
months post-transplantation by flow cytometry. In addition, recovery of thymopoiesis 
was assessed using signal joint T cell receptor rearrangement excision circle (sjTREC) 
analysis. The impact of recovery of lymphocyte subsets and thymopoiesis at 3 months 
post-transplantation on the incidence of subsequent infections, infection-related mor-
tality, non-relapse mortality, relapse-free survival and overall survival was assessed by 
Cox regression analysis.
results 
T cell recovery was severely protracted in the majority of patients: the lower reference 
limit of absolute cell counts of CD4+ and CD8+ cells was not reached 24 months post-
transplant in 64% and 73% of patients, respectively. SjTREC+ T cells were undetectable in 
38% and 27% of patients at 3 and 12 months post-transplantation, respectively. A total 
of 128 CTC grade 3-4 infections were observed in the first year post-transplantation, 
of which most infections occurred in the first 30 days post-transplant. The cumulative 
incidence of grade 2-4 and grade 3-4 infections was 89% and 83% at 6 months post-
transplant and 95% and 87% at 12 months post-transplant, respectively. Non-relapse 
mortality at 12 months post-transplant was 16%, of which 78% infection-related mortal-
ity. One-year overall survival was 73%. Patients who failed to recover thymopoiesis at 3 
months post-transplant were at a 3.3-fold higher risk of subsequent severe grade 3-4 
infections. (HR 3.25, 95% CI 1.26-8.43, p=0.015). 
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overall conclusion
Immune reconstitution, and especially T cell recovery and thymopoiesis, is impaired after 
double umbilical cord blood transplantation. Patients who fail to recover thymopoiesis at 
3 months post-transplantation are at high risk for subsequent severe infections. 
IntroDUCtIon
Umbilical cord blood (UCB) is an important alternative hematopoietic stem cell (HSC) 
source for patients needing an allogeneic stem cell transplantation (allo-SCT) who lack a 
suitable matched related or unrelated donor (1). However, UCB transplantation (UCBT) is 
associated with retarded hematopoietic recovery and immune reconstitution, resulting 
in higher rates of infection compared to conventional HSC sources (2-4). Especially, the 
relatively low number of progenitor cells present in the graft is associated with a higher 
rate of graft failure and retarded recovery (5-7). Alternatively, two UCB grafts (double, 
dUCBT) instead of one were applied to increase the total nucleated cell (TNC) and 
progenitor cell dose (8-10). That approach appeared associated with less graft failure, 
however hematopoietic recovery is still slow and results most time from one predomi-
nating unit (8, 11). 
Immune reconstitution upon allo-SCT is a complex process that consists of both the 
innate and the adaptive immune system. Recovery of innate immunity, characterized by 
restoration of mucosal barriers, neutrophil recovery and natural killer (NK) cell recovery 
occurs within the first weeks post- transplant (12). T cell reconstitution, which is part of 
the adaptive immune system, can take years to fully recover (13, 14). T cell recovery after 
allo-SCT occurs via two independent routes. Initially, lymphopenia-induced homeostatic 
proliferation of mature T cells (either present in the graft or residual host T cells) results 
in the expansion of a T cell population with a limited T cell receptor (TCR) repertoire (4). 
Long-term effective immune reconstitution with a broad T cell repertoire depends on 
thymic production of new naïve T cells (thymopoiesis) (15). The presence of these newly 
formed naïve T cells can be detected by the measurement of signal joint T-cell receptor 
rearrangement excision DNA circles (sjTREC), that are formed during TCR rearrangement. 
Previously, we showed that retarded thymopoiesis strongly predicts for opportunistic 
infections in recipients of matched related and unrelated transplants (16). Several stud-
ies showed higher rates of infectious morbidity and mortality upon single unit UCBT as 
compared to related or unrelated donor allo-SCT, which appeared to be due to delayed 
functional T cell recovery (17-19). Delayed immune recovery and a high incidence of in-
fectious complications were observed in patients with high-risk haematological diseases 
after dUCBT preceded by either myeloablative (MA) or reduced intensity conditioning 
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(RIC) (20). However, it is still unclear to what extend impaired T cell recovery and thymo-
poiesis predicts for subsequent severe infections in dUCBT patients.
In the current study, hematopoietic recovery and immune recovery, including recovery 
of thymopoiesis, were evaluated in 55 poor-risk hematological patients receiving dUCBT 
upon conditioning using a RIC regimen, without T cell depletion. Additionally, it was ex-
plored whether impaired recovery of thymopoiesis predicted for subsequent infections 
or was associated with infection-related mortality (IRM), non-relapse mortality (NRM), 
relapse-free survival (RFS) and overall survival (OS). 
mEtHoDS
Patients and cord blood units
Patients receiving a dUCBT in the Erasmus MC Cancer Institute between September 2007 
and December 2013 were included in this study. Patients were eligible for inclusion if 
they met the following criteria: (i) a diagnosis of a high-risk hematologic malignancy 
(as defined in (21)) in need for an allogeneic stem cell transplantation but lacking a 
matched related or unrelated donor and therefore eligible for dUCBT; (ii) receiving a RIC 
regimen without in vivo T cell depletion and (iii) presence of a peripheral blood sample 
to determine immune reconstitution and thymopoiesis available at 3 months post-
transplantation. The institutional review board approved the protocols and all patients 
provided written informed consent. All patients were treated according to the HOVON 
106 (11) and 115 study protocols (EudraCTnr.: 2008-000053-35 and 2012-001188-55 / 
Netherlands Trial Registry: NTR1573 and NTR3535).
Cord blood unit (CBU) selection was based on TNC dose and human leukocyte antigen 
(HLA) match. The minimum TNC dose required was set at 1.5 x 107/kg recipient body 
weight for each individual CBU and at 4.0 x 107/kg for both CBUs combined. HLA match-
ing of CBUs and recipient was performed for HLA-A and -B antigens at the serological split 
resolution level and for HLA-DRB1 at the 4-digit resolution level. A minimal match grade 
of 4/6 between both individual CBUs and recipient and between CBUs was required. 
Conditioning regimen, supportive care and transplantation procedures
Conditioning, supportive care and graft-versus-host disease (GVHD) prophylaxis were 
as previously described (11). In short, all patients received a RIC regimen, consisting of 
cyclophosphamide at day -7 (60 mg/kg), fludarabine at days -6, -5, -4 and -3 (total dose of 
160 mg/m2) and total-body irradiation (TBI) at days -2 and -1 (total dose 4 Gy). CBU were 
routinely infused on two consecutive days (day 0 and day +1). No hematopoietic growth 
factors were prescribed post-transplant per institution policy. GVHD prophylaxis consist-
ed of cyclosporine A and mycophenolate mofetil. Patients received infection prophylaxis 
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by ciprofloxacin and fluconazole at least until neutrophil counts measured ≥ 0.2 x 109/L 
on two consecutive days. In addition, patients received valaciclovir for prevention of 
herpes infections starting at day 0. Cotrimoxazol for prevention of pneumocystis jirovecii 
was started after neutrophil recovery for at least one year following transplantation.
Infections
All infections diagnosed following transplantation between day +1 and day +365 
post-transplant were evaluated and scored by grade, localization and causative micro-
organism according to the NCI common toxicity criteria (CTC) version 3.0, as described 
before (16, 22, 23). CTC grade 3-4 infections were defined as severe (CTC grade 3) or 
life-threatening (CTC grade 4) with the need for admission and intravenous treatment. 
An infection was defined and scored as recurrent if an asymptomatic period of at least 4 
weeks was documented between two infectious episodes. Patients were excluded from 
evaluation of infections when cytogenetic or morphological relapse was diagnosed, 
starting at the day the relapse was diagnosed. Death was considered associated with 
infection if findings consistent with an infection were present at the time of death or 
if the pathogen was detected in an autopsy specimen. In addition, death caused by an 
infection could be either direct (e.g. pneumonia) or indirect (e.g. sepsis leading to respi-
ratory distress). Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations were 
diagnosed and treated as described previously (22). Both CMV and EBV reactivations 
were scored as infections. 
Immune reconstitution analysis
Peripheral blood samples were acquired at baseline (after conditioning, but prior to 
dUCBT) and at 1, 2, 3, 6 and 12 months post-transplantation to determine post-transplant 
recovery of lymphocyte subsets i.e. CD3+, CD4+, CD8+, CD19+ and CD3-CD16/56+ cells, 
using four-color single platform flow cytometry as described before (16). In addition, the 
3, 6 and 12 month samples were used to determine the frequency and absolute number 
of sjTREC+ T cells. 
Quantification of signal joint t cell receptor rearrangement excision circles
The frequency of sjTREC+ cells per 105 CD3+ T cell was determined at 3, 6 and 12 months 
post-transplant. CD3+ cells were isolated from whole blood using immunomagnetic posi-
tive purification (RoboSep™, Stemcell Technologies, Grenoble, France) according to the 
instructions of the manufacturer. This resulted in a median purity of 99.0% (range 81.0% 
- 100%). DNA was purified from the CD3+ T cells using the Illustra blood genomicPrep 
Mini Spin Kit (GE Healthcare Life Sciences, Eindhoven, the Netherlands) according to 
manufacturer’s instructions. SjTRECs were quantified by a previously described 5’nucle-
ase based real time quantitative polymerase chain reaction (RT-qPCR) assay using the 
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ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA, USA) (24). To 
compensate for variations in input DNA we used the constant gene segment of the TCRA 
gene (C-alpha) as an endogenous reference gene. The sequences for detection of both 
the C-alpha gene and of sjTREC+ T cells are described earlier (16). The sjTREC frequency in 
CD3+ lymphocytes was calculated by normalizing the sjTREC RT-qPCR data to the C-alpha 
RT-qPCR data. SjTREC frequency per 105 T cells was calculated by the following formula: 
[(2x105/2ΔCT)/percentage of purity of T cells]. Since the frequency of sjTREC+ T cells in 
peripheral blood is not only influenced by thymic output, but by peripheral expansion 
as well (25), we calculated the content of sjTREC+ T cells per milliliter blood, which is not 
influenced by post-rearrangement expansion and may therefore be a better estimate of 
thymic output (26). SjTREC+ T cell content (sjTREC+ T cells/ml blood) was calculated by 
multiplying the absolute number of CD3+ T cells (in 105/ml) by the sjTREC+ frequency.
Statistical considerations
Endpoints of the study were neutrophil and platelet recovery, chimerism, acute GVHD 
(aGVHD), chronic GVHD (cGVHD), CTC grade 2-4 infections, IRM, NRM, relapse-related 
mortality (RM) and OS. 
Time to neutrophil recovery was defined as the first two consecutive days on which 
neutrophils exceeded 0.5 x 109/L. Time to platelet recovery was defined as the first of three 
consecutive days on which platelets exceeded 50 x 109/L without platelet support for 7 
days. Successful engraftment was defined as neutrophil recovery in association with do-
nor hematopoiesis of > 10% in the bone marrow. Complete donor chimerism was defined 
as > 95% donor hematopoiesis (single or both donors) and < 5% recipient hematopoiesis 
in bone marrow; mixed chimerism was defined as 10% to 95% donor hematopoiesis and 
> 5% recipient hematopoiesis in the bone marrow. Chimerism analysis was performed 
as previously described (11). aGVHD was graded according to the Glucksberg criteria 
updated according to Przepiorka et al. (27, 28). cGVHD was scored according to the Seattle 
classification for limited and extensive chronic GVHD (29). Relapse before the occurrence 
of aGVHD or cGVHD was considered a competing risk at the day of one of these events for 
calculating the cumulative incidence of aGVHD and cGVHD. The time to occurrence of CTC 
grade 2-4, 3-4 and 4 infections was calculated from the day of transplantation (day 0) to 
the day of occurrence. Three time intervals were constructed, the first one starting at the 
day of transplantation and ending 30 days post-transplant, the second interval ranging 
from day +31 to +180 and the third interval from day +181 and day +365. Infections were 
expressed as ‘infection rate’ defined by the total number of infections per 100 patient days. 
OS was calculated from the date of transplantation until death. Patients still alive at the 
date of last contact were then censored. Causes of death were classified as RM or NRM 
and these were considered competing risks. IRM was defined as mortality in which any 
infection was involved, with relapse as a competing risk. 
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Risk scores used for the prediction of NRM included the European Group for Blood and 
Marrow Transplantation (EBMT) risk score (30) and the hematopoietic cell transplanta-
tion comorbidity index (HCT-CI), developed by the Seattle group (31). Univariate logistic 
regression was performed to evaluate factors associated with sjTREC+ T cell presence 
(as a dichotomous outcome present versus absent). Parameters analyzed were age 
(continuous), gender, infused CD34+ cells (continuous), infused CD3+ cells (continuous), 
number of infused CD34+ cells winning cord (continuous), number of infused CD3+ cells 
winning cord (continuous), EBMT risk score (2-3 vs 4-5 vs 6-7), HCT-CI score (0 vs 1-2 vs 
>=3), aGVHD (grade 2-4) and HLA match of recipient versus winning cord (4/6 vs 5/6-
6/6). Recovery of thymopoiesis was defined as the presence of detectable sjTREC+ T cells. 
Univariate Cox regression analyses was performed to evaluate the impact of the recovery 
of thymopoiesis at 3 months (dichotomous; present versus absent), age (continuous), 
gender, infused CD34+ cells (continuous), infused CD3+ cells (continuous), infused CD34+ 
cells winning cord (continuous), infused CD3+ cells winning cord (continuous), total 
number of CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells and NK cells in PB at 3 months 
(all continuous), EBMT risk score (2-3 vs 4-5 vs 6-7), HCT-CI score(0 vs 1-2 vs >=3), CMV 
status of the patients (positive versus negative), HLA matching of the winning cord blood 
graft (4/6 versus 5/6-6/6) and preceding grade 2-4 aGVHD (present versus absent) on 
clinical outcome beyond that time point. Multivariate analysis of logistic regression and 
Cox regression was performed for parameters with a p-value <0.05 in univariate analysis. 
For parameters significant in Cox multivariate regression analysis hazard ratios (HR), cor-
responding 95% confidence intervals (95% CI), and p-values were calculated accordingly. 
Differences in Kaplan-Meier curves were calculated using the log-rank test, or the log-rank 
test for trend if appropriate. All reported p-values are two-sided, and a significance level 
α = 0.05 was used. All data analyses were performed with Stata/SE version 12 (StataCorp 
LP, College Station, TX, USA). 
rESULtS
Patient characteristics
Fifty-five patients were included. Patients’ characteristics are shown in table 1. The 
median age at inclusion was 51 years (range 23-68 years). Diagnoses included acute leu-
kemia (53%), chronic leukemia (9%), lymphoma (11%), and myelodysplastic syndromes, 
myeloproliferative diseases or bone marrow failure (MDS/MPL/BMF; 27%). Seventeen 
percent of the patients had a high (6 or 7) EBMT risk score, while 34% of patients were 
at higher risk for NRM according to the HCT-CI. The majority of patients received either 
two 4/6 matched units (36%) or one 4/6 matched unit combined with a 5/6 matched unit 
(42%). 
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table 1. Baseline characteristics (n=55)
median age, years (range) 51 (23 – 68)
Sex, male/female (%) 31/24 (56/44)
Diagnosis, n. (%)
Acute leukemia 29 (53) 
Chronic leukemia 5 (9) 
Lymphoma  6 (11) 
MDS/MPL/BMF 15 (27) 
HCt-CI score, n. (%)
0 18 (33) 
1 - 2 18 (33) 
≥ 3  19 (34) 
EBmt risk score, n. (%)
2-3 15 (27) 
4-5 31 (56) 
6-7 9 (17) 
median number infused total nucleated cells x107/kg, (range)
Both CBU together 4.98 (3.34 – 9.44) 
Winning CBU 2.42 (1.38 – 5.72) 
median number infused CD34+ cells x105/kg, (range)
Both CBU together 0.53 (0.08 – 2.00) 
Winning CBU 0.24 (0.00 – 1.29) 
median number infused CD3+ cells x106/kg, (range)
Both CBU together 0.88 (0.18 – 2.98) 
Winning CBU 0.39 (0.05 – 2.10) 
HLa match grade, n. (%)
4/6 + 4/6 20 (36) 
4/6 + 5/6 23 (42) 
5/6 + 5/6 9 (17) 
5/6 + 6/6 3 (5) 
HLa matching recipient versus winning CBU, n. (%)
4/6 27 (49) 
5/6 26 (47) 
6/6 2 (4) 
CmV status of recipient, n. (%)
Negative 23 (42) 
Positive 32 (58) 
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Engraftment and chimerism
Fifty-two patients (95%) met the criteria for engraftment with a median time to neutro-
phil recovery of 34 days (figure 1, range 12-57 days). Of the patients that did not meet 
the criteria for engraftment, one suffered from primary graft failure and two from relapse. 
Platelet recovery (≥50 x 109/L) occurred at a median of 45 days (figure 1, range 23-139 
days). Three patients did not achieve neutrophil recovery (5%), while four patients did 
not achieve platelet recovery (7%). At 3 months post-transplantation complete donor 
chimerism in the bone marrow, either single or double donor derived, was observed in 
49/55 patients (table 2, 89%). Mixed chimerism was observed in 4 patients (7%), while 2 
patients (4%) still showed full recipient chimerism. One of these patients suffered from 
relapse, the other from primary graft failure. 
Immune reconstitution
Lymphocyte recovery was assessed at baseline and at 1, 2, 3, 6, 12 and 24 months post-
transplantation. 
Following conditioning, CD3+ (both CD4+ and CD8+) T cells, CD19+ B cells and 
CD3-CD16/56+ NK cells were virtually absent in all patients (figures 2 & 3). B cells showed 
an initial slow recovery during the first months post-transplantation (figure 2a), but 
reached normal levels in the majority of patients at 6 months post-transplantation. NK 
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figure 1. Recovery of neutrophils and platelets post-transplantation.
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cells recovered rapidly and returned within the normal range between 1 and 2 months 
post-transplantation (figure 2B).
CD3+ T cell reconstitution was severely retarded (figure 3a). At 24 months post-
transplantation, the median level of CD3+ T cells had not reached the lower normal range 
limit. Reconstitution of both CD4+ helper T cells as CD8+ cytotoxic T cells appeared to be 
very slow (figure 3B and 3C) and a significant number of patients did not reach the lower 
normal range limit at 24 months post-transplantation (64% and 73% respectively).
The presence, content and frequency of sjTREC+ T cells were assessed at 3, 6 and 12 
months post-transplantation. SjTREC+ T cells were detectable in 62% of patients at 3 
months, in 80% at 6 months and in 73% at 12 months post-transplantation. The median 
sjTREC+ T cell content measured per milliliter blood was 150 (range 0-1070) at 3 months, 
260 (range 0-24920) at 6 months and 410 (range 0-87000) at 12 months post-transplan-
tation (figure 3D). The median frequency of sjTREC+ T cells per 105 CD3+ T cells was 63 
(range 0-619) at 3 months, 62 (range 0 - 22402) at 6 months and 116 (range 0 - 5558) at 12 
months (figure 3E). Despite this increase over time, at 12 months post-transplantation, 
sjTREC+ cell frequency and content had not recovered to normal values as measured 
in healthy donors (median content 19044/ml, range 1873 – 77952; median frequency 
1205/105 CD3+ T cells, range 147 - 3962(16)). 
We evaluated whether pre-transplant variables, transplant characteristics and post-
transplant variables would affect sjTREC+ T cell recovery. In multivariate analysis the ab-
sence of sjTREC+ T cells at 3 months was associated with higher recipient age (p=0.015). 
No differences were observed in sjTREC+ T cell recovery at 3 months based on recipient 
table 2. Levels of chimerism at 3 months post-transplantation
Bone marrow chimerism, n. (%)
Single donor chimerism 46 (84) 
Double donor chimerism 3 (5) 
Mixed chimerism 4 (7) 
Recipient chimerism 2 (4) 
Peripheral blood chimerism, n. (%)
Single donor chimerism 46 (84) 
Double donor chimerism 3 (5) 
Mixed chimerism 4 (7) 
Recipient chimerism 2 (4) 
Peripheral blood CD3+ fraction chimerism, n. (%)
Single donor chimerism 46 (84) 
Double donor chimerism 1 (2) 
Mixed chimerism 5 (9) 
Recipient chimerism 3 (5) 
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gender, number of infused CD34+ cells (from either both grafts or predominant graft), 
number of infused CD3+ cells (from either both grafts or predominant graft), EBMT risk 
score, HCT-CI score, preceding aGVHD or HLA-matching grade of the predominant graft. 
In addition, at 6 and 12 months post-transplantation, none of the tested variables were 
associated with the presence or absence of sjTREC+ T cells. 
Infections
The total number of infections was recorded in detail in surviving patients up to one year 
after dUCBT, resulting in a total of 197 CTC grade 2-4 and 128 CTC grade 3-4 infections. 
The cumulative incidence of CTC grade 2-4 and grade 3-4 infections, respectively, was 
89% and 83% at 6 months and 95% and 87% at 12 months. In the first 30 days post-
transplantation, the rate of infections was 3.16 CTC grade 3-4 infections per 100 patient-
days (table 3), with 69% of patients experiencing at least one severe infection during 
that time period. Patients experienced a median of one CTC grade 3-4 infection in the 
first time period (range 0-3). 75% of the reported infections within the first month post-
transplantation was either due to neutropenic fever, a central venous catheter infection 
or a positive blood culture without additional symptoms. The CTC grade 3-4 infection 
rate was much lower in the second (day 30-180) and third (day 180-365) time interval 
(0.74 and 0.29, respectively). In the second time interval, the majority of severe infec-
tions was caused by viral infections (38%), followed by bacterial (24%) and fungal (9%) 
infections. In 29% of the patients with severe infections in that time interval, no causative 
micro-organism could be identified. Out of the 32 CMV-seropositive patients (table 1), 
14 developed at least one CMV reactivation (45%) at any time point in the first year 
post-transplantation. However, none of these patients developed clinical CMV disease. 
CTC grade 2 infections appeared to be scarce within the first and second time period 
compared to CTC grade 3-4 infections with a CTC grade 2 infection rate of 0.30 and 0.56 
respectively (table 3). In the third time period, CTC grade 2 infections outnumbered the 
CTC grade 3-4 infections (CTC grade 2 infection rate 0.39 versus CTC grade 3-4 infection 
ate 0.29 respectively). 
table 3. Rate of infections per 100 patient days
Interval CtC Grade 2 CtC Grade 3-4
0-30 days 0.30 3.16
31-180 days 0.56 0.74
181-365 days 0.39 0.29
outcome
Median follow-up was 20 months. At one year post-transplantation, 40 of 55 patients 
(73%) were still alive (figure 4a). The EBMT risk score significantly impacted on OS (fig-
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ure 4B, HR 2.36, 95% CI 1.35-4.12, p=0.003). The HCT-CI score was also associated with OS 
(HR 1.51, 95% CI 0.96-2.39), however this did not reach statistical significance (p=0.076). 
Fifteen patients had died within the first year after transplantation. Death was due to 
relapse in 6 patients (40%), allo-SCT related causes in 7 patients (47%) and other causes 
in 2 patients (13%; peritonitis of unknown cause and death of unknown cause, respec-
tively). In the 7 patients who died from allo-SCT related causes, infectious complications 
contributed in all patients and were the primary cause of death in 6 out of 7 patients. In 
4 patients the infection co-occurred with GVHD. By day 100 post-transplant, 28 patients 
(51%) had developed grade II-IV aGVHD, and 4 patients (7%) developed grade III-IV 
aGVHD. Limited or extensive cGVHD was observed in 9 and 15 out of 55 patients (16% 
and 27%, respectively) at 1 year post-transplant. 
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Impact of the recovery of thymopoiesis on outcome 
Next it was explored whether recovery of sjTREC+ T cells at 3 months post-transplantation 
was associated with severe infections (CTC grade 3-4), IRM, NRM, RFS and OS determined 
from 3 months post-transplantation. In univariate analysis (table 4), the absence of 
sjTREC+ T cells was the only factor associated with a higher risk of severe infection beyond 
3 months post-transplantation (HR 3.25, 95% CI 1.26-8.43, p=0.015). Univariate analysis 
for NRM beyond 3 months post-transplantation also revealed the absence of sjTREC+ T 
cells to be associated with NRM, however this did not reach statistical significance (HR 
2.80, 95% CI 0.91-8.56, p=0.071). The absence of sjTREC+ T cells was not associated with 
OS beyond 3 months post-transplant, but higher age (p=0.013) and the EBMT risk score 
(p=0.003) were. Multivariate analysis revealed that the EBMT risk score was more strongly 
associated with OS beyond 3 months post-transplant (HR 2.0, 95%CI 1.12-3.59, p=0.02) 
than the age at transplantation (HR 1.03, 95%CI 0.99-1.07), p=0.077). None of the tested 
parameters were associated with RFS or IRM beyond 3 months post-transplantation in 
univariate analysis. To further address the observed association between recovery of 
sjTREC+ T cells and severe infections, patients were divided in three tertiles based on the 
sjTREC+ T cell content per milliliter blood. A higher content of sjTREC+ T cells was associ-
ated with a decreased risk for severe infection, with patients with the highest sjTREC+ T 
cell content not developing any severe infections (figure 5). 
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figure 5. Association between sjTREC+ T cell content per milliliter blood (in tertiles) at 3 months post-trans-
plantation and the occurrence of CTC grade 3-4 infection rate beyond 3 months post-transplantation.
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DISCUSSIon
Immune reconstitution upon UCBT is severely retarded and as a direct consequence, 
UCBT is associated with a significant risk of opportunistic infections (32). Kinetics of 
immune reconstitution upon UCBT have been widely studied, although most of these 
studies were performed in a single graft setting and are based on mixed populations 
of patients, receiving various conditioning and immunosuppressive regimens (15, 17-
19, 33-35). Few studies reported on recovery of thymopoiesis upon dUCBT (20, 36, 37). 
This study, to our knowledge, is the first to describe immune reconstitution including 
thymopoiesis in a uniform population of 55 adult patients, receiving dUCBT upon a RIC 
regimen omitting in vivo T cell depletion. In addition, the present study is the first to 
correlate recovery of thymopoiesis with clinical outcome upon dUCBT and shows the 
predictive impact of impaired sjTREC+ T cell recovery at 3 months on the risk of severe 
infections beyond that time point. 
Although CD3+ T cell recovery was severely protracted and the majority of patients had 
CD3+ T cell levels below the normal range up to 24 months post-transplantation, sjTREC+ 
T cells were detected at low levels in 62% of patients at 3 months post-transplantation. 
Our results are in contrast to several other studies, were sjTREC+ T cells were detected 
in 20% (20), 11% (37) and 0% (38) of patients around the same time point upon dUCBT. 
However, in these studies, patients received either MA conditioning or a RIC regimen 
combined with antithymocyte globulin (ATG), a polyclonal antibody raised against 
thymocyte antigens resulting in profound in vivo T cell depletion (39). Cytotoxic che-
motherapy and radiation negatively affect thymic reconstitution (40, 41). RIC regimens 
may therefore cause less damage to the thymus compared to MA conditioning, resulting 
in faster recovery of thymopoiesis. In addition, several studies showed an association 
between the use of a RIC regimen and enhanced immune reconstitution (42-44). The 
use of ATG results in a lower incidence of GVHD, but however, might result in delayed 
immune reconstitution as well. Enhanced B and T cell recovery is reported upon the 
use of ATG-free conditioning regimens in UCBT, both MA or RIC, in both pediatric and 
adult cohorts (45-47). Therefore, the high incidence of patients with detectable sjTREC+ 
T cells at 3 months post-transplantation could be well explained by the relatively mild 
conditioning regimen used in our study. In a comparable cohort of 46 adult patients 
receiving a matched related (n=33) or unrelated (n=13) allo-SCT upon an ATG-free RIC 
regimen (Fludarabine 90 mg/m2 and TBI 2 Gy) in our center, detectable sjTREC+ T cells 
were observed in 67% of patients at 3 months and 86% at 12 months, which is similar to 
the above described proportions of sjTREC+ T cell positivity in patients receiving dUCBT. 
These results indicate, that upon an ATG-free RIC regimen, dUCBT and adult donor allo-
SCT show comparable reconstitution of thymopoiesis. Previously, both age and GVHD 
have been implicated to impact the reconstitution of thymopoiesis (44, 48-50). While an 
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association between higher age and undetectable sjTREC+ T cells was observed in the 
current study, this association was not observed for the presence of GVHD.
In an earlier study, we showed that insufficient thymopoiesis predicted for severe 
infections and NRM in patients receiving a matched related or unrelated donor allo-SCT 
upon MA conditioning (16). In the current study, patients who failed to recover thymo-
poiesis at 3 months post-transplantation had a 3.3-fold higher risk for subsequent severe 
infections. This association was not observed between CD3+, CD4+ and CD8+ T cell counts 
at 3 months post-transplantation and subsequent severe infections, indicating that the 
newly formed naïve T cells are pivotal for adequate infectious immunity. In addition, the 
content of sjTREC+ T cells was associated with the risk for severe infection at that time 
point. These results compare well with Brown et al. (37) who demonstrated that clear-
ance of CMV viremia after dUCBT depended on the recovery of thymopoiesis. Although 
several other studies assessed thymopoiesis upon dUCBT(20, 36-38) and infectious 
complications are a known problem upon UCBT(32, 46), severe infections after dUCBT 
were not yet linked to recovery of thymopoiesis. 
In line with Sauter et al. (46) the highest infection rate was observed in the first 30 days 
post-transplantation. They described 61% of patients experiencing at least one infection 
in this time period, which compares well to the cumulative incidence of 69% of severe 
infections in our cohort. Of note is that most of the infections scored in the present 
study in the first month post-transplantation were neutropenic fevers, central venous 
catheter infections or positive blood cultures without an evident focus. These infections 
may have occurred and been reported more frequently because of longer hospitaliza-
tion and therefore increased surveillance, leading to an overestimation of infections in 
the first 30 days post-transplantation. In a comparable adult donor recipient cohort, as 
mentioned earlier, the highest rate of CTC grade 2-4 infections was observed in the first 
30 days post-transplantation as well, although this rate was markedly lower compared 
to the observed infection rate upon dUCBT (adult donor 1.09 CTC grade 2-4 infections 
per 100 patient-days versus 3.46 in the dUCBT group). In the second time interval of 30 
days to 180 days post-transplantation, viral infections were the most common cause of 
infectious morbidity, which is in line with literature (4, 20, 32). In addition, 45% of the 
CMV-seropositive patients developed one or more CMV reactivation during the first year 
post-transplant. This is in line with the study performed by Sauter et al. (46), where a CMV 
reactivation rate of 51% was observed in 180 CMV-seropositive patients that received 
dUCBT upon conditioning omitting in vivo T cell depletion. However, clinical CMV disease 
was reported in 25 patients, whereas no cases of clinical CMV disease were observed in 
the current study. This difference might be due to the prophylactic use of valaciclovir 
for the prevention of herpes infections in our center. Although primarily used for the 
prevention of herpes infections, valaciclovir is a more potent CMV suppressor in patients 
receiving allo-SCT than acyclovir (51), which was used by Sauter and colleagues. 
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As mentioned earlier, this study is the first to assess immune reconstitution including 
thymopoiesis in a homogeneous cohort of 55 adult patients, receiving a RIC regimen 
omitting in vivo T cell depletion and to correlate recovery of thymopoiesis to clinical out-
come. Although this population of 55 patients is larger than any other cohort described 
in this context, the limited cohort size was a limitation for the present study, especially 
for associations with clinical outcomes in which there were only a few events. 
In conclusion, failure to recover thymopoiesis after RIC-dUCBT without in vivo T cell 
depletion resulted in a higher risk of developing subsequent severe infections. This may 
lead to increased NRM and adverse outcome. These results highlight the need to improve 
thymic function post-transplantation, for example by the administration of the cytokines 
interleukin-7 or keratinocyte growth factor (52-54). Furthermore, risk of infections might 
be reduced by adoptive transfer of virus or fungal specific T cells (55, 56). In addition, 
patients lacking thymic recovery at 3 months post-transplantation might benefit from 
intensified supportive measures in order to prevent infections and associated mortality. 
Therefore, we propose to consider monitoring sjTREC+ T cell recovery in dUCBT patients, 
to identify patients in need for intensified support.
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aBStraCt 
The Wnt signaling pathway has been implicated to play a role in the regulation of mouse 
hematopoietic stem cell  fate decisions between self-renewal and differentiation. How-
ever, the role of Wnt proteins in ex vivo cultures of hematopoietic stem cells remains 
controversial. Here, it is shown that exogenous Wnt3a combined with hematopoietic 
growth factors leads to a reduction in the number of Lin-, Sca1-, and c-Kit+ (LSK) cells 
in a stroma-free, serum-free culture system. The same negative effect on the number 
of CD48-, CD150+, CD34low primitive LSK cells was observed when a more stable Wnt 
signal, provided in the form of a lipid-stabilized Wnt3a protein or the GSK3β inhibitor 
CHIR99021, was used. The decrease in mouse LSK number occurred at later stages of the 
culture. Inducible overexpression of the anti-apoptotic BCL2 protein did not prevent the 
Wnt-induced loss of primitive LSK cells, suggesting that the loss was not due to apopto-
sis. These data suggest that Wnt signals impede the maintenance of hematopoietic stem 
cells in serum-free cultures. 
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IntroDUCtIon
Wingless-related integration site (Wnt) signals have been shown to act as self-renewal 
factors for both embryonic [1] and adult stem cells in a diversity of mammalian tissues, 
including intestines, skin and mammary gland [2]. They also provide critical cues for 
maintenance or expansion of stem cells in cultures of a variety of adult stem cells both 
from mouse and man [3–8]. Several signal transduction cascades may be induced upon 
binding of Wnt ligands to their receptors [9], the best-characterized one being the ca-
nonical or β-catenin pathway. In this pathway, β-catenin is phosphorylated by glycogen 
synthase kinase-3β (GSK-3β) to be targeted for proteasomal degradation. Upon binding 
of a Wnt protein to the Frizzled (Fz) family of receptors and to low-density lipoprotein 
receptor-related protein 5 (LRP5) or LRP6 co-receptors, the phosphorylation of β-catenin 
is inhibited. Stabilized β-catenin translocates into the nucleus where it interacts with 
TCF/LEF transcription factors to activate targeted gene expression [10]. 
Over the past decades, a variety of studies have implicated a possible role for canoni-
cal Wnt signaling in the control of mammalian hematopoietic stem cell (HSC) function. 
Mice carrying a null allele of Wnt3a [11] or overexpressing the Wnt inhibitor Dickkopf1 
in the bone marrow niche [12] display impaired HSC self-renewal. When stimulated by 
a constitutively active form of β-catenin or by purified Wnt3a protein, Wnt signaling 
increased self-renewal capacity of apoptosis-resistant, transgenic HSC ex vivo [13,14]. 
However, mouse models with constitutively activated Wnt signaling displayed a multi-
lineage differentiation block and loss of HSCs [15,16], and later studies using purified 
Wnt proteins in ex vivo cultures of normal mouse HSC reported controversial outcomes. 
In one study, Wnt5a was suggested to improve repopulation capacity of mouse HSC by 
inhibiting canonical Wnt pathway induced by Wnt3a protein [17], while in another it was 
shown to impede maintenance of HSC [18]. Several other studies showed that active 
β-catenin induces apoptosis in HSPC [19,20]. Taken together, these studies underscore 
the controversies on the effect of Wnt activation on HSC proliferation, differentiation and 
apoptosis. 
It has been known for some time that Wnt proteins have a very short half-life in serum-
free cell culture media, losing its activity within several hours [21]. This complicates the 
interpretation of the results obtained for the role of exogenous Wnt proteins on ex vivo 
HSC proliferation. Thus, addition of Wnt3a protein to cell cultures would result in inter-
mittent rather than continuous activation of the pathway, which may be insufficient to 
inhibit HSC differentiation. In this study, the effect of Wnt signals in combination with 
hematopoietic growth factors on ex vivo cultures of mouse HSC is studied and the role 
of apoptosis and of Wnt3a protein stability on the response of HSC to Wnt signals is 
investigated. 
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mEtHoDS anD matErIaLS
mice
All animal procedures were performed in accordance with institutional and national 
guidelines and regulations, and approved by the Erasmus MC Animal Experiment Com-
mittee (DEC). Animals were euthanized using carbon dioxide. C57BL/6 and TRE-BCL2 
mice used in this study were bred and maintained in the animal facility at Erasmus Medi-
cal Center (Erasmus MC), and handled according to institutional guidelines. All proce-
dures were carried out in compliance with the Standards for Care and Use of Laboratory 
Animals. All mice were used at 12-24 weeks of age. 
For generation of TRE-BCL2 mice, a human BCL2 cDNA (accession number BC027258) 
was amplified, and a Kozak sequence and C-terminal FLAG tag added. The vector p2Lox.
GFP [22] was digested with XhoI and NotI to remove the GFP sequence, and the XhoI/
NotI-digested BCL2-FLAG sequence ligated into its place to create p2Lox.BCL2. 25 µg of 
p2Lox.BCL2 was electroporated into A2Lox.Cre ES cells, followed by induction of the cells 
with 1 µg/ml doxycycline overnight to induce recombination, and the cells selected on 
250 μg/mL of G418, as previously described [23]. The cells were then used for blastocyst 
injections into C57Bl/6 blastocysts. Chimeras were mated against C57Bl/6 mice and 
readily gave germline transmission. Mice containing the BCL2 transgene and the reverse 
tetracycline transactivator (rtTA, expressed from the Rosa26 locus in A2Lox.Cre ES cells) 
were identified by PCR using the following primers: 
BCL2: forward GGATGCCTTTGTGGAACTGT, reverse GCTCACTTGTCGTCATCGTC; rtTA: 
forward GGACGAGCTCCACTTAGACG, reverse GGCATCGGTAAACATCTGCT.
Isolation of LSK and LSK CD48- cells
For LSK or LSK CD48- cell isolation, femurs and tibias from mice were removed, BM flushed, 
and mononuclear cells were isolated by Lymphoprep™ according to manufacturer’s in-
structions (Stem Cell Technologies, Grenoble, France). Lineage-positive (Lin+) cells were 
depleted by magnetic cell sorting (MACS) with the use of a lineage cell depletion kit 
according to manufacturer’s instructions (Miltenyi Biotech, GmBH, Bergisch Gladbach, 
Germany). Lin depleted cells were further stained with a Lin-PE cocktail (anti-CD3e-PE, 
anti-CD45R-PE, anti-CD11b-PE, anti-Gr1-PE, and anti-Ter119-PE) as well as with anti-c-
Kit-APC and anti-Sca-1-PE-Cy7 (all from BD Pharmingen, Heidelberg, Germany) where 
indicated. Hoechst (BD Biosciences, San Jose, CA, USA) was added to allow live/dead 
cell discrimination. Cell sorting for Lin-, c-Kit+, Sca-1+ (LSK) cells was performed using BD 
FACSAriaIII™ (BD Biosciences, San Jose, CA, USA). 
For sorting LSK CD48- population, cells were stained with Lin-PE cocktail, anti-CD48-PE 
(BD Pharmingen, Heidelberg, Germany) anti-c-Kit-APC-Cy7 (eBioscience, Vienna, Austria) 
and anti-Sca-1-PE-Cy7. For further analysis of the starting population, these cells were 
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also stained with CD34-FITC (BD Pharmingen, Heidelberg, Germany), and/or CD150-APC 
(Biolegend, London, UK) where indicated. 
Expansion cultures
Sorted LSK or LSK CD48- cells were cultured in StemSpan™ Serum-Free Expansion Me-
dium (SFEM, Stem Cell Technologies, Grenoble, France) supplemented with 1% penicil-
lin/streptomycin (Sigma, St Louis, MO, USA), 10 μg/ml low molecular weight heparin 
(Abbott, Wiesbaden, Germany), SCF (10 ng/ml, Biovision, Milpitas, CA, USA) and TPO (20 
ng/ml, Cell Sciences, Canton, MA, USA). Cells were cultured in a volume of 200 µl medium 
in a U-bottom 96-well plate at a range of 3000-30.000 cells/ml at 37 °C in 5% CO2. Where 
indicated purified Wnt3a (250 ng/ml, if not indicated otherwise), liposomal Wnt3a (250 
ng/ml), Wnt antagonist Fz8CRD (5 µg/ml) and CHIR99021 (1µM, Stemgent Cambridge, 
MA, USA) were added to the cultures daily by half medium refreshment or splitting. 
To induce BCL2 expression in sorted cells derived from TRE-BCL2 mice, doxycycline 
(1µg/ml, Sigma, St Louis, MO, USA) was added to cultures at the start of the experiment 
as well as during the refreshments or splitting. 
flow cytometry
For analysis of cultures after the indicated culture period, cells were harvested, washed 
and resuspended in PBS containing 10% FCS. Absolute numbers of viable subpopula-
tions (LSK, LSK CD48-, and LSK, CD48-, CD150+, CD34low) cells were determined by a single 
platform flow cytometric analysis, using the same panel of monoclonal antibodies that 
was used for sorting and a calibrated number of Cyto-Cal™ Control Count counting 
microspheres (Thermo Scientific, Waltham, MA, USA). For apoptosis analysis, cells were 
simultaneously stained with anti-Annexin V-APC in binding buffer (BD Biosciences, San 
Jose, CA, USA) in PBS containing 10% FCS. Flow cytometric analysis was performed using 
a BD FACSFortessa™ (BD Biosciences, San Jose, CA, USA) and data was analyzed using 
FlowJo software (Tree Star Inc, Ashland, OR, USA). 
Purification of Wnt3a protein and preparation of liposomal Wnt3a
Mouse Wnt3a was purified from Wnt3a-conditioned medium, collected from Drosophila 
S2 cells, using Blue Sepharose affinity and gel filtration chromatography as described 
previously [14]. Liposomes containing DMPC (1,2-dimyristoyl-sn-glycero-3-phospho-
choline), DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol) (both Lipoid AG, 
Ludwigshafen, Germany) and Cholesterol (Sigma, St Louis, MO, USA) at a 10:1:10 molar 
ratio were prepared as described in chapter 4 of this thesis. Briefly, purified Wnt3a was 
mixed with liposomes and incubated for one hour by rotating at 4°C. CHAPS was re-
moved by dialysis (10 kDa molecular weight cut-off ) in Hepes-buffered saline at 4°C. The 
Wnt liposomes were stored at 4°C until use. 
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Luciferase reporter assay
Mouse LSL cells, which express luciferase in response to TCF promoter binding [24], were 
routinely cultured at 37oC and 5% CO2 in culture medium containing DMEM (Invitrogen, 
Life Technologies, Bleiswijk, The Netherlands), 10% FCS (HyClone, Thermo Scientific, 
Waltham, MA, USA), 100 U/ml Penicillin and 100 µg/ml Streptomycin (both from Invitro-
gen, Life Technologies, Bleiswijk, The Netherlands). Prior to the activity assays, 25,000 LSL 
cells were plated in each well of a 96-well plate and grown for 24 hours. Wnt3a reagents 
were separately incubated in culture medium with or without serum for various periods of 
time at 37oC in 96-well plates. After the incubation intervals, media with Wnt3a reagents 
were added to LSL cells. Upon an additional overnight incubation with the indicated 
reagents, relative luciferase units were measured with a Glomax multiplate reader.
Western blotting
Lineage-negative (Lin-) cells from TRE-BCL2 mice were isolated by FACS sorting as de-
scribed above. 100,000 cells were seeded for each condition and were cultured for 24h 
with and without doxycycline (1µg/ml, Sigma, St Louis, MO, USA) treatment. Whole-cell 
extracts were then isolated from total cells. Cells were washed twice in PBS and lysed in 
RIPA buffer (Thermo Scientific, Waltham, MA, USA) including protease and phosphatase 
inhibitors. Protein concentrations were measured by BCA protein assay kit (Thermo Sci-
entific, Waltham, MA, USA) and equal amounts of protein were subjected to SDS-PAGE, 
followed by western blot analysis using anti-Flag antibody (1:1500, Sigma, St Louis, MO, 
USA). 
Statistical analysis
Data are presented as mean ± SD. Statistical significance was determined by a Student’s 
two-tail t-test (unpaired and ratio-paired), performed using GraphPad Prism software 
(version 6.0; GraphPad), and p<0.05 was defined as statistically significant.
rESULtS
Wnt/beta-catenin signals reduce the number of mouse LSK cells in stroma- and 
serum-free cultures
The effect of the combination of hematopoietic growth factors and exogenous Wnt3a 
on HSPC in stroma- and serum-free cultures was assessed. For this, FACS-sorted LSK cells 
were cultured for 10 days in serum-free medium containing stem cell factor (SCF) and 
Thrombopoietin (TPO). Addition of Wnt3a protein did not significantly affect the expan-
sion of total nucleated cells (figure 1a). However, treatment with purified Wnt3a protein 
resulted in a 2-fold decrease in the number of Lin- cells relative to control condition 
Wnt3a reduces the number of mouse HSPC in culture 65
3
Figure 2
C
A
Fo
ld
 c
ha
ng
e 
re
la
tiv
e 
to
 in
pu
t
Total cell expansion
B
D
Fo
ld
 c
ha
ng
e 
re
la
tiv
e 
to
 in
pu
t
Co
ntr
ol
Pu
rifi
ed
 W
nt3
a
CH
IR
99
02
1
Fz
8C
RD
Fz
8C
RD
+ P
uri
fie
d W
nt3
a
0.0
0.2
0.4
0.6
0.8
LSK 
*
*
E
Fz8CRD
2.95% 18.4%24.8%
Purified Wnt3aControl
7.33%18.9%
Fz8CRD
+Purified Wnt3a CHIR99021
c-
K
it
Sca-1
Lin-
Co
ntr
ol
Pu
rifi
ed
 W
nt3
a
CH
IR
99
02
1
Fz
8C
RD
Fz
8C
RD
+ P
uri
fie
d W
nt3
a
0
2
4
6
8
10
Fo
ld
 c
ha
ng
e 
re
la
tiv
e 
to
 in
pu
t
**
**
Co
ntr
ol
Pu
rifi
ed
 W
nt3
a
CH
IR
99
02
1
Fz
8C
RD
Fz
8C
RD
+ P
uri
fie
d W
nt3
a
0
1
2
3
4
Lin-
Co
ntr
ol
Pu
rifi
ed
 W
nt3
a
CH
IR
99
02
1
Fz
8C
RD
Fz
8C
RD
+ P
uri
fie
d W
nt3
a
0
20
40
60
80
100
P
er
ce
nt
ag
e 
(%
) o
f L
in
 +
 c
el
ls *
figure 1. Purifi ed Wnt3a protein reduces the num-
ber of LSK cells in stroma-free, serum-free cultures. 
FACS-sorted LSK cells were cultured in serum-free 
medium containing SCF and TPO, with treatment of 
purifi ed Wnt3a (1 µg/ml), CHIR99021 or Wnt-antago-
nist Fz8CRD. After 10 days, the cells were harvested 
and analysed by fl ow cytometry. (A-B) Fold change of 
total the total nucleated cells (A) and Lin- cells (B) rela-
tive to input. (C) Analysis of Lin- population for c-kit 
and Sca-1 markers. Percentages of c-kit+Sca-1+ cells 
among Lin- population (gated region) are shown. (D) 
Fold change of LSK relative to input is plotted. (E) The 
frequency of Lin+ cells within total cells. (Error bars 
indicate S.D.) (n=2). Statistical signifi cance was deter-
mined by a two-tail t-test. (*p<0.05).
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(figure 1B, p<0.01). Moreover, while approximately half of the LSK cells were maintained 
in control conditions, treatment with Wnt3a led to a 6-fold decrease in the number of 
LSK cells (figure 1C+D, p=0.01). These effects were reversed upon simultaneous addi-
tion of Fz8CRD, a soluble domain of the Wnt receptor that sequesters Wnt proteins [25], 
indicating they were specific for the Wnt3a protein (figure 1a-D). A similar effect on the 
number of total nucleated cells, Lin- cells and LSK cells was observed when the canonical 
Wnt pathway was activated using the GSK3 inhibitor CHIR99021 (figure 1a-D), indicat-
ing that the effect was specific for the beta-catenin pathway. The frequency of Lin+ cells 
was not significantly affected by Wnt3a protein (figure 1E, p=0.09). However, a higher 
frequency of Lin+ cells when cells were induced with CHIR99021 was observed, which 
might be due to a stronger or more prolonged activation of the Wnt pathway, or by 
effects other than Wnt/β-catenin induction (figure 1E, p<0.05). These data collectively 
show that the addition of Wnt3a protein decreased the number of LSK cells in serum-free, 
stroma-free cultures and that this is a consequence of the binding of Wnt3a to its recep-
tor and subsequent activation of the canonical Wnt pathway.
Recent data indicates that stability of purified Wnt proteins depends on the presence 
of detergent or serum [21], implying that its activity may be rapidly lost in serum-free 
culture systems. This may explain its inability to support LSK cells in serum-free culture. 
Luciferase reporter assays demonstrated that purified Wnt3a protein, while retaining its 
activity for several days in medium containing serum, loses its activity within a few hours 
in serum-free medium (figure 2a). Even daily addition of purified Wnt3a to serum-free 
cultures would therefore result in brief pulses of Wnt3a activity instead of a sustained 
Wnt signal, which may be insufficient to support LSK cells. It was recently shown that 
association with lipid vesicles prolongs the stability of Wnt ligands [26,27], allowing us 
to achieve a more sustained Wnt signal in serum-free culture (figure 2B). It was there-
fore investigated whether lipid-stabilized Wnt3a protein would be able to support LSK, 
CD48- cells in stroma-free, serum-free conditions. After 7 days of culture, no significant 
differences between regular and liposomal Wnt3a for total nucleated cell expansion was 
observed (figure 2C), and the frequency of Lin+ CD48+ cells remained similar in all condi-
tions (figure 2D). Moreover, like purified Wnt3a, liposomal Wnt3a induced a decrease in 
the more immature LSK, CD48-, CD150+, CD34low population, which is highly enriched 
for HSCs (figure 2E, p<0.05 and p<0.01 for purified and liposomal Wnt3a, respectively). 
Thus, the failure of purified Wnt3a to support mouse LSK cells in our serum-free culture 
system was not due to insufficient stability of the Wnt ligand since it also occurred in the 
presence of lipid-stabilized Wnt3a protein.
Wnt3a signaling does not induce apoptosis in short-term cultures 
Previous studies suggest that Wnt signals may induce apoptosis in HSC, and that com-
bined activation of Wnt signaling and inhibition of apoptosis may be required to sup-
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port HSC expansion [17,19]. To assess whether Wnt activation leads to early apoptosis, 
FACS-sorted LSK CD48- cells were cultured in our stroma-free, serum-free system in the 
presence or absence of exogenous Wnt3a protein. After 4 days of culture, no difference 
in total cell numbers or in the frequency of Hoechst-, Annexin V+ early apoptotic cells was 
observed (figure 3a-C). In contrast to longer-term cultures, as described above, addition 
of Wnt3a protein did not significantly affect the number of LSK CD48- or LSK CD48- CD-
34low cells (figure 3D-E). Moreover, no increase in levels of early apoptotic LSK cells in 
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figure 2. Stable Wnt activity by liposomal Wnt3a reduces the number of primitive LSK cells in vitro. (A) Quan-
tification of Wnt activity retained after incubation for 0, 8, 24, 48 and 72 hours at 37°C in cell culture media 
with or without serum. Activity plot displays average increase of luminescence relative to background. Puri-
fied Wnt3a was added at 250 ng/ml (Error bars indicate S.E.M., n=6). (B) Quantification of Wnt3a activity 
retained after incubation of the indicated reagents in serum-free cell culture medium at 37°C for 0,8 and 
24 hours. Purified and liposomal Wnt3a were added at 250 ng/ml. (Error bars indicate S.E.M., n=10). (C-E) 
FACS sorted LSK CD48- cells, were cultured with purified Wnt3a, liposomal Wnt3a, and Fz8CRD. Total cells 
were analysed by flow cytometry after 7 days of culture. The graphs display the total nucleated cell ex-
pansion relative to input (C), the frequency of Lin+ cells within total cells (D), and the fold change of LSK 
CD48-CD150+CD34low cells compared to input (E). (Error bars indicate S.D.) (n=2). Statistical significance was 
determined by a two-tail t-test (*: p<0.05; **: p<0.01).
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figure 3. Wnt3a protein does not induce apoptosis of LSK cells in short-term stroma-free, serum-free cul-
tures. FACS-sorted LSK cells were cultured in serum-free conditions with the addition of purifi ed Wnt3a. Cells 
were analysed by fl ow cytometry after 4 days of culture. (A-B) The graphs display fold change of total nucle-
ated cells (A) and the frequency of Annexin-V+Hoechst- early apoptotic cells among the same population (B). 
(C) Representative fl ow cytometry plots for Annexin-V analysis within Hoechst- viable total cells. Percentages 
of Annexin-V-Hoechst- and Annexin-V+Hoechst- cells are shown. Shown are graphs for fold change of LSK 
CD48- (D), and LSK CD48-CD34low cells (E). (F) The graph displays the frequency of Annexin-V+Hoechst- early 
apoptotic LSK CD48-CD34low cells among the same population. (G) Representative fl ow cytometry plots for 
Annexin-V analysis within LSK CD48-CD34low cells. Percentages of Annexin-V+Hoechst- cells are shown. (Error 
bars indicate S.D.) (n=2).
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the presence of Wnt3a was observed (figure 3f-G). This suggests that Wnt-mediated 
reduction in the number of LSK occurs at later stages of culture and cannot be explained 
by an increase in early apoptotic events. 
Inhibition of apoptosis does not rescue Wnt3a-induced loss of LSK cells 
To further investigate a possible role for apoptosis in Wnt-induced loss of LSK cells in 
our cultures, a novel transgenic anti-apoptotic mouse model was developed. Using 
Cre-mediated transgenesis in embryonic stem cells, an anti-apoptotic FLAG-tagged hu-
man BCL2 transgene was placed under control of a doxycycline-responsive promoter 
targeted in the HPRT locus. The reverse tetracycline transactivator was constitutively 
expressed from the Rosa locus. Thus, the cells could be induced to express BCL2 upon 
treatment with doxycycline, inhibiting the induction of apoptosis. Transgenic mice were 
generated using blastocyst injection of the cells, which allowed us to obtain LSK cells car-
rying the transgenes. It was verified that doxycycline indeed induced BCL2 in primitive 
hematopoietic Lin- progenitors by Western blot analysis (figure 4a). This system enabled 
us to investigate the effect of BCL2 overexpression in otherwise fully comparable cell 
populations. Doxycycline treatment substantially enhanced total nucleated cell expan-
sion upon culture of LSK CD48- cells for 10 days (figure 4B,  p<0.05), confirming the 
effectivity of BCL2 induction. Moreover, a strong increase in LSK CD48- cells and of the 
more immature LSK CD48- CD150+ CD34low population was observed upon doxycycline 
induction (figure 4C+D, p<0.05 and p<0.01, respectively), indicating that apoptosis was 
indeed an important factor limiting the expansion of these cells in culture. However, with 
combined doxycycline and liposomal Wnt3a treatment, the total nucleated cell expan-
sion was reduced compared to doxycycline only condition (figure 4B, p<0.05). Likewise, 
the expansion of LSK CD48- cells and of LSK CD48- CD150+ CD34low cells in response to 
BCL2 induction was repressed by liposomal Wnt3a treatment (figure 4C,  p<0.05, and 
figure 4D, p<0.01 and p<0.001). Combined, our data showed no evidence that Wnt3a 
induced early apoptosis in LSK cells, or that inhibition of apoptosis by BCL2 supported 
LSK cell expansion in response to Wnt3a protein. 
DISCUSSIon
This study investigated the role of Wnt3a-induced signaling in regulation of mouse HSC 
ex vivo. Purified Wnt3a protein combined with hematopoietic growth factors induced a 
decrease in the number of LSK cells in stroma- and serum-free culture systems. This effect 
was reversed by a competitive Wnt antagonist, indicating that it was due to binding of 
Wnt3a to its receptor. The hypothesis that the failure of Wnt3a protein to support LSK 
cells in a serum-free context was due to its very short half-life in these conditions was 
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explored, by developing a lipid-stabilized Wnt3a formulation able to provide a sustained 
Wnt signal. However, lipid-stabilized Wnt3a protein induced a similar reduction in the 
number of LSK cells, as did GSK3β inhibition, strongly suggesting that the effect was 
due to activation of the canonical Wnt pathway. Finally, it was investigated whether the 
induction of apoptosis by Wnt signals caused the loss of LSK cells. However, no evidence 
that Wnt signals induced apoptosis was found. Moreover, a transgenic mouse model in 
which apoptosis can be inhibited by the inducible expression of BCL2 was developed. 
While on its own this greatly supported the expansion of LSK cells, it did not prevent their 
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figure 4. The negative effect of Wnt signals on LSK cell number is not reversed by BCL2 overexpression. 
(A) Western blotting for F AG in Lin- cells from TRE-BCL2 mice cultured for one day with doxycycline. (B-
D) LSK CD48- cells from TRE-BCL2 mice were cultured with and without liposomal Wnt3a and doxycycline 
treatment for 10 days. The graphs display fold change of the total nucleated cells (B), LSK CD48- (C) and LSK 
CD48-CD150+CD34low cells (D) normalized to control. (Error bars indicate S.D.) (n=3). Statistical significance 
was determined by a two-tail t-test. (*p<0.05, ** p<0.01 and 0.001).
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loss in response to Wnt signals. Since the loss of LSK cells in response to Wnt signals was 
not mediated by apoptosis, the most likely explanation would be that Wnt signals induce 
differentiation of the cells. 
A number of studies indicate an important role for Wnt ligands in the maintenance/
expansion of HSPC in vitro [13,14]. Willert et al. and Reya et al. report that Wnt signaling 
activation by either purified Wnt3a protein or a constitutively active form of β-catenin 
in vitro induced expansion of mouse BCL2-overexpressing HSCs [13,14]. In contrast, 
Nemeth et al. observed that activation of Wnt signaling by purified Wnt3a proteins in-
duced a decrease in the number of wild-type mouse HSCs during culture in serum-free 
medium [17]. These studies did not account for the rapid loss of Wnt protein activity 
that occurs in the absence of serum [21]. In the present study, it is shown that lipid-
stabilized Wnt3a protein, which retains activity for more than 24 hours in the absence of 
serum, also induced loss of mouse LSK cells. Several in vivo studies indicated increased 
apoptosis of HSC by activated Wnt signaling, suggesting the need for additional survival 
signals [19,20]. This could explain the observations of Reya et al. and Willert et al. as they 
used HSC carrying a constitutively expressed BCL2 transgene [13,14]. In our stroma- and 
serum-free culture system however, the level of apoptotic cells did not respond to Wnt 
agonists. Moreover, induction of the BCL2 anti-apoptotic protein could not rescue the 
negative impact of Wnt signals on LSK cells. Although the different outcomes of our stud-
ies and the ones indicating increased numbers of HSC upon Wnt3a treatment [13,14] 
might still be attributed to the differences in the culture systems, the latter studies lack 
direct comparisons to control conditions: while HSCs cultured with Wnt3a protein were 
shown to repopulate recipient mice, the repopulation efficiency in the absence of Wnt3a 
protein was not reported. 
A tripartite balance of proliferation, apoptosis and differentiation is of vital importance 
to maintain functional HSC in vivo. Skewing the balance towards proliferation to achieve 
ex vivo expansion of functional HSC, therefore, requires inhibition of both apoptosis and 
differentiation. Since our data indicates that Wnt3a has no apparent effect on the total 
cell proliferation and that the Wnt-mediated loss of LSK cells is not mediated by apopto-
sis, the most likely explanation would be that Wnt signals induce differentiation of the 
LSK cells. Indeed, a small increase in the number of differentiated cells in the presence of 
Wnt signaling agonists was observed (figure 1E). 
Luis and colleagues considered the dosage of canonical Wnt signaling on HSCs in vivo, 
using a series of mutations in APC to constitutively activate the Wnt pathway at a range 
of intensities [28]. This showed that low level Wnt activation resulted in enhanced HSC 
function, while high level constitutive activation impaired repopulation capacity. More-
over, two other studies report that in vivo constitutive activation of Wnt signaling blocks 
differentiation of HSC and causes loss of repopulation capacity [15,16]. In the current 
setting however, using transient Wnt3a activation, a block in differentiation of LSK cells 
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which would have caused their numbers to increase was not observed. Therefore, it is 
unlikely that the negative effect on the number of LSK cells was due to too high levels of 
Wnt activation in our in vitro culture system. 
Collectively, this study shows that Wnt signaling induced by Wnt3a protein reduces the 
expansion of mouse LSK cells in serum-free expansion cultures by apparently promoting 
their differentiation without affecting their survival. Future studies may address whether 
additional differentiation-blocking signals may promote HSC expansion. 
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aBStraCt
Ex vivo expansion of hematopoietic stem and progenitor cells (HSPC) is a promising 
approach to improve insufficient engraftment after umbilical cord blood stem cell 
transplantation. Although culturing HSPC with hematopoietic cytokines results in robust 
proliferation, it is accompanied with extensive differentiation and loss of self-renewal 
capacity. Wingless-related integration site (Wnt) signaling has been implicated in regu-
lating HSPC fate decisions in vivo and in promoting HSPC self-renewal by inhibition of 
differentiation, but the effects of Wnt on the ex vivo expansion of HSPC are controversial. 
Here, we demonstrate that exogenous Wnt3a protein suppresses rather than promotes 
the expansion of UCB-derived CD34+ cells in serum free expansion cultures. The reduced 
expansion was also observed in cultures initiated with Lin-CD34+CD38lowCD45RA-CD90+ 
cells which are highly enriched in HSC and was also observed in response to activation 
of beta-catenin signaling by GSK3beta inhibition. The presence of Wnt3a protein during 
the culture reduced the frequency of multilineage CFU-GEMM and the long-term re-
population ability of the expanded HSPC. These data suggest that Wnt signaling reduces 
expansion of human HSPC in growth factor-driven expansion cultures by promoting 
differentiation of HSPC. 
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IntroDUCtIon
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an important part of 
treatment for patients suffering from hematological disorders, including leukemia, my-
elodysplastic syndromes, and aplastic anemia. However, many patients lack a suitable 
sibling or human leucocyte antigen (HLA) matched unrelated donor (MUD). Because of 
its rapid availability and less stringent matching criteria[1], umbilical cord blood (UCB) 
is an important alternative source for hematopoietic stem and progenitor cells (HSPC). 
However, UCB-derived HSPC significantly differ from bone marrow- and peripheral 
blood-derived HSPC quantitatively and qualitatively. UCB grafts contain a relatively low 
number of HSPC which are relatively more primitive, resulting in impaired engraftment 
and a delayed hematopoietic recovery [1-5], during which patients are at increased risk 
for severe complications, including infections and bleeding. Several approaches have 
been pursued to improve engraftment after UCB transplantation, including the ex vivo 
expansion of HSPC.
HSC are defined by their self-renewal capacity and the ability to generate all different 
hematopoietic lineages. Although in vivo studies demonstrated that HSPC expand after 
transplantation [6], robust ex vivo expansion of long-term repopulating HSC remains a 
challenge. Culturing HSPC with different combinations of hematopoietic cytokines such 
as stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), Thrombopoietin 
(TPO) and granulocyte-macrophage colony-stimulating factor (GM –CSF) resulted in mas-
sive expansion of committed HPC which is accompanied by a loss or at best maintenance 
of primitive HSC with long-term repopulation ability [7-11]. Additional signals are needed 
to support the expansion of primitive HSC in ex vivo culture systems. Several novel factors, 
such as the immobilized Notch-ligand Delta1, copper chelator tetra-ethylenepentamine 
(TEPA) and signals derived from mesenchymal stromal cells, were identified that may 
affect self-renewal of HSC and inhibit differentiation, thereby having the potential to 
improve ex vivo expansion protocols [12-14]. In addition, numerous promising factors 
have been tested in a pre-clinical setting, including developmental regulators such as 
fibroblast growth factor signaling, insulin-like growth factor, Angiopoietin-like proteins 
and Pleiotrophin and chemical modulators like all-trans retinoic acid, stemregenin1 and 
prostaglandin E2 (reviewed by Walasek et al. [15]).
The Wingless-related integration site (Wnt)/beta-catenin signaling pathway regulates 
cell fate decisions in many developmental processes in embryo and adult. Stimulation of 
cells with Wnt signaling proteins induces the stabilization and accumulation of the signal 
transducer protein beta-catenin, which then localizes into the nucleus where it regulates 
target gene expression (reviewed by Clevers et al. [16]). When combined with other 
growth factors, Wnt proteins can promote self-renewal in several types of stem cells, such 
as mammary, intestinal and embryonic stem cells [17-20]. Several studies, using different 
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approaches to inhibit the Wnt signaling pathway, showed that Wnt signaling is pivotal 
for normal HSC function in mouse [21-23]. In addition, some reports show that treatment 
with recombinant Wnt3a protein or overexpression of activated beta-catenin enhances 
the self-renewal capacity of mouse HSC ex vivo [24-26]. These studies offer hope that Wnt 
signals may be of use in the expansion of human UCB-derived HSPC. However, other 
studies show that constitutive activation of beta-catenin blocks multilineage differentia-
tion [27] and that active beta-catenin induces apoptosis in HSPC [28, 29]. 
In this study we investigate the effect of Wnt signals on growth factor-driven ex vivo 
expansion of human HSPC. We show that Wnt3a signaling reduces growth factor driven 
expansion of human HSPC by promoting differentiation. 
matErIaL anD mEtHoDS
Cord blood processing, CD34+ cell selection and HSC sorting
Umbilical cord blood was collected in several hospitals using Stemcare/CB collect blood 
bag system (Fresenius Kabi Norge AS) containing citrate phosphate dextrose (CPD) as an 
anticoagulant. Approval for collection was obtained from the Medical Ethical Committee 
of the Erasmus University Medical Centre (MEC-2009-410) and written informed consent 
from the mother was obtained prior to donation of the cord blood. Within 48 hours after 
collection, mononuclear cells were isolated using ficoll (Lymphoprep, Fresenius Kabi 
Norge AS). CD34+ cells were isolated with double positive immunomagnetic selection 
using Magnetic Activated Cell Sorting (MACS) technology according instructions of the 
manufacturer (Miltenyi Biotech GmBH, Bergisch Gladbach, Germany). MACS-selected 
CD34+ cells were either used directly in experiments or stained with anti-Lin-FITC, 
anti-CD38-PerCP-Cy5.5, anti-CD90-PE (all from eBioscience, Vienna, Austria), anti-CD34-
PE-Cy7, anti-CD45RA-APC-H7 (both from BD Biosciences, San Jose, CA, USA) and DAPI 
(Sigma-Aldrich, St Louis, MO, USA) after which viable DAPI-Lin-CD34+CD38lowCD45RAl
owCD90+ cells, highly enriched for hematopoietic stem cells (HSC)[30], were sorted using 
BD FACSAria Cell Sorting System (BD Biosciences, San Jose, CA, USA).
Expansion cultures 
Selected CD34+ cells and sorted DAPI-Lin-CD34+CD38lowCD45RAlowCD90+ cells were 
cultured in serum free Glycostem Basic Growth Medium (GBGM, Glycostem, Oss, The 
Netherlands) or StemSpan Serum-Free Expansion Medium (SFEM, Stemcell Technologies, 
Grenoble, France) supplemented with 20 μg/ml low molecular weight heparin (Abbott, 
Wiesbaden, Germany) and the early acting growth factors SCF (50 ng/ml, Cellgenix, 
Freiburg, Germany), Flt3L (50 ng/ml, Cellgenix, Freiburg, Germany) and TPO (50 ng/ml, 
Cellgenix, Freiburg, Germany) (from now on referred to as ‘SFT medium’) with or without 
 Wnt3a reduces growth-factor driven expansion of human HSPC 81
4
the addition of 250 ng/ml purified Wnt3a unless indicated otherwise. Cells were cultured 
in a volume of 1 ml in 24-well plate at a concentration of 105/ml at 37 °C in 5% CO2. Every 
2 to 3 days, wells were split or half of the medium was refreshed. In some experiments, we 
used GSK3β inhibitor CH99021 (1 µM, Stemgent, Cambridge, MA, USA) as an alternative 
activator of the canonical Wnt pathway. Frizzled8CRD (Fr8CRD, which blocks the binding 
of Wnt3a to its receptor) was produced as described[31] and used at a concentration of 15 
µg/ml. Wnt3a was combined in some experiments with the Aryl hydrocarbon Receptor 
(AhR) antagonist StemRegenin1 (SR1, 1 µM, Cellagen Technology, San Diego, CA, USA).
Purification of Wnt3a and preparation of liposomal Wnt3a
Wnt3a-conditioned medium was collected from Drosophila S2 cells grown in suspen-
sion culture. Wnt3a was further purified using Blue Sepharose affinity and gel filtration 
chromatography as described [24]. Liposomes containing DMPC (1,2-dimyristoyl-sn-
glycero-3-phosphocholine), DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol) 
(both Lipoid AG) and Cholesterol (Sigma-Aldrich, St Louis, MO, USA) at a 10:1:10 molar 
ratio were prepared by extrusion method. Purified Wnt3a was mixed with liposomes at 
a 1:7.5 ratio to achieve a total concentration of 7-10 µg/ml of Wnt3a. After mixing, the 
Wnt liposomes were incubated for at least one hour on the roller coaster at 4 °C. Next, 
CHAPS was removed from the Wnt liposomes by dialysis at least three times in PBS 1 hour 
each, using dialysis membrane with molecular weight cut-off of 10 kDa at 4 °C. The Wnt 
liposomes were stored at 4 °C. Activity of purified Wnt3a protein and liposomal Wnt3a 
was determined in a luciferase reporter assay (see below).
Luciferase reporter assay
Mouse LSL cells, which express luciferase in response to TCF promoter binding, were rou-
tinely cultured at 37 °C and 5% CO2 in culture medium composed of DMEM (Invitrogen, 
Life Technologies, Bleiswijk, The Netherlands), 10% FCS, and 1% Penicillin/Streptomycin. 
For the activity assays, Wnt3a reagents at a concentration of 250 ng/ml were incubated 
in culture medium without FCS for various periods of time at 37 oC in U-bottom 96-well 
plates. These media were then transferred to F-bottom 96-well plates containing LSL 
cells, which were plated the day before at a density of 25,000 cells/well. After overnight 
incubation with the indicated Wnt reagents, relative luciferase units were measured with 
Glomax multiplate reader.
flowcytometry
At serial time points in culture, absolute numbers of viable CD34+ cells were 
determined by a single platform flowcytometric assay, using anti-CD45-FITC, anti-
CD34-PE, DAPI and a calibrated number of Stem-Count Fluorospheres (all from Beck-
man Coulter, Fullerton, CA, USA). Within the CD34+ population, the frequency of 
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DAPI-Lin-CD34+CD38lowCD45RAlowCD90+ cells was determined using the antibody panel 
as described above for the sorting of these cells. Absolute numbers of DAPI-Lin-CD34+
CD38lowCD45RAlowCD90+ cells were determined by multiplying the absolute number of 
CD34+ cells obtained in the single platform analysis by the percentage of DAPI-Lin-CD34
+CD38lowCD45RAlowCD90+ cells within the CD34+ cell population. Flowcytometric analysis 
was performed using a BD FACSCanto (BD Biosciences, San Jose, CA, USA) and data was 
analyzed using FlowJo software (Tree Star Inc, Ashland, OR, USA). 
transplantation of human hematopoietic cells into noD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (nSG) mice
This study was carried out in accordance to the Dutch law on Animal Welfare and Ex-
periments. The protocol was approved by the Committee on the Ethics of Animal Experi-
ments of the Erasmus University Medical Centre Rotterdam, The Netherlands. Intrabone 
transplantations were performed under isoflurane anesthesia. All animals were housed 
in groups in individually ventilated cages. Food and water were available ad libitum. NSG 
mice were sublethally irradiated (3 Gy) and subsequently transplanted with the progeny 
generated from 1,00E+05 UCB-derived CD34+ cells cultured in our SFT medium, with 
or without the addition of 250 ng/ml Wnt3a for 7 days. Each group contained 5 mice. 
Engraftment was assessed every 2 weeks starting at 3 weeks after transplantation by 
flowcytometric analysis of the peripheral blood, using a flowcytometric panel including 
anti-mouseCD45-eFluor450, (eBioscience, Vienna, Austria) and anti-humanCD45-APC-
Cy7 (BioLegend, London, UK). Mice were considered engrafted when human CD45 levels 
were higher than 0.1%. At 17 weeks after transplantation, the mice were sacrificed by 
cervical dislocation and cells from femurs were analysed. 
← figure 1. Exogenous Wnt3a reduces growth factor-driven expansion of CD34+ cells. UCB-derived CD34+ 
cells were cultured in serum free SFT medium with or without the addition of Wnt3a. Cells were analyzed 
using flow cytometry at 7 and 14 days of culture. Shown are (A) the total nucleated cell expansion com-
pared to input (n=8), (B) the frequency of CD34+ cells within the TNC population during culture (n=8), (C) 
expression of CD45 and CD34 after 14 days of culture in SFT with (lower panel) or without (upper panel) 
Wnt3a (representative experiment out of 8), (D) the expansion of CD34+ cells compared to input (n=8) and 
(E) the frequency of cells expressing lineage markers after 7 and 14 days of culture (n=6). (F) Frequency of 
CFU-GEMM, BFU-E and CFU-GM in 250 CD34+ cells cultured for 2 weeks in SFT or SFT+Wnt3a (n=2, 3 dishes 
per experiment). (G) CD34+ cell expansion compared to SFT medium after 14 days of culture with different 
dosages of Wnt3a (n=2). (H) Levels of human chimerism at several time points after transplantation with 
the progeny of 105 CD34+ cells cultured for 7 days in SFT or SFT+Wnt3a medium (n=5 mice per group). (I) 
Levels of human chimerism in bone marrow 17 weeks after transplantation with the progeny of 105 CD34+ 
cells cultured for 7 days in SFT or SFT+Wnt3a medium (n=5 mice per group). * p<0.05, ** p<0.01, *** p<0.001
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Wnt3a reduces growth factor-driven expansion of UCB derived CD34+ cells 
To assess whether Wnt signals affect expansion of human HSPC in culture, UCB-derived 
CD34+ cells were cultured in serum-free medium supplemented with SCF, Flt3L and 
TPO (SFT medium) with or without purified Wnt3a protein. After 14 days, no significant 
change in total nucleated cell expansion was observed in response to Wnt3a protein (fig-
ure 1a, p=0.74). However, Wnt3a accelerated the decline in the frequency of CD34+ cells 
that was observed during culture (figure 1B, p<0.001 for both 7 and 14 days of culture 
and figure 1C), resulting in a significantly reduced expansion of CD34+ cells after 2 weeks 
of culture (figure 1D). In addition, we observed a higher frequency of cells expressing 
lineage markers after 14 days of culture in the presence of Wnt3a protein compared with 
SFT medium only (figure 1E, p<0.05). Next, we assessed the functionality of the cultured 
CD34+ cells by performing colony forming unit (CFU) assays. The presence of Wnt3a dur-
ing culture reduced the frequency of multi-lineage CFU-GEMM (granulocyte, erythrocyte, 
monocyte, megakaryocyte), while no effect was seen in the frequency of lineage com-
mitted BFU-E (Burst Forming Unit-Erythrocyte) and CFU-GM (granulocyte, macrophage) 
(figure 1f). The reduction in frequency of most immature CFU and the higher frequency 
of lineage positive cells suggest that exogenous Wnt3a protein promotes rather than 
inhibits growth factor-driven differentiation of CD34+ cells in expansion cultures. Next, 
we evaluated the dose-response relationship of Wnt signaling on the in vitro expansion 
of CD34+ cells. At the lowest concentration of 25 ng/ml, Wnt3a had no effect on the 
expansion of CD34+ cells relative to control SFT cultures (figure 1G). On the other hand, 
the highest concentration of 2500 ng/ml Wnt3a protein resulted in a decline of total cell 
number (not shown) and a complete loss of CD34+ cells (figure 1G). The effect of Wnt3a 
on the repopulating ability of the expanded CD34+ cells was assessed by transplantation 
of the expanded population of cells into sublethally irradiated NSG mice after 7 days of 
culture. All transplanted mice showed engraftment (defined as >0.1% human CD45+ cells 
in the peripheral blood at 7 weeks after transplantation). However, the kinetics of human 
chimerism development in peripheral blood appeared delayed when cells were cultured 
in the presence of Wnt3a (figure 1H). Lower levels of human chimerism were also ob-
served in the bone marrow of mice 17 weeks after transplantation of cells cultured in the 
presence of Wnt3a (figure 1I,  36.9% versus 10.1% respectively, p<0.05). This indicates 
that Wnt3a protein reduces the long-term repopulation ability of cultured CD34+ cells. 
Wnt3a reduces growth factor-driven expansion of HSC
CD34+ cells constitute a heterogeneous population, including only a minor fraction of 
the most immature HSC subset. Wnt3a may act differentially on primitive HSC and CD34+ 
cells with committed progenitor properties A putative differentiation-inhibiting effect of 
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Wnt3a on HSC may be obscured by a differentiation-inducing effect on the large popula-
tion of committed progenitor cells in culture. To study the effects of Wnt3a on the most 
immature HSC subset, we expanded Lin-CD34+CD38low CD45RAlowCD90+ cells, highly 
enriched for HSC [30] in the presence or absence of Wnt3a. A similar effect of Wnt3a was 
observed on the expansion of the sorted Lin-CD34+CD38lowCD45RAlowCD90+ cells. A ro-
bust total nucleated cell expansion, approximately 100-fold, was observed regardless of 
the presence of Wnt3a (figure 2a). However, Wnt3a again accelerated the decline in the 
frequency of CD34+ cells (figure 2B, p<0.05 and p<0.01 for 7 and 14 days of culture, re-
spectively) and led to a significantly reduced expansion of CD34+ cells (figure 2C, p<0.01). 
Moreover, Wnt3a strongly reduced the number of Lin-D34+CD38lowCD45RAlowCD90+ cells 
obtained after culture, while these cells were maintained in the absence of Wnt3a (figure 
2D). These data suggest that Wnt3a inhibits the expansion of both multilineage commit-
ted progenitors and HSC.
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figure 2. Wnt3a reduces growth factor-driven expansion of HSC. UCB-derived DAPI-Lin-CD34+CD38lowCD4
5RAlowCD90+ cells were sorted out of CD34-selected cells and were cultured in SFT medium with or without 
Wnt3a. Flowcytometric analysis was performed at day 7 and 14. Depicted are (A) the total nucleated cell 
expansion in SFT and SFT+Wnt3a medium at 7 and 14 days of culture (n=4), (B) the CD34+ cell frequency 
during culture (n=4), (C) the fold expansion of CD34+ cells at day 7 and 14 of culture (n=4) and (D) the to-
tal number of DAPI-Lin-CD34+CD38lowCD45RAlowCD90+ cells at input and after 14 days of culture in SFT or 
SFT+Wnt3a medium (n=4). * p<0.05, ** p<0.01
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Prolongation of Wnt3a activity does not result in increased expansion of CD34+ 
cells.
Purified Wnt3a has been shown to have a half-life that is considerably shorter than 24 
hours upon dilution in serum free media [32]. Thus, daily addition of Wnt3a protein to cell 
cultures would result in intermittent rather than continuous activation of the pathway. 
A possible explanation for our observations of reduced HSPC expansion in response to 
daily Wnt3a addition is that these intermittent pulses are unable to inhibit HSC differen-
tiation. At the same time, Wnt signals may promote the differentiation of more mature 
CD34+ cells, leading to an overall reduction of HSPC. The stability of Wnt3a protein can 
be increased by association with liposomes [33, 34], and we therefore tested whether 
such stabilized Wnt ligands were able to prevent the decline in HSPC that we observed in 
response to regular Wnt3a protein. We compared the stability of purified Wnt3a protein 
and of Wnt3a protein associated with liposomes by incubating the proteins in serum 
free medium at 37°C and assessing the remaining Wnt-activity at several time points by 
a luciferase reporter assay. Whereas purified Wnt3a lost its activity within 8 hours, liposo-
mal Wnt3a retained significant activity after 24 hours (figure 3a). Despite this increased 
stability however, liposomal Wnt3a induced a 3.3-fold decline of CD34+ cell expansion 
(figure 3B), similar to purified Wnt3a. In conclusion, prolongation of Wnt3a activity does 
not result in increased expansion of CD34+ cells.
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figure 3. Liposomal Wnt3a reduces expansion of CD34+ cells. (A) Purified Wnt3a and liposomal Wnt3a were 
incubated for 0, 8, and 24 hours at 37oC in cell culture media, and transferred to LSL cells. Remaining Wnt ac-
tivity was assayed by luminescence measurements. Activity plot displays average increase of luminescence 
over incubation time relative to background (n=10). (B) CD34+ cell expansion in SFT medium with or without 
liposomal Wnt3a after 7 days of culture (n=1). 
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Enhanced differentiation of CD34+ cells is dependent on activation of the 
canonical Wnt pathway
Binding of Wnt3a to its receptor can be blocked with the Wnt antagonist Fz8CRD, a 
soluble domain of the Wnt receptor that sequesters Wnt proteins [31]. To demonstrate 
that the observed effects of Wnt3a were indeed dependent on binding to its receptor 
on HSPC, CD34+ cells were cultured with or without Wnt3a and/or Fz8CRD. The negative 
effect of exogenous Wnt3a on the expansion of CD34+ cells and the decline in frequency 
of CD34+ cells during culture was reversed by the addition of Fz8CRD (figure 4a+B). An 
alternative way to activate the canonical Wnt pathway is by inhibiting glycogen synthase 
kinase 3β (GSK3β) which results in stabilization of the cytoplasmic β-catenin pool and 
subsequent transfer to the nucleus. To confirm that activation of the canonical Wnt 
pathway by exogenous Wnt3a underlies the inhibitory effects of Wnt3a on the expansion 
of CD34+ cells we used a synthetic GSK3β-inhibitor (CHIR99021). Addition of CHIR99021 
supressed the expansion of CD34+ cells (figure 4C) to a similar extend as purified Wnt3a 
protein (figure 1D). Collectively these data show that the reduced expansion of CD34+ 
cells is due to binding of Wnt3a protein to its receptor on HSPC and subsequent activa-
tion of canonical Wnt pathway.
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figure 4. Wnt3a-mediated inhibition of 
HSPC expansion is due to activation of the 
canonical Wnt3a pathway. (A) Expansion 
of CD34+ cells after 7 and 14 days of cul-
ture in SFT, SFT+Wnt3a, SFT+Fr8CRD and 
SFT+Wnt3a+Fr8CRD (n=2). (B) CD34+ cell 
frequency within the TNC population during 
these cultures (n=2). (C) CD34+ cell expan-
sion in SFT and SFT+CHIR99021 after 7 and 
14 days of culture (n=2). 
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Wnt3a inhibits expansion of CD34+ cells driven by the aryl hydrocarbon 
receptor antagonist Stemregenin1
The Aryl hydrocarbon Receptor (AhR) is implicated to play a role in the proliferation and 
differentiation of HSPC. AhR-KO mice have increased number of LSK cells in the bone 
marrow and these LSK are hyperproliferative [35] and hematopoietic progenitors of 
donor mice treated with the AhR agonist TCDD show impaired competitive engraftment 
[36]. In addition, the AhR antagonist StemRegenin1 (SR1) has been shown to effectively 
enhance the expansion of human HSPC [37, 38]. SR1 was included in our cultures as a 
positive control for enhancing growth factor-driven CD34+ cell expansion and in addi-
tion, to evaluate putative cooperative effects of the Wnt and AhR signalling pathways. 
Expectedly, SR1 indeed promoted CD34+ cell expansion to a similar extent as reported 
before [37], indicating the suitability of our SFT medium, while Wnt3a reduced CD34+ cell 
expansion (figure 5). Addition of both Wnt3a and SR1 resulted in an increased expan-
sion compared to Wnt alone, but a reduced expansion compared to SR1 alone (figure 
5, p<0.01 and p<0.05 respectively), showing that even in the presence of AhR pathway 
inhibition, Wnt3a suppresses the expansion of CD34+ cells. 
DISCUSSIon
The effects of Wnt signaling on human HSPC proliferation, differentiation and survival 
are still poorly understood. In this study, we show that Wnt3a protein suppresses rather 
than promotes growth factor-driven expansion of UCB-derived CD34+ cells in serum-free 
expansion cultures. Wnt3a induced accelerated differentiation of both HSC and multi-
potent progenitors, resulting in the production of more differentiated cells. The reduced 
expansion of human HSPC, appeared to be dependent on activation of the canonical Wnt 
signaling pathway upon binding of Wnt3a to its receptor at the cell surface. 
Our findings compare well to those by Nemeth et al., who observed a decrease in 
expansion of mouse LSKI (Lineage negative, Sca-1+, c-kit+, IL-7Rα-) cells after culture in 
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figure 5. Wnt3a inhibits SR1-enhanced CD34+ cell 
expansion. UCB-derived CD34+ HSPC were cultured 
for 14 days in SFT or SFTSR1 medium with or with-
out the addition of Wnt3a. Flowcytometric analysis 
was performed at day 14. Depicted is the CD34+ cell 
expansion after 14 days of culture (n=5). * p<0.05, 
** p<0.01
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serum-free medium containing SCF, Flt3L and Wnt3a compared to culture conditions 
with growth factors only. In addition, they showed no enhanced repopulation capacity of 
Wnt3a-cultured LSKI cells compared to control-cultured cells[25]. Earlier, several studies 
showed that overexpression of beta-catenin in HSC resulted in a functional defect of 
hematopoiesis and loss of repopulating activity [27, 39]. These results are in line with 
our observations of enhanced differentiation of HSPC upon stimulation of the canonical 
Wnt pathway. However, Malhotra et al. reported that overexpression of activated beta-
catenin may expand the pool of HSC, both phenotypically and functionally in long term 
cultures [40] . In addition, overexpression of the Wnt inhibitor Dickkopf-related protein 1 
(Dkk1) was shown to significantly impair the self-renewal capacity of adult HSC[21, 22]. 
How to reconcile these contradictory results? Although at first sight contradictory, the 
many differences in types of cultures, cells growth factors added may explain some of 
the observed differences. 
Willert et al. and Reya et al. earlier showed that purified Wnt3a induced proliferation, 
while inhibiting differentiation of HSC in growth-factor based cultures of mouse LSKT 
(Lineage negative, Sca-1+, c-kit+, Thy-1.1lo) [24, 26]. However, they used cells derived from 
BCL2 transgenic mice. The BCL2 anti-apoptotic signal in HSPC may counteract possible 
apoptotic signals induced by Wnt3a signaling. Moreover, they used serum, which may 
supply additional signals that allow canonical Wnt signaling to exert a differentiation 
inhibitory effect or a more pronounced effect on self-renewal. It would compare well 
to several other studies [28, 41], which show that the presence of additional factors is 
required to balance the activated Wnt pathway. Trowbridge et al. showed enhanced 
long-term repopulation after treating mice with a GSK3beta inhibitor, which regulates 
the canonical Wnt pathway and several other pathways as well[41]. Perry et al. showed 
that the combination of a PTEN deletion and activation of beta-catenin results in en-
hanced self-renewal and expansion of HSC [28]. Another important pathway involved 
in HSC self-renewal and inhibition of differentiation is the pathway initiated by the aryl 
hydrocarbon Receptor (AhR). It is now well established that AhR-KO mice have increased 
number of LSK cells in the bone marrow and these LSK are hyperproliferative [35], while 
hematopoietic progenitors of donor mice treated with AhR agonist TCDD show impaired 
competitive engraftment[36]. In addition, the AhR antagonist StemRegenin1 (SR1) 
promotes expansion of human hematopoietic stem cells [37, 38]. We evaluated whether 
combined inhibition of the AhR pathway and activation of the Wnt pathway would result 
in enhanced expansion of HSPC. However, Wnt signaling also reduced the expansion of 
CD34+ HSPC in the presence of the aryl hydrocarbon receptor antagonist SR1. Another 
important factor that may affect the response of HSPC to Wnt signaling is the level of 
oxygenation. Expansion cultures are usually performed at normoxic levels. However, it is 
well established that the response of HSPC to hematopoietic cytokines is different under 
normoxic and hypoxic conditions, which mimics the in situ bone marrow environment 
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[42]. The effect of stimulation of the canonical Wnt pathway on HSC expansion may be 
modulated by the level of oxygenation, which was already shown for the effect of the 
Wnt4-dependent pathway on the functional capacities of mesenchymal stem cells [43]. 
 Apart from other cytokines and pathways involved, the dose and timing of Wnt activa-
tion might play an important role. Our data show that both intermittent pulses of Wnt3a 
and more continuous exposure to Wnt3a have a similar negative effect on the expansion 
of CD34+ cells in serum-free expansion cultures. Luis et al reported that Wnts are tightly 
regulated in a dose-dependent fashion [44], which may affect their biological activity. 
Thereby, varying results (exerted via the canonical Wnt pathway) may result from differ-
ent levels of Wnt signaling, such as can be achieved in different experimental conditions. 
The optimal level of Wnt signaling for HSC was suggested to be only slightly increased 
over normal physiological values, while higher levels resulted in impaired engraftment 
potential of HSC fashion [44]. 
Collectively, we show that exogenous Wnt3a proteins reduces the expansion of human 
HSPC in serum-free growth factor-driven HSPC expansion cultures by promoting their 
differentiation without apparently affecting their proliferation or survival. It cannot be 
excluded that additional signals, such as the induction of a hypoxic cellular response, 
are needed for a possible positive effect of canonical Wnt signaling on HSPC expansion. 
Future studies may address the fragile balance between canonical Wnt signaling and 
other pathways to determine whether combined activation of Wnt signaling and other 
signaling pathways may promote human HSPC expansion.
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aBStraCt
The slow hematopoietic recovery following umbilical cord blood stem cell transplanta-
tion (UCB-SCT) is considered to be primarily due to the relatively low number of hema-
topoietic stem and progenitor cells (HSPC) in the graft. Aryl hydrocarbon receptor (AhR) 
antagonists, such as StemRegenin1 (SR1), have been shown to promote ex vivo expansion 
of UCB-derived CD34+ cells. Here, the effects of SR1 on the expansion of the most primi-
tive subset of UCB-derived CD34+ cells were evaluated. It is shown that the combination 
of SR1 and the hematopoietic growth factors Stem Cell Factor (SCF), FMS-like tyrosine 
kinase 3 ligand (Flt3L) and Thrombopoietin (TPO) resulted in a 27-fold expansion of the 
phenotypically most primitive CD34+ cell subset (i.e. Lin-CD34+CD38lowCD45RAlowCD90+ 
cells) following serum-free culture of 2 weeks. That combination also resulted in a 105-fold 
expansion of the functionally most primitive subset as assessed by the long-term culture 
initiating cell (LTC-IC) assay. Transplantation of SR1-expanded cells into sublethally irradi-
ated NSG mice resulted in robust long-term multilineage human engraftment in blood 
and bone marrow, although mice transplanted with expanded cells, with or without 
SR1, developed lower levels of human chimerism as compared to mice transplanted 
with non-expanded cells. The number of CD34+C10+ lymphoid progenitors was strongly 
reduced in the expanded population of cells, cultured with or without SR1, which might 
account for the lower level of human B cell chimerism, being the primary endpoint in the 
B cell-prone NSG mouse model. In conclusion, the combination of proliferation induc-
ing cytokines combined with the differentiation inhibiting factor SR1 resulted in strong 
augmentation of phenotypic HSC with long-term repopulating capacity in vivo.
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IntroDUCtIon
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an important treatment 
modality in many patients suffering from severe hematological disease. Umbilical cord 
blood (UCB) has become an attractive alternative source of hematopoietic stem and 
progenitor cells (HSPC) for patients lacking a suitable HLA-matched related or unrelated 
donor. Recently, interest in haplo-identical allo-SCT as an alternative source of stem 
cells has met increasing attention (1, 2). As compared to haplo-identical allo-SCT, UCB 
transplantation (UCBT) is associated with prolonged hematopoietic recovery due to 
the relatively low number of hematopoietic stem and progenitor cells (HSPC) present 
in the graft (3-5). The retarded recovery may explain a somewhat higher non relapse 
mortality (NRM) rate (6) upon UCBT as compared to matched unrelated donor (MUD) 
transplantation. Given the relatively low number of HSPC in UCB, several strategies 
were studied to expand the progenitor cells ex vivo prior to transplantation (7-16). Ex 
vivo expansion of HSPC was initially explored using hematopoietic cytokines, including 
stem cell factor (SCF), Fms-related tyrosine kinase 3 ligand (Flt3L), thrombopoietin (TPO) 
and granulocyte-macrophage colony-stimulating factor (GM –CSF) (7-10). While strong 
expansion of total cell numbers were observed, expansion appeared accompanied by 
rapid differentiation, and the most primitive subsets of HSC were hardly expanded or 
even exhausted (7-10). Therefore, in order to expand the true multipotent self-renewing 
HSC, expansion protocols were developed in which hematopoietic growth factors were 
combined other factors that might inhibit HSC differentiation. We earlier explored the 
inhibitory effect of Wingless-related integration site protein 3a (Wnt3a) in combina-
tion with hematopoietic cytokines, but were unable to demonstrate inhibition of dif-
ferentiation (17). Alternative factors explored included agents that may influence HSC 
fate decisions, such as the Notch ligand Delta1, nicotinamide and the copper chelator 
tetraethylenepentamine (TEPA) (18-20). The Aryl hydrocarbon Receptor (AhR) antagonist 
StemRegenin1 (SR1) combined with early acting hematopoietic cytokines was also 
explored based on the hypothesis that induction of proliferation accompanied by inhibi-
tion of differentiation might result in expansion of HSC (15). The AhR pathway is critically 
involved in in HSC self-renewal and inhibition of differentiation: AhR-KO mice have an 
increased number of hyperproliferative Lin-Sca+c-Kit+ cells (enriched for HSC) (21), while 
treatment of donor mice with AhR agonist TCDD resulted in impaired competitive en-
graftment (22). In vitro studies suggested that SR1 combined with SCF, Flt3L, TPO and 
IL-6 resulted in a 17,100-fold and 47-fold increase of CD34+ cells compared to input and 
control cultures supplemented with the cytokine cocktail but lacking SR1, respectively, 
after 5 weeks of culture (15). Subsequently in vivo studies showed that SR1-expanded 
HSPC were capable of hematopoietic reconstitution in both mice (15) and men (23) and 
neutrophil and platelet recovery were significantly shortened upon transplantation of 
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an SR1-expanded graft in a double UCBT (dUCBT) setting compared to unmanipulated 
dUCBT (23). In addition, UCB-HSPC cultured in the presence of an AhR antagonist re-
tained the potential to differentiate towards the T cell lineage(24), which is pivotal for 
full immune reconstitution post-transplantation (25). Recently, Gu et al. showed that in 
vitro culture of adult HSPC in the presence of an AhR antagonist maintained but failed to 
increase the number of in vivo engrafting cells (26). As a result, it was suggested that SR1 
does not affect the true long-term HSC, responsible for long-term multilineage engraft-
ment, but rather a population of cells with short-term repopulation potential (27, 28). 
However, all studies were performed with CD34+ HSPC, which comprise a heterogeneous 
population, including only a minor subset with the most immature HSC. Given these 
conflicting findings, we set out to study the effect of SR1 on the expansion of the most 
primitive Lin-CD34+CD38lowCD45RAlowCD90+ cells, which are highly enriched for HSC (29).
matErIaL anD mEtHoDS
Cord blood processing, CD34+ cell selection and cell sorting
Umbilical cord blood was collected in several hospitals using Stemcare/CB collect blood 
bag system (Fresenius Kabi Norge AS) containing citrate phosphate dextrose (CPD) as an 
anticoagulant. Approval for collection was obtained from the Medical Ethical Committee 
of the Erasmus University Medical Centre (MEC-2009-410) and written informed consent 
from the mother was obtained prior to donation of the cord blood. Within 48 hours after 
collection, mononuclear cells were isolated using ficoll (Lymphoprep, Fresenius Kabi 
Norge AS). CD34+ cells were isolated with double positive immunomagnetic selection 
using Magnetic Activated Cell Sorting (MACS) technology according to instructions of 
the manufacturer (Miltenyi Biotech GmBH, Bergisch Gladbach, Germany). MACS-selected 
CD34+ cells were either used directly in experiments or stained with anti-Lin-FITC, 
anti-CD38-PerCP-Cy5.5, anti-CD90-PE (all from eBioscience, Vienna, Austria), anti-CD34-
PE-Cy7, anti-CD45RA-APC-H7 (both from BD Biosciences, San Jose, CA, USA) and DAPI 
(Sigma-Aldrich, St Louis, MO, USA) after which viable DAPI-Lin-CD34+CD38lowCD45RAl
owCD90+ cells, highly enriched for hematopoietic stem cells (HSC)(29), were sorted using 
BD FACSAria Cell Sorting System (BD Biosciences, San Jose, CA, USA).
Expansion cultures 
Selected CD34+ cells and sorted DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells were 
cultured in serum free Glycostem Basic Growth Medium (GBGM, Glycostem, Oss, The 
Netherlands), StemSpan Serum-Free Expansion Medium (SFEM, Stemcell Technologies, 
Grenoble, France) or Serum-free Stem Cell Growth Medium (SCGM, CellGro, CellGenix, 
Freiburg, Germany). Culture media were supplemented with 20 μg/ml low molecular 
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weight heparin (Abbott, Wiesbaden, Germany) and the early acting growth factors SCF, 
Flt3L and TPO (50 ng/ml each, all from Cellgenix, Freiburg, Germany) (from now on re-
ferred to as ‘SFT medium’) with or without the addition of 1 µM StemRegenin1 (SR1, Cel-
lagen Technology, San Diego, CA, USA or Axon Medchem, Groningen, The Netherlands) 
unless indicated otherwise. Cells were cultured in a volume of 1 ml in a 24 well plate 
at a concentration of 105/ml at 37 °C in 5% CO2. Every 2 to 3 days, wells were split with 
addition of an equal volume of culture medium.
flow cytometry
At serial time points in culture, absolute numbers of viable CD34+ cells were determined 
by a single platform flow cytometric assay, using anti-CD45-FITC, anti-CD34-PE, DAPI and 
a calibrated number of Stem-Count Fluorospheres (all from Beckman Coulter, Fullerton, 
CA, USA). Within the CD34+ population, the frequency of DAPI-Lin-CD34+CD38lowCD45
RAlowCD90+-cells was determined using the antibody panel as described above for the 
sorting of these cells. Absolute numbers of DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells 
were determined by multiplying the absolute number of CD34+ cells obtained in the 
single platform analysis by the percentage of DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-
cells within the CD34+ cell population. 
For cell division tracking during culture, the CellTrace™ Violet Cell Proliferation Kit 
(Life Technologies, Eugene, OR, USA) was used. Prior to culture, selected and sorted cells 
were labeled using CellTrace™ Violet, according to instructions of the manufacturer. Flow 
cytometry was performed at day 5 of culture. Flow cytometric analysis was performed 
using a BD FACSCanto (BD Biosciences, San Jose, CA, USA) and data was analyzed using 
FlowJo software (Tree Star Inc, Ashland, OR, USA).
Long term culture-initiating cell (LtC-IC) assays
The LTC-IC assay was performed as described(30). In short, confluent MS-5 stromal layers 
in 96-well plates were overlaid with sorted subsets of (expanded) CD34+ cells in a limiting 
dilution set-up, with 3000 cells per well as the highest concentration and titrating down 
by 1/3, using 20 wells per condition. Cells were cultured for 5 weeks at 37 °C in 5% CO2 
in IMDM medium, containing 12% horse serum, 12% fetal calf serum, 2mM L-glutamine, 
100 U/ml penicillin and 100 U/ml streptomycin, with medium change every week. After 
5 weeks, the medium was removed and methylcellulose containing medium (Methocult 
GF H84434, Stemcell Technologies, Vancouver, BC, Canada) was added to each well. Upon 
another 14 days of culture, the percentage of wells containing a colony (=positive wells) 
was determined. The frequency of LTC-IC within each cell population was calculated us-
ing the number of negative wells per dilution and Poisson statistics. 
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transplantation of human hematopoietic cells into noD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (nSG) mice
NSG mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and 
housed under specific pathogen-free conditions in the Erasmus MC animal facility. The 
mice experiments were carried out in accordance to the Dutch law on Animal Welfare 
and Experiments. The protocol was approved by the Committee on the Ethics of Animal 
Experiments of the Erasmus University Medical Centre Rotterdam, The Netherlands. All 
animals were housed in groups in individually ventilated cages. Food and water were 
available ad libitum. All NSG mice were sublethally irradiated (2.5 – 3.5 Gy) and trans-
planted intravenously with the indicated number of CD34+ cells, the progeny thereof or 
sorted subsets of CD34+ cells. Engraftment was assessed by flow cytometric analysis of 
the peripheral blood, using a panel including anti-mouseCD45-eFluor450, (eBioscience, 
Vienna, Austria) and anti-humanCD45-APC-Cy7 (BioLegend, London, UK). For the assess-
ment of multilineage engraftment, peripheral blood and bone marrow cells were stained 
with anti-humanCD56-PE-Cy7, anti-humanCD33-PerCP-eFluor710, anti-humanCD3-APC 
and anti-humanCD19-PE (all from eBioscience, Vienna, Austria). Mice were considered 
engrafted when human CD45+ cell levels were higher than 0.1% in the bone marrow. The 
mice were sacrificed by cervical dislocation and cells from femurs were analyzed at the 
time points described in the results section.
Statistics
Paired or unpaired two-tailed t-tests were performed to test the differences between 
the different culture conditions, as appropriate. Differences were considered to be sta-
tistically significant is p < 0.05. Statistical tests were performed in GraphPad Prism 5.0 
(GraphdPad software, San Diego, CA, USA).
rESULtS
Serum-free cultures combining hematopoietic growth factors and StemRegenin1 result in 
expansion of the phenotypically most immature CD34+ cells that are enriched for LTC-IC
To confirm the effect of Stemregenin1 (SR1) on the expansion of HSPC in culture, puri-
fied UCB-derived CD34+ cells were cultured in serum-free medium supplemented with 
SCF, Flt3L and TPO (SFT medium), with or without the addition of SR1. No significant 
difference was observed in expansion of CD45+ cells after 14 days of culture in either SFT 
or SFT+SR1 medium (table 1, figure 1a, p=0.23). During expansion, the frequency of 
CD34+ cells gradually declined due to concomitant differentiation of the expanding cells. 
Addition of SR1 delayed the decline in frequency of CD34+ cells, resulting in a higher 
frequency of CD34+ cells at both 7 and 14 days compared to SFT medium alone (table 
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1, figure 1B, p<0.001 for both time points), suggesting inhibition of differentiation by 
SR1. The increased frequency of CD34+ cells led to an increased expansion of CD34+ cells 
after 1 and 2 weeks of culture (table 1, figure 1C, p=0.0083 and p=0.006 respectively). 
A 55-fold (SD ±44.46) expansion of CD34+ cells upon addition of SR1 after 2 weeks of 
culture was observed, compared to a 23-fold (SD ±20.78) expansion upon culture in SFT 
medium alone. These results are in line with the results reported by Boitano et al. (15).
CD34+ cells are a heterogeneous population, of which the most immature HSC are only 
a minor subset. Next, it was evaluated whether the expanded CD34+ cells still contained 
cells with the most immature phenotype, i.e. Lin-CD34+CD38lowCD45RAlowCD90+ cells (re-
ferred to as “CD34+CD90+ cells” hereafter), which are highly enriched for HSC (29). Before 
culture, CD34+CD90+ comprised 4.0% (SD ±2.1) of the CD34+ cell population (figure 1D). 
After 14 days of culture, the frequency of CD34+CD90+ cells within the CD34+ cell popu-
lation remained stable in both culture conditions (table 1, figure 1D,  p=0.38 for SFT; 
p=0.18 for SFT+SR1). The number of cells with the most immature phenotype expanded 
26.9-fold (SD ±9.6) in the presence of SR1 and 8.9-fold (SD ±9.5) in the absence of SR1 
(table 1, figure 1E, p=0.0003). 
During expansion, a population of CD45RA+CD90+ cells appeared within the CD34+ 
cell population that was not present in unexpanded CD34+ cells (figure 1f). To assess 
whether after ex vivo expansion in the presence of SR1, the functionally most immature 
cells were primarily present within the phenotypic most immature CD45RAlowCD90+ 
subset or also present in the new CD45RA+CD90+ subset, 3 populations of cells were 
sorted, namely Lin-CD34+CD38lowCD45RAlowCD90+ cells, Lin-CD34+CD38lowCD45RAlowCD9
0low cells and Lin-CD34+CD38lowCD45RA+CD90+ and long term culture-initiating (LTC-IC) 
assays were performed. At present, the LTC-IC assay is the best in vitro surrogate assay for 
primitive HSPC. The highest frequency of LTC-IC was found in the CD45RAlowCD90+ popu-
lation (figure 1G, 1 in 23.3 cells), indicating that after culture, the phenotypically most 
immature cells are still enriched for LTC-IC. The new CD45RA+CD90+ subset contained a 
table 1. Fold expansion and frequency of CD45+, CD34+ and CD34+CD90+ cells upon culture in SFT or 
SFT+SR1 medium
Day 7 Day 14
Sft Sft+Sr1 p-value Sft Sft+Sr1 p-value
fold expansion compared to input
CD45+ cells 47.3 47.6 0.88 100.3 113.3 0.23
CD34+ cells 19.9 31.2 <0.01 23.3 55.2 <0.01
CD34+CD90+ cells 10.8 21.6 0.09 8.9 26.9 <0.001
frequency 
CD34+ cells (within CD45+ cells) 36.9% 63.0% <0.0001 19.2% 42.5% <0.0001
CD90+ cells (within CD34+ cells) 5.8% 7.1% <0.05 5.5% 4.5% 0.18
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much lower frequency of LTC-IC (~1/400), whereas the CD90low population contained no 
detectable LTC-IC. To quantify the increase in LTC-IC in expansion cultures in the presence 
and absence of SR1, LTC-IC frequencies upon 14 days of culture in either SFT or SFT+SR1 
medium, without prior cell sorting, were determined. Upon 14-day culture in either the 
absence or presence of SR1, an increase in the frequency of LTC-IC in CD34+ cells was 
observed (fi gure 1H, input: 1 in 466 cells; SFT: 1 in 109 cells; SFT+SR1: 1 in 90 cells), 
resulting in a 105-fold expansion of LTC-IC upon culture in SFT+SR1 medium (fi gure 1I). 
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figure 1. Serum-free cultures combining hematopoietic growth factors and StemRegenin1 result in expan-
sion of the phenotypically most immature CD34+ cells that are enriched for LTC-IC. UCB-derived CD34+ cells 
were cultured in serum free SFT medium with or without the addition of SR1. Cells were analyzed using fl ow 
cytometry at 7 and 14 days of culture. Shown are (A) the CD45+ cell expansion compared to input (n=10), 
(B) the frequency of CD34+ cells within the CD45+ cell population (n=10), (C) the fold expansion of CD34+ 
cells compared to input (n=10), (D) the frequency of CD90+ cells within the CD34+ cell population (n=6) and 
(E) the expansion of CD34+CD90+ cells compared to input (n=6).(F) shows the expression of CD45RA and 
CD90 in either uncultured (left panel) or cultured (right panel) Lin-CD34+CD38low cells (representative out of 
6). (G) and (H) show the frequency of negative wells versus the number of cells plated in a LTC-IC assay. In 
(G), LTC-IC frequency for several sorted populations upon SFT+SR1 culture are shown. (H) shows the LTC-IC 
frequency in uncultured and cultured CD34+ cells. (I) Fold expansion of LTC-IC after 14 days of culture com-
pared to input. * p<0.05, ** p<0.01, *** p<0.001
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To specifi cally assess the eff ect of the combination of SR1 and hematopoietic growth 
factors on the phenotypically most immature cells in the absence of more mature CD34+ 
cells, sorted CD34+ CD90+ cells were expanded in SFT medium in the presence and ab-
sence of SR1. Similar to our results in cultures with CD34+ cells, robust expansion of total 
nucleated cells, with no diff erence between both conditions after 14 days of culture, was 
observed (fi gure 2a, 100-fold versus 128-fold for SFT and SFT+SR1 respectively, p=0.36). 
The gradual decline in the frequency of both CD34+ cells and CD34+ CD90+ cells during 
culture was retarded in the presence of SR1, again indicating inhibition of diff erentiation 
by SR1 (fi gure 2B+C). The expansion of CD34+ cells (fi gure 2D, p<0.05) and CD34+CD90+ 
cells (fi gure 2E, p<0.05) after 14 days of culture in SFT+SR1 was increased compared to 
SFT alone. Taken together, our data show that the combination of hematopoietic growth 
factors and SR1 not only results in robust expansion of CD34+ cells, but also of the phe-
notypically most immature Lin-CD34+CD38lowCD45RAlowCD90+ cells and the functionally 
most immature cells as assessed by the in vitro LTC-IC assay.
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figure 2. SR1 combined with hematopoietic growth factors promotes expansion of CD34+CD90+ cells. 
UCB-derived Lin-CD34+CD38lowCD45RAlowCD90+ cells were sorted out of CD34-selected cells and were 
cultured in SFT medium with or without SR1. Flow cytometric analysis was performed at day 7 and day 
14. Depicted are (A) the expansion of CD45+ cells (n=8), the frequency of (B) CD34+ cells (n=8) and (C) 
Lin-CD34+CD38lowCD45RAlowCD90+ cells (n=7) within the CD34+ cells population and the expansion of (D) 
CD34+ cells (n=8) and (E) Lin-CD34+CD38lowCD45RAlowCD90+ cells (n=7). * p<0.05, ** p<0.01, *** p<0.001
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Sr1 induces retention of CD34- and CD90-expression following cell division
The phenotypically most immature CD34+CD90+ subset expanded in the presence of 
SR1, but the frequency of those immature cells within CD34+ cells remained similar dur-
ing culture. To address the question how many cell divisions the immature phenotype 
is retained in expansion cultures, sorted CD34+CD90+ cells were cultured for 5 days in 
cultures supplemented with hematopoietic growth factors in the absence or presence 
of SR1. Prior to culture, cells were labeled with a CellTrace™ Violet labeling. Using flow 
cytometry, populations of cells could be distinguished based on the number of cell 
division. Most cells had undergone 3 or 4 cell divisions in both culture conditions (SFT: 
26,5% and 41%; SFT+SR1: 35% and 38% respectively). Addition of SR1 resulted in a lower 
frequency of cells that had undergone 5 or 6 cell divisions, suggesting that SR1 might 
slightly delay cell division in the total cell population. While CD34 expression was re-
tained in the majority of cells up to the 5th cell division in SFT+SR1 cultures, the frequency 
of CD34+ cells rapidly declined after the 4th cell division in SFT cultures (figure 3a). CD90 
expression was already lost in the majority of the cells after 4 cell divisions both in the 
presence or absence of SR1 (figure 3B). The loss of CD90 expression was somewhat 
delayed in cells cultured with SR1 (figure 3a-C). The percentage of cells retaining their 
CD90+ phenotype within the CD34+ population after 3 and 4 cell divisions was 40.1% and 
16.8% in SFT-cultured cells versus 49.5% and 24.2% in SFT+SR1 cultured cells, respectively 
(figure 3C). Next, it was evaluated whether cells that retained their immature phenotype 
after 3 and 4 cell divisions also retained their LTC-IC frequencies. CD34+CD90+ cells that 
had undergone 3 or 4 cell divisions in SFT+SR1 culture were sorted and evaluated in a 
LTC-IC assay. The frequency of LTC-IC appeared to be higher in the cell population that 
had undergone 3 cell divisions compared to the population that had undergone 4 cell 
division (figure 3D, 1 in 1,8 cells versus 1 in 9,9 cells respectively). Thus, part of the cells 
that retained their immature phenotype after 4 cell divisions had lost their immature 
functional characteristics (LTC-IC activity).
Engraftment potential and hematopoietic repopulation ability of CD34+ cells 
expanded by the combination of hematopoietic growth factors and Sr1
To evaluate the engraftment potential and repopulation ability of UCB-derived CD34+ 
cells expanded in the presence of hematopoietic growth factors and SR1, sublethally 
irradiated NSG mice were transplanted with either 105 purified unmanipulated CD34+ 
cells or the input-equivalent (i.e. the number of expanded cells that is derived from 105 
CD34+ cells) after expansion in SFT or SFT+SR1 medium. In time, the level of human 
chimerism in blood gradually increased (figure 4a). All mice engrafted, with human chi-
merism levels 72.9% for non-expanded cells and 33.3% and 28.2% for SFT- and SFT+SR1 
expanded cells, respectively (figure 4B). Multilineage engraftment was established both 
in the peripheral blood and bone marrow of all transplanted mice (figure 4C-E). More 
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figure 3. SR1 induces the retention of CD34- and CD90-expression following cell division. Sorted CD34+CD90+ 
cells were labeled with CellTrace™ Violet and subsequently cultured for 5 days in SFT or SFT+SR1 medium. 
On day 5, flow cytometric analysis and a LTC-IC assay were performed. Shown are expression of CellTrace™ 
Violet, indicating the number of cell divisions undergone versus (A) CD34 expression and (B) CD90 expres-
sion for cells cultured in SFT (left panels) or SFT+SR1 (right panels) medium. The red dotted lines represent 
the cutoff point of either CD34+ or CD90+ cells (representative experiment out of 2). (C) shows the percent-
age of cells expressing CD34 (solid lines) within total life cells and CD90 (dotted lines) within CD34+ cells. 
(D) depicts the percentage of negative wells in a LTC-IC assay versus the number of sorted CD34+CD90+ cells 
seeded that had undergone 3 (triangle) or 4 (square) cell divisions. 
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figure 4. Engraftment potential and hematopoietic repopulation ability of CD34+ cells expanded by the 
combination of hematopoietic growth factors and SR1 105 Selected, non-expanded CD34+ cells and the 
input-equivalent of those cells upon 8 days of culture in SFT of SFT+SR1 medium were intravenously trans-
planted into NSG mice (input: n=25; SFT: n=18; SFT+SR1; n=15). Short-term repopulation was measured in 
the peripheral blood every 2 weeks, starting 3 weeks after transplantation. At week 15 or 17, mice were sac-
rificed and long-term human chimerism was measured in the bone marrow. Shown are (A) levels of human 
chimerism in the peripheral blood (Y-axis) over time (X-axis), (B) levels of human chimerism at 15 or 17 weeks 
post-transplantation in the bone marrow , (C) representative FACS blots showing the gating strategy deter-
mining the different subsets within the human CD45+ population, (D) the representation of CD19+ B cells 
(black squares), CD33+ myeloid cells (white squares), CD56+ NK cells (black triangles) and CD3+ T cells (white 
triangles) within the human CD45+ population in the peripheral blood over time upon transplantation of 
non-expanded (left panel), SFT-expanded (middle panel) or SFT+SR1-expanded cells (right panel) and (E) 
the distribution of CD19+ B cells (black bar), CD33+ myeloid cells (white bar), CD56+ NK cells (striped bar) and 
CD3+ T cells (dotted bar) in the bone marrow 15 or 17 weeks after transplantation . ** p<0.01, *** p<0.001
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than 80% of human cells in blood were CD19+ B-cells, but CD33+ myeloid cells, CD3+ T 
cells and CD56+ NK-cells were also detected, albeit at much lower levels (figure 4D). Mul-
tilineage engraftment was also established in bone marrow of mice transplanted with 
either input or expanded CD34+ cells (figure 4E). Thus, expanded CD34+ cells retain their 
multilineage hematopoietic repopulation capacity in NSG mice. However, the levels of 
human chimerism observed upon transplantation of expanded CD34+ cells (either in SFT 
or SFT+SR1 medium) were lower compared to the levels observed after transplantation 
of non-expanded cells. 
The SR1-enhanced expansion of the phenotypically most immature subset, as assessed 
by flowcytometry, and of the functionally most immature subset, as assessed by the 
LTC-IC assay, in expansion cultures supplemented with hematopoietic growth factors, 
did not result in a corresponding increase in repopulation capacity in NSG mice. The 
repopulation ability of a stem cell graft depends on its subset composition. Human cell 
development in NSG mice is skewed towards the B-lymphoid lineage. Therefore, reduced 
numbers of B cell progenitors in the expanded graft may cause lower levels of human 
chimerism in NSG mice. Non-expanded CD34+ HSPC contain a subpopulation (5 - 10%) 
of committed CD10+ lymphoid precursors (figure 5a, left panel). Our expansion protocol 
however induced a shift in the subset composition of CD34+ HSPC. After expansion, 
either in the presence or absence of SR1, the CD34+CD10+ committed lymphoid precur-
sor subset was markedly reduced (figure 5a, right panel). To demonstrate that the high 
levels of human chimerism levels in blood after transplantation of unexpanded CD34+ 
cells were indeed derived from lymphoid progenitors in the graft, CD34+CD10-CD90+ 
CD34
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figure 5. Lymphoid progenitors contribute to early hematopoietic recovery and are markedly reduced 
upon expansion cultures (A) shows the expression of CD34 (X-axis) and lymphoid progenitor marker CD10 
(Y-axis) in uncultured cells (left panel) and in cells cultured for 1 week in SFT+SR1 medium (right panel) and 
(B) shows levels of human chimerism in the peripheral blood of NSG mice upon transplantation with105 
non-expanded CD34+ cells or 5000 non-expanded sorted CD34+CD10-CD90+ cells.
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cells were sorted and transplanted into NSG mice (5000 cells per mice, total of 15 mice). 
As expected, the removal of committed progenitors from the fresh CD34+ HSPC resulted 
in a delayed recovery of human cells and lower levels of human chimerism in blood of 
transplanted mice (figure 5B). These results demonstrate that the observed high levels 
of chimerism after transplantation of non-expanded CD34+ cells are mainly derived from 
lymphoid progenitors, which are markedly reduced after culture in SFT+SR1 medium. 
DISCUSSIon
SR1 has been shown to promote the expansion of human HSPC capable of hematopoi-
etic reconstitution in mice (15) and men (23). However, some studies suggested that 
SR1 predominantly affects committed progenitor cells with short-term repopulation 
potential, rather than the true long-term repopulating HSC (27, 28). Therefore, this 
study evaluated whether the combination of SCF, Flt3L and TPO (SFT) with SR1 would 
be able to expand a very immature subset of human UCB-derived phenotypic HSPC, 
characterized as Lin-CD34+CD38lowCD45RAlowCD90+ cells, which are highly enriched for 
HSC (29). In addition, functional evaluation included LTC-IC assays as well as an in vivo 
mice model. It is shown that the combination of SFT and SR1 expands purified immature 
Lin-CD34+CD38lowCD45RAlowCD90+ cells in serum-free expansion cultures. Most stud-
ies claiming expansion used either the number of CD34+ cells or the more immature 
population of CD34+CD38low cells as an endpoint (11-13), but few studies addressed the 
effect on the phenotypically most immature subset (Lin-CD34+CD38low CD45RAlowCD90+ 
cells). Boitano et al. observed a ten-fold expansion of human CD34+CD90+ cells in cultures 
supplemented with SCF,Flt3L, TPO, IL-6 and SR1 compared to cultures supplemented 
with SFT6 only. Fold expansion compared to input was not shown. These cultures were 
initiated with mobilized peripheral blood-derived CD34+ cells from adult patients (15). 
However, Gu et al. (26) reported a reduced frequency of CD34+CD90+ cells upon 1 week 
culture of mobilized adult peripheral blood CD34+ cells in a serum-free culture system 
with a combination of SR1 and the growth factors SCF, Flt3L, TPO and IL-6. Despite that 
reduced frequency, absolute number of CD34+CD90+ cells were increased compared 
to input cell numbers due to strong expansion of the total CD34+ population. Fares et 
al. observed only a two-fold increase in CD34+CD38lowCD45RAlowCD90+ cells in cul-
tures using a combination of SFT and SR1 compared to cultures initiated with growth 
factors only (27). In contrast to those studies, cell sorting of a more primitive subset 
(Lin-CD34+CD38lowCD45RAlowCD90+ cells) was performed prior to initiate cultures in the 
present study enabling the evaluation of proliferation and inhibition of differentiation of 
HSPC more closely. It is shown that a combination of SFT and SR1 enhanced both the fre-
quency and absolute number of Lin-CD34+CD38lowCD45RAlowCD90+ cells in cultures initi-
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ated with purified immature cells. Cell division analysis showed a retention of both CD34 
and CD90 expression following cell division, suggesting a delay of the differentiation of 
actively dividing cells by SR1. Moreover, a robust expansion of LTC-IC was observed fol-
lowing evaluation of expanded cells in a 6-week LTC-IC system. Virtually all LTC-IC activity 
resided in the phenotypically most immature Lin-CD34+CD38lowCD45RAlowCD90+ cells. The 
subset of Lin-CD34+CD38lowCD45RA+CD90+ cells, which was generated during culture as 
a more differentiated subset, hardly contained any LTC-IC activity. These results suggest 
that expansion of phenotypically immature CD34+CD90+ cells cannot be taken as a surro-
gate marker for expansion of functional HSC with LTC-IC capacity. Apart from expanding 
the subset of Lin-CD34+CD38lowCD45RAlowCD90+ cells our data indicate that SR1 is able 
to inhibit the differentiation of actively dividing Lin-CD34+CD38lowCD45RAlowCD90+ cells 
with retention of most LTC-IC activity. 
Although SR1-expanded cells retained long-term multilineage repopulation ability in 
NSG mice, lower levels of human chimerism were observed upon intravenous transplan-
tation of SR1-expanded cells compared to transplantation of unexpanded cells. These 
results may seem in contrast to those by Boitano et al., who reported a 17-fold increase in 
SCID-repopulating cells (SRC) (15). In addition, several other groups have reported that 
SR1 induces at best maintenance of SRC rather than an increase (26, 27) and Fares et al. 
proposed that SR1 does not affect the true long-term HSC, but rather a less primitive sub-
type, the short-term HSC (28). How to explain these contradictory results? A possible clue 
may come from the differences of cytokines and time periods used in expansion cultures. 
The growth factors used in the present study included SCF, FLT3L and TPO, while IL-6 
was left out considering its predominant effect on committed lymphoid progenitors and 
the absence of the IL-6 receptor on human HSC. Fares et al. evaluated the combination 
of SCF, Flt3L, TPO and SR1, which compares more closely to the present study (27). Their 
results indicated a two-fold expansion of CD34+CD38lowCD45RAlowCD90+ cells compared 
to the growth factor only condition. Gu et al. (26), however, also included IL-6 in their ex-
pansion cultures and reported a 10-fold decrease in SRC upon 7 day expansion cultures 
using SFT6+SR1 compared to overnight SFT6+SR1-culture. This clearly differs from the 
17-fold increase in SRC that was described by Boitano et al. Of note, transplantation of 
non-expanded cells was not included in the latter study, excluding the comparison of hu-
man chimerism levels to unmanipulated cell transplantation, as presented here. Several 
publications have suggested that IL-6 has a positive effect on the maintenance of long-
term HSC in in vitro expansion cultures (31, 32). However, these results may need to be 
interpreted cautiously, because the endpoints are related to either committed progeni-
tor cells (CFC activity directly upon culture (32)) or related indirectly to HSC by evaluating 
secondary transplantations (31). SRC numbers assessed in primary transplantations did 
not differ between the conditions with and without IL-6 in the study by Duchez et al (31), 
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while the effect on the expansion of Lin-CD34+CD38lowCD45RAlowCD90+ cells and LTC-IC 
was not addressed. Collectively, these results suggest that the contributory effect of IL-6 
in expansion cultures is questionable. In addition, the use of IL-6 might explain the dif-
ferent in vivo results in the present study as compared to the study by Boitano. The effect 
of IL-6 on the in vivo repopulating capacity of expanded UCB-derived progenitor cells 
needs to be interpreted cautiously, because of severe limitations of the model to assess 
SRC numbers. Increased SRC numbers are generally considered the ‘golden standard’ to 
address whether the true long-term HSC has actually been expanded. However, early 
hematopoietic recovery after transplantation in NSG mice originates from committed 
progenitor cells. In the NSG mouse model human repopulation rapidly starts after 
transplantation and 80-90% of human cells are CD19+ B cells, indicating that commit-
ted lymphoid progenitors predominantly account for human engraftment in NSG mice. 
The present study showed that ex vivo CD34+ cell expansion without IL-6 resulted in an 
almost complete loss of lymphoid progenitors, which may explain the lower levels of 
human chimerism in NSG mice as compared to transplantation of uncultured cells and as 
compared to earlier studies that included IL-6 in their expansion protocol (15). In order 
to assess the contribution of lymphoid progenitors to early recovery, CD34+CD90+CD10- 
cells were sorted and thereby the CD10+ lymphoid progenitor subset was removed to 
specifically study repopulation capacity of immature HSPC. A delayed recovery and lower 
levels of human chimerism were observed demonstrating early hematopoietic recovery 
and chimerism is predominantly accounted for by lymphoid progenitors in the graft. 
Collectively, these results question whether numbers of SRC as assessed in NSG mice 
upon transplantation reflect the number of HSC in the graft. As a result, increasing SRC 
number cannot be interpreted as evidence of expansion of HSC and the LTC-IC analysis 
may be preferred to functionally evaluate expanded cell fractions. However, secondary 
transplantation and long-term T cell reconstitution might alternatively be considered as 
primary endpoint in NSG mice and might reflect more closely the number and functional 
capacity of expanded human HSC. In addition, the use of a more myeloid skewed mouse 
model, such as the MISTRG mice (33) may be preferred over the current NSG mouse mod-
el, allowing to evaluate both myeloid and lymphoid recovery in addition to long-term 
recovery, which might yield a more complete picture of HSC content of the transplanted 
and expanded graft. Despite the limitations of the in vivo model, both the expansion 
of the immature subset of Lin-CD34+CD38lowCD45RAlowCD90+ cells and the strong 
increase of LTC-IC in the present study suggest effective expansion of HSC. 
Recently, the safety and feasibility of SR1-expanded HSPC was evaluated clinically in a 
dUCBT setting. Wagner and colleagues observed rapid neutrophil and platelet recovery 
upon transplantation of SR1-expanded cells (15 days and 49 days, respectively) in 17 
patients. Recovery originated from the expanded graft in 11 out of 17 patients. Of note, 
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no graft failures were observed, indicating long-term engraftment capacity of the SR1-
expanded cells. These favorable results have set the stage to study SR1-expanded UCB in 
a single UCBT setting, which is currently underway by us and others. Ultimately, prospec-
tive randomized trials comparing transplantation of (SR1-)expanded and non-expanded 
cells are needed to assess whether transplantation with expanded UCB may result in 
more rapid and qualitative better recovery that may result in a reduction of non-relapse 
mortality. The encouraging results of the present study, showing robust expansion of the 
phenotypic most immature cells and of LTC-IC cells, combined with the work by Wagner 
et al. in a dUCBT setting, may lead the way to improved hematopoietic recovery following 
UCBT, that may match the recovery currently observed with haplo-identical allo-SCT. 
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aBStraCt
Impaired homing and delayed recovery upon hematopoietic stem cell transplantation 
(HSCT) with hematopoietic stem cells (HSC) derived from umbilical cord blood (UCB) is 
a major problem. Tracking transplanted cells in vivo will be helpful to detect impaired 
homing at an early stage and allows early interventions to improve engraftment and 
outcome after transplantation. In this study, we show sufficient intracellular labeling 
of UCB-derived CD34+ cells, with 19F-containing Poly(Lactic-co-Glycolic Acid) (PLGA) 
nanoparticles which were detectable with both flow cytometry and magnetic resonance 
spectroscopy (MRS). In addition, labeled CD34+ cells maintain their capacity to proliferate 
and differentiate, which is pivotal for successful engraftment after transplantation in vivo. 
These results set the stage for in vivo tracking experiments, through which the homing 
efficiency of transplanted cells can be studied. 
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IntroDUCtIon
Cell transplantation is an important therapeutic strategy for various malignant and non-
malignant diseases. Migration of transplanted cells to their designated organs (‘homing’) 
is pivotal for treatment success. Information about transplanted cell localization can be 
of great value in the evaluation and development of stem cell-based therapies [1]. This 
information follows from magnetic resonance imaging (MRI) data, when cells of interest 
are labeled so that they can be discriminated from surrounding tissue. The stable nature 
of MRI cell labels facilitates longitudinal measurements, respecting the dynamic process 
of stem cell homing. Multiple studies have shown effective magnetic labeling and subse-
quent in vivo imaging in a variety of medical fields, including cardiovascular disease [2], 
neurodegenerative disease [3], neurological trauma [4], diabetes [5] and others. Using 
fluorine (19F) as a label has the advantage that 19F [6] has no detectable background in 
vivo [7]. Therefore, detection of 19F in cell labels is highly specific. 
Labeling cells with 19F is mostly done using perfluorocarbons (PFCs), because PFCs are 
high in fluorine content [8]. Because of their insolubility in both lipophilic and hydrophilic 
solvents, PFCs need to be incorporated in emulsion droplets, nanoparticles or micelles 
before they can be used for cell labeling. Another reported 19F labeling strategy is to 
fluorinate sugars or peptides [9-11] but then the 19F content of the label is low compared 
to the 19F content of PFCs. 
Transplantation of hematopoietic stem and progenitor cells from umbilical cord blood 
(UCB) is an example of the need for information about homing. UCB is an important 
alternative stem cell source for patients lacking a sibling or matched unrelated stem cell 
donor, because of its rapid availability and less stringent matching criteria [12]. However, 
adult patients who receive a UCB transplantation have a delayed neutrophil and platelet 
recovery time and a higher incidence of graft failure as compared to patients who receive 
CD34+ cells from adult donors [13, 14]. During the delayed recovery period, patients are 
at high risk for severe complications such as infections and bleeding, resulting in a high 
mortality rate. Several factors may contribute to the delayed hematopoietic recovery 
following UCB transplantation. Besides the relative higher immaturity of UCB-derived 
CD34+ cells as compared to adult bone marrow-derived CD34+ cells [15] , delayed recov-
ery may also be due to the relatively low number of CD34+ cells in UCB grafts [12, 16]. 
In addition, it is known that CD34+ cells derived from UCB do not home as efficiently to 
the bone marrow as their adult-donor-derived counterparts, due to a lack of binding 
of UCB-HSC to the P- and E-selectin adhesion molecules expressed by the recipients 
bone marrow endothelial cells [17]. Tracking stem cell homing after transplantation, as 
a means to study engraftment kinetics, will be helpful to detect impaired homing at an 
early stage after transplantation, allowing interventions to improve engraftment and 
outcome after transplantation.
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In this preclinical study, the aim is to label umbilical cord blood (UCB)-derived CD34+ 
cells with fluorine (19F)-containing nanoparticles while maintaining cell viability and 
functionality. This will set the stage for further in vivo studies in order to track the homing 
of CD34+ cells upon hematopoietic stem cell transplantation.
matErIaL anD mEtHoDS
Synthesis and characterization of 19f- Poly(Lactic-co-Glycolic acid) (PLGa) 
nanoparticles 
Nanoparticles were produced as described [18]. Subsequently, the nanoparticles were 
resuspended in PBS (Invitrogen, the Netherlands) and stored at 4°C until use. The final con-
centration of 19F-PLGA nanoparticles was 76 mg/ml, as measured from a lyophilized sample. 
Analysis of the 19F -PLGA nanoparticles using dynamic light scattering (Zetasizer Nano 
Series, Malvern Instruments, Worcestershire, UK) showed a mean particle diameter ± SD 
(n = 4) of 290 nm ± 56 nm. The mean polydispersity index ± SD was 0.17 ± 0.04, indicating 
particles were fairly homogenous in diameter. 
Umbilical cord blood processing and cell selection 
Umbilical cord blood was collected in several hospitals using Stemcare®/CB collect blood 
bag system (Fresenius Kabi Norge AS) containing citrate phosphate dextrose (CPD) as an 
anticoagulant. The Medical Ethical Committee of the Erasmus University Medical Centre 
approved collection of the cord blood (MEC-2009-410) and written informed consent 
from the mother was obtained prior to donation. Within 48 hours after collection, mono-
nuclear cells were isolated using ficoll (Lymphoprep™, Fresenius Kabi Norge AS). CD34+ 
cells were isolated with positive immunomagnetic selection using Magnetic Activated 
Cell Sorting (MACS) technology according instructions of the manufacturer (Miltenyi 
Biotech GmBH, Bergisch Gladbach, Germany). 
Labeling CD34+ cells with 19f -PLGa nanoparticles 
Cells were resuspended at 200,000 cells/ml in serum-free Glycostem Basal Growth Medi-
um (GBGM®, Glycostem Therapeutics, 's Hertogenbosch, The Netherlands) supplemented 
with thrombopoietin (TPO), stem cell factor (SCF) and Flt3 ligand (Flt3L) (Cellgenix, 
Freiburg, Germany) at 50 ng/ml each. Labeling of cells was performed at concentrations 
ranging from 5 to 40 μl/ml of 19F -PLGA nanoparticles. Standard concentration was 20 µl/
ml. After addition of the label, cells were incubated in the dark at 37°C and 5.0% CO2 for 
4 or 20 hours. Control cells were mock-labeled, i.e. treated identically until the end of the 
incubation time, but without the addition of nanoparticles. After incubation, cells were 
processed as required for further analysis. 
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flow cytometry
Labeling efficiency and median labeling intensity were determined using flow cytometry. 
Cells were stained with anti-CD45-APC-H7, anti-CD34-PE-Cy7 (both from BD Biosciences, 
San Jose, CA, USA) and diamidinophenylindole (DAPI) (Sigma-Aldrich, St Louis, MO, USA). 
Only viable (DAPI-) CD45+CD34+ cells were included in the analysis. The maximal fluores-
cence intensity of mock-labeled control cells in the FITC-channel was set as threshold 
for considering a cell labeled. Flow cytometric analysis was performed using a BD FACS-
Canto™ (BD Biosciences, San Jose, CA, USA) and data was analyzed using FlowJo software 
(Tree Star Inc, Ashland, OR, USA). 
To assess 19F-PLGA labeling intensity in cells that divided 0-3 times, cells were labeled 
with 5µM CellTrace Violet (Molecular Probes, Eugene, Oregon, USA) upon 19F-PLGA label-
ing and subsequently cultured for 4 days in our culture medium as described above.
Confocal microscopy 
Cells were labeled at a 19F -PLGA nanoparticle concentration of 20 μl/ml with an incuba-
tion time of 4 hours. Labeled-cells were separated from free 19F -PLGA particles using ficoll 
separation. Washed labeled or mock-labeled control cells were transferred to microscopy 
slides by centrifugation. Subsequently, slides were air dried and mounted in Prolong® 
Gold Antifade Reagent with DAPI (Molecular Probes, Eugene, Oregon, USA). Cells were 
imaged using a Leica SP5 CLSM equipped with Ar-He/Ne lasers (Leica Microsystems, 
Wetzlar, Germany) and a Zeiss 63x Plan-Apochromat oil immersion objective (Carl Zeiss, 
Oberkochen, Germany). A 405 nm laser was used for DAPI excitation (with a 413-476 nm 
acousto-optical beam splitter (AOBS)), and a 488 nm laser was used for FITC excitation 
(with a 503-596 nm AOBS). 
Colony forming unit (CfU) assays
Washed labeled or mock-labeled cells were resuspended in methylcellulose containing 
medium (Methocult GF H84434, Stemcell Techonologies, Vancouver, BC, Canada) and 
seeded in triplicate at 500 cells per 35 mm dish. Dishes were incubated for 14 days in a 
humidified tray at 37°C and 5.0% CO2, after which two trained non-blinded observers 
enumerated the colonies. We accepted an interobserver variation of 10%. Three types of 
colonies were distinguished: burst forming unit-erythroid (BFU-E), colony forming unit-
granulocyte/monocyte (CFU-GM) and colony forming unit-granulocyte/erythrocyte/
monocyte/megakaryocyte (CFU-GEMM). 
magnetic resonance spectroscopy 
Cells were labeled at a concentration of 20 µl/ml for 20 hours and subsequently fixed 
in 4% formaldehyde solution for at least 15 minutes at room temperature, washed in 
PBS, and resuspended in agar solution (0.3%). An MR 901 Discovery 7T magnet (Agilent 
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Technologies, Santa Clara, CA, USA) with a preclinical front-end (GE Healthcare, Little 
Chalfont, UK) was used for MRS acquisition. The system is equipped with a gradient set 
with a maximum gradient strength of 300 mT m-1, a rise-time of 600 T m-1 s-1 and an 
inner diameter of 310 mm. For transmission and reception, an in-house-built dual tuned 
1H/19F single channel surface coil with a diameter of 2 cm was used. The 19F MRS spectrum 
was recorded using a EchoSCI sequence (TR/TE = 1250/15 ms, NEX = 128, FOV = 6 cm, 
slice thickness = 2,5 cm). 
MRS processing was performed in SAGE 7.6.2 (GE Healthcare, Little Chalfont, UK) on 
the MR 901 Discovery system. For processing of the data, time domain signals were 
apodized with a 17.6 Hz line broadening function, after which the signal was zerofilled 
to 4096 points. Subsequently the time domain signal was Fourier transformed and the 
resulting spectrum was properly phased to show an absorption mode resonance line. 
For signal intensity the maximum intensity of the resonance line was determined, and 
noise was estimated from the standard deviation of the signal intensity of the baseline. 
19F in the sample was quantified by reference to a standard curve, which was obtained by 
measuring a dilution series of PFCE with known 19F content. 
Statistics 
Unpaired two-tailed t-tests were performed to test the difference in median labeling 
intensity between different incubation times and to test the difference in number of 
colonies between labeled and mock-labeled CD34+ cells for both incubation times in 
CFU experiments. Differences were considered to be statistically significant if p < 0.05. 
Statistical tests were performed in Excel (Microsoft Corporation, Redmond, WA, USA). 
rESULtS
CD34+ cells are efficiently labeled with 19f -PLGa nanoparticles
Cells were labeled with 5, 10, 20 and 40 µl/ml 19F -PLGA nanoparticles for 4 or 20 hours 
respectively, in order to address whether CD34+ cells could be labeled using 19F -PLGA 
nanoparticles and which labeling time and concentration would be most optimal. In 
all conditions tested, incubation of CD34+ cells with 19F -PLGA nanoparticles resulted in 
labeling of nearly all cells. The lowest percentage of labeled cells (94.5%) was observed 
following incubation with a 19F -PLGA nanoparticle concentration of 5 μl/ml for 4 hours; 
all other conditions resulted in > 99% labeled cells (table 1). However, the median 
fluorescence intensity of labeled cells varied across labeling conditions (table 1, figure 
1a). Higher 19F -PLGA nanoparticle concentrations were associated with higher median 
fluorescence intensity of viable CD45+CD34+ cells. At each labeling concentration, a 
longer incubation time was associated with higher median fluorescence intensity of 
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CD34+ cells (figure 1B). However, the increase in median fluorescence caused by longer 
incubation time consistently decreased with increasing labeling concentration. An incu-
bation time of 20 hours led to a statistically significantly higher median labeling intensity 
than 4 hours of labeling at 20 μl/ml (figure 1C, p<0.05). In summary, we can discriminate 
table 1. Labeling efficiency of CD34+ cells in relation to 19F -PLGA NP concentration and incubation time
Labeling concentration 
(µl/ml)
Percentage of cells labeled (%) median fluorescence intensity
4 hours incubation 20 hours incubation 4 hours incubation 20 hours incubation
5 94.5 99.2 461 733
10 99.1 99.9 781 1169
20 99.7 99.9 1618 1879
40 99.7 99.9 2628 2709
PLGA: poly(lactic-co-glycolic acid); NP: nanoparticle
A 
B C 
figure 1. CD34+ cells can be labeled efficiently with 19F -PLGA nanoparticles with the intensity increasing 
with longer incubation time and higher labeling concentration. (A) Fluorescence histograms of cells labeled 
with 0 (red), 5 (turquoise), 10 (orange), 20 (green) and 40 (blue) µl/ml nanoparticles at incubation times of 
4 (left panel) or 20 (right panel) hours. Horizontal axes show the intensity of the FITC signal, representing 
the 19F -PLGA nanoparticles. (B) Median fluorescence intensity per labeling concentration after 4 (circle) and 
20 (square) hours of labeling. Figures A and B show a representative experiment out of 2 experiments. (C) 
Median fluorescence intensity of cells labeled with 20 µl/ml 19F -PLGA nanoparticles for 4 and 20 hours (n=5). 
* = p<0.05.
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labeled CD34+ cells from mock-labeled control cells using FACS in each of the conditions 
tested, with the labeling intensity increasing with longer incubation time and higher 
labeling concentration. We chose a labeling time of 20 hours with a concentration of 20 
μl/ml for further experiments. 
Detection of 19f-PLGa labeled CD34+ cells by magnetic resonance spectroscopy
We recorded a 19F MRS spectrum of 2 agar gel phantoms containing 105 and 104 labeled 
CD34+ cells in 150 µl respectively. The respective signal to noise ratio (SNR) was 58,6 for 
the sample containing 105 labeled CD34+ cells and 5,3 for the sample containing 104 
labeled CD34+ cells (figure 2). Data acquisition took 65 minutes to recover sufficient SNR 
in the sample containing 104 cells. 5,06x1019 19F spins were measured in the sample with 
105 labeled CD34+ cells and 6,65x1018 19F spins in the sample with 104 labeled CD34+ cells.
Uptake of the label is an active process and results in intracellular accumulation 
of the label
To discriminate between active uptake of the label and binding of the label to the mem-
brane, we performed labeling with 20 µl/ml 19F -PLGA nanoparticles at both 4°C and 37 
°C. We observed a decrease in frequency of labeled cells from 99.9% at (37°C) to 28.2% (at 
4°C). In addition, the median fluorescence intensity decreased from 2061 after labeling 
at 37°C to 82.2 after labeling at 4°C (table 2 and figure 3a). This indicates that CD34+ 
cells actively incorporate the 19F -PLGA nanoparticles. To further investigate the intracel-
lular accumulation of the label, we performed confocal microscopy of 19F -PLGA-labeled 
CD34+ cells. figure 3B clearly shows FITC-positive 19F -PLGA nanoparticles within the 
figure 2. Detection of labeled CD34+ cells by magnetic resonance spectroscopy and imaging. Left and right 
panel show the 19F MRS spectrum of 2 agar gel phantoms containing 105 and 104 labeled CD34+ cells in 
150 µl respectively. Shown is the 19F resonance line, the horizontal axes shows the frequency offset from 
the transmitter. Here the transmitter frequency has been set to the resonance frequency of the 19F in PFCE. 
Labeled cells were labeled with 20 µl/ml 19F -PLGA nanoparticles with an incubation time of 20 hours.
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cytoplasm of the labeled CD34+ cells. Mock-labeled control cells showed no FITC-signal 
(image not shown). Combined, these data show active uptake of the label by the CD34+ 
cells, leading to intracellular accumulation of the label.
19f-PLGa labeling does not affect the relative proportion of committed 
hematopoietic progenitors and cell viability
To test the ability of the labeled cells to proliferate and differentiate, colony forming 
unit (CFU) assays were performed. 19F -PLGA labeled and mock-labeled CD34+ cells were 
plated on the basis of baseline cell counts (counted prior to labeling) and after 14 days 
of culture, three different colony types were scored by 2 trained observers. Relevant 
to the interpretation of CFU results are the total number of colonies and the relative 
distribution of colony types, indicating the relative proportion of distinct committed 
hematopoietic progenitors, compared between labeled and mock-labeled conditions. 
With an incubation time of 4 hours, the average total number of colonies and the relative 
distribution of the colony subtypes are similar among the labeled and control condi-
tions (figure 4a, p=0.96 for the total number of colonies and p=0.31, p=0.53 and p=0.83 
for the frequency of BFU-E, CFU-GM and CFU-GEMM respectively). With an incubation 
time of 20 hours, the total number of colonies in the labeled condition is lower than in 
the mock-labeled control (90.6 versus 79.7 colonies per 500 CD34+ cells in control and 
A B 
figure 3. Uptake of the label is an active process and results in intracellular accumulation of the label. (A) 
Fluorescence histogram for mock-labeled control cells (red) and cells labeled 20 hours at 37 °C (turquoise) or 
4 °C (orange). Horizontal axes show the intensity of the FITC signal, representing the 19F -PLGA nanoparticles. 
(B) Differential Interference Contrast image (left) and fluorescent image (right) of CD34+ cells labeled with 
19F -PLGA nanoparticles, showing the blue DAPI-signal (nucleus of the cell) and the green FITC-signal (19F 
-PLGA nanoparticles).
table 2. Effect of incubation temperature on uptake of 19F -PLGA NPs by CD34+ cells.
Incubation temperature Percentage of cells labeled (%) median fluorescence intensity
37 °C 99.9% 2061
4 °C 28.2% 82.2
PLGA: poly(lactic-co-glycolic acid); NPs: nanoparticles
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labeled cells respectively, p=0.04), although no significant decrease is observed in any of 
the colony types. Irrespective of this small decrease in total colony number after 20 hours 
of labeling, these results show that both after 4 and 20 hours of labeling, cells are still 
capable of proliferation and differentiation and the relative proportions of committed 
hematopoietic progenitors are similar. 
To study whether 19F-PLGA labeling affects cell viability, flow cytometric analysis was 
performed using diamidinophenylindole (DAPI). The percentage life CD34+ cells prior to 
labeling and after labeling with 19F -PLGA for 4 and 20 hours were similar (figure 4B), 
indicating no toxic effect of the internalization of the 19F -PLGA nanoparticles.
19f-PLGa labeled cells remain detectable over time and upon cell division, 
although label intensity decreases
To assess the stability of the label in non-dividing cells and loss of label intensity upon 
cell division, we labeled 19F -PLGA-labeled CD34+ cells with the cell division tracker Cell-
Trace and evaluated the fluorescence intensity upon 4 days of culture. At day 0, all cells 
showed a high intensity of both the CellTrace label and the 19F -PLGA label (figure 5a). 
After 4 days of culture, cells had divided 0, 1, 2 or 3 times respectively (figure 5B). We 
observed a decrease in fluorescence intensity in cells that had not divided, compared 
to the day 0 population (figure 5C, left panel), indicating some leakage of the label in 
time. However, labeled cells were still easily detectable using flow cytometry. In addition, 
upon every cell division we observed a halving of the fluorescence intensity, indicating 
an equal distribution of the 19F -PLGA nanoparticles over both daughter cells upon cell 
division. Despite the decrease in label intensity, labeled cells were still detectable by flow 
cytometry upon 3 cell divisions (figure 5C, right panel). 
figure 4. Labeling with 19F-PLGA does not affect the relative proportion of committed hematopoietic pro-
genitors and cell viability. (A) Total number of colonies per 500 CD34+ cells for BFU-E (red), CFU-GM (white) 
and CFU-GEMM (gray). (B) Percentage of life cells at input (white), and after 4 (green) and 20 (black) hours of 
labeling with 20 µl/ml 19F-PLGA (n=5).
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DISCUSSIon 
This study shows the feasibility of labeling CD34+ cells with 19F-containing PLGA nanopar-
ticles. In addition, labeled CD34+ cells maintain viable and retain their capacity to prolif-
erate and differentiate, which is pivotal for successful engraftment after transplantation 
in vivo. In the future, this technique can be used to monitor homing evaluating efficacy 
of hematopoietic stem cells transplantation and the information obtained may have 
implications to further improve treatment outcome.
Several conditions must be met in order to consider cell labeling and subsequent MR 
detection as feasible. Firstly, MR detection of the labeled cells should be feasible in vivo. 
MR-based imaging has advantages regarding its high spatial resolution, the absence 
of ionizing radiation and the ability to provide anatomical information [1]. However, as 
compared to nuclear imaging of isotopes, MRI may be a less sensitive technique, with a 
higher detection limit in a reasonable measurement time. Higher MR detection sensitiv-
ity may provide more detailed information about the distribution of the labeled cells 
A B 
C 
figure 5. 19F-PLGA labeled cells remain detectable over time and upon cell division, although label intensity 
decreases. Fluorescence histograms for CellTrace and 19F -PLGA-labeled CD34+ cells (A) Population shown is 
labeled cells at day 0. Horizontal axes show the intensity of the CellTrace Violet signal (left panel) and of the 
FITC signal, representing the 19F -PLGA nanoparticles (right panel). (B) Population shown is labeled cells after 
4 days of culture. The horizontal axes show the intensity of the CellTrace Violet signal, indicating the number 
of cell divisions. (C) Populations shown are labeled cells after 4 days of culture who had undergone 0, 1, 2 or 
3 cell division respectively (depicted in the panels from left to right). Horizontal axes show the intensity of 
the FITC signal, representing the 19F -PLGA nanoparticles. 
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after transplantation. Since MRS has a higher sensitivity than MRI, we decided to first 
perform MRS experiments in order to create a starting point from which our MRS results 
can serve for increasing signal and cell detection sensitivity. This may be achieved by 
optimizing the 19F content of the nanoparticles, increasing the cellular uptake of the label 
and refining MR hardware and acquisition [19]. A second prerequisite involves preserva-
tion of viability and functionality of the cells during the labeling process. We observed 
comparable percentage of life cells and total colony numbers after an incubation period 
of 4 and 20 hours compared to control samples. In addition, all different types of colonies 
were formed by the labeled cells, in similar frequencies as by non-labeled cells. Thirdly, 
stable cell-label association is pivotal for successful MR detection of labeled cells. The 
stability of the cell-label association is partly determined by the localization of the label. 
Both surface labels and intracellular labels may be applied, but intracellular labels may be 
preferred due to a lower risk of detachment. Our data indicates that cellular label uptake 
is an active, energy-dependent process, resulting in a stable intracellular localization of 
the label. This finding is consistent with the results of previous studies, which identified 
endocytosis as the cellular mechanism responsible for uptake of PLGA NPs in other cell 
types [20-22]. Future research should address the question whether such intracellular 
labels are useful to investigate homing of transplanted CD34+ cells in the first 24 hours 
after transplantation. We observed decrease in label intensity over time and dilution of 
the signal upon cell division. This dilution of the signal may have consequences in imag-
ing sensitivity, provided the 19F concentration per imaging voxel is reduced by migration 
of cells out of the area of interest. However, when cells do not migrate upon division 
dilution through cell division would not affect detection sensitivity since for 19F MRI/
MRS the total amount of 19F in a voxel determines detection sensitivity and not how it is 
spread within a voxel. This was already shown in previous studies using gadolinium-DTPA 
containing liposomes to label mesenchymal stem cells. Guenoun et al. showed a stable 
amount of label in all cells over time, even though the amount per cell decreased as 
a result of mitosis [23]. In our studies, the voxel dimensions were dictated by the area 
of interest and a similar approach could be followed for clinical applications. Lastly, in 
order to develop this technique further also for clinical applications, it is crucial that the 
label is biocompatible. All components of our nanoparticles are biocompatible and are 
already used in other applications in humans. PLGA polymer is approved by the FDA 
and European Medicine Agency for use in humans as a drug delivery system [24, 25]. 
Because of their susceptibility to hydrolysis and subsequent clearance by the Krebs cycle 
[26], PLGA polymers have very minimal systemic toxicity[27]. PFC emulsion droplets are 
cleared by macrophages of the reticuloendothelial system and eliminated from the body 
by exhalation [28]. Possible adverse effects are caused by stimulation of the macrophages 
and are dose-dependent. Therefore, they may not apply to cell tracking studies using 
low doses of PFC[8]. Finally, PVA is used as an emulsifier in the production of PFCE-PLGA 
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nanoparticles. Some PVA remains despite extensive washing of the nanoparticles [29]. 
PVA is biocompatible and applied in humans through oral administration [30] or implan-
tation [31]. 
Helfer et al. [32]labeled CD34+ cells from adult bone marrow using a 19F label in emul-
sion droplets. Similar to our results, they found an increase in labeling intensity and 
frequency of labeled cells with increasing labeling concentration. However, we found no 
evidence of a detrimental effect of labeling on viability or functionality after 4 hours of 
labeling, whereas Helfer et al. found a slight decrease in viability. Both studies measured 
comparable 19F payloads. In addition, Partlow et al. showed internalization of 19F label 
in emulsion droplets in UCB mononuclear cells that were grown towards endothelial 
cells[6], which are different from the CD34+ cells we used in our study. The cells remained 
functional in vivo as well. We preferred to incorporate 19F in PLGA nanoparticles, because 
these are more stable than emulsion droplets, easier to store and the association with 
fluorescent dyes is more stable.
In a recent study, Ahrens et al. efficiently labeled human dendritic cells with a clini-
cal grade PFC agent without changes in viability or phenotype. In this phase 1 study, 
patients suffering from stage IV colorectal cancer subsequently received intradermal 
administration of 1x106 or 1x107 labeled dendritic cells and underwent a MRI scan at 2 
and 24 hours after administration. In the patients that received 1x106 dendritic cells, no 
19F signal was observed. However, 1x107 administered dendritic cells could be detected 
by MRI at both the 2 and 24 hour time point, although the number of dendritic cells de-
creased to approximately half of the original values at 24 hours, due to either cell efflux, 
cell migration or cell death [33]. Although dendritic cells are different from CD34+ cells as 
used in our experiments and the required number of injected cells is high, these results 
are very promising first steps in in vivo tracking of labeled human cells. 
In conclusion, CD34+ cells can be labeled efficiently with PFCE-PLGA NPs without af-
fecting cell functionality or viability. Labeled cells can be detected using MRS on a 7T 
MRI scanner. These results set the stage for in vivo tracking experiments, through which 
homing efficiency of transplanted cells can be studied.
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The preclinical development studies described in chapter 5 of this thesis served as the 
basis for the development of an expansion protocol for clinical application. In this chap-
ter, the translation of our experimental expansion protocol into a ‘Good Manufacturing 
Practice’ (GMP)-compliant expansion protocol for StemRegenin1 (SR1)-expanded umbili-
cal cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPC) products 
is described. In addition, the design and objectives of the clinical feasibility study to 
evaluate umbilical cord blood transplantation (UCBT) using a single SR1-expanded UCB 
unit is described.
manUfaCtUrE of GmP-GraDE Sr1-ExPanDED UCB-DErIVED HSPC 
ProDUCtS
Development of manufacturing process
In the experimental expansion protocol, research-grade SFEM medium was used in com-
bination with research-grade cytokines and SR1. To adapt the experimental protocol to 
GMP requirements, two commercially available media were compared with the research-
grade SFEM medium: i.e. StemSpan ACF medium, which is used in FDA-approved cell 
therapy trials in the USA, and CellGro SCGM medium, which is manufactured in compli-
ance with GMP guidelines. The three media were found to be more or less equally potent 
in total nucleated cell expansion and CD34+ cell expansion (figure 1). Also the yields of 
Lin-CD34+CD38lowCD45RA-CD90+ cells, which are highly enriched for primitive HSC, were 
similar. Based on these results and the fact that the CellGro SCGM medium is manufac-
tured according to GMP guidelines, it was decided to use the Cellgro SCGM medium in 
the GMP-compliant expansion protocol. Overall a stable and reproducible expansion of 
CD34+ cells of at least 30-fold in Cellgro SCGM medium within 12 days was observed.
figure 1. Expansion of total nucleated cells (left panel), CD34+ cells (middle panel) and 
Lin-CD34+CD38lowCD45RAlowCD90+ cells (right panel) after 12 days using StemSpan SFEM medium, Stem-
Span ACF medium and CellGro SCGM medium supplemented with SCF, Flt3L, TPO and 1µM of SR1 (n=3).
Next, the research-grade cytokines Stem Cell Factor (SCF), FMS-like tyrosine kinase 3 
ligand (Flt3L) and Thrombopoietin (TPO) were replaced by GMP-grade cytokines and a 
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similar fold expansion of total cells and CD34+ cells was found (data not shown). Finally, 
the research-grade SR1 which was used in the experimental protocol was changed into 
a custom-made GMP-grade SR1, produced by ChemConnection BV which holds a GMP 
license. The fold expansion of total nucleated cells and CD34+ cells and the yield of 
Lin-CD34+CD38lowCD45RA-CD90+ cells after 12 days of culture with research-grade and 
GMP-grade SR1 were found to be similar (figure 2). 
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figure 2. Expansion of total nucleated cells (left panel), CD34+ cells (middle panel) and 
Lin-CD34+CD38lowCD45RAlowCD90+ cells (right panel) after 11 or 12 days in expansion cultures supplemented 
with SCF, Flt3L, TPO and 1µM of SR1 from Axon Medchem or ChemConnection (n=3)
After showing that replacement of research-grade materials by GMP-grade materials re-
sulted in similar folds expansion of UCB-derived CD34+ cells, the production process was 
up-scaled and the open culture system in wells and flasks was transferred into a closed 
culture system in Vuelife® 290AC gas-permeable culture bags. The median CD34+ cell 
expansion after 12 days of culture in bags was 85.6 ± 28.8 fold. The fold expansion in bags 
was similar to the fold expansion in wells/flasks (figure 3). These results demonstrate that 
UCB-derived CD34+ cells can be efficiently expanded during 2 weeks of culture in Vuelife® 
culture bags.
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figure 3. Expansion of total nucleated cells (left panel) and CD34+ cells (right panel) in 12 days using Vuelife® 
290AC bags and wells and flasks (n=5). Cultures were supplemented with SCF, Flt3L, TPO and 1µM of SR1.
Description of the manufacturing process
A flowchart of all successive steps in the manufacturing process is shown in figure 4. 
The manufacturing process of SR1-expanded UCB-derived HSPC starts with a minimal 
manipulation of the selected cryopreserved UCB product. The acceptance criteria of 
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UCB units for ex vivo expansion and UCB units for direct infusion into patients are identi-
cal. The cryopreserved UCB product is thawed and washed, after which the CD34+ cell 
population is selected using CE-marked CliniMACS technology. The CD34+ cell fraction 
is released by the Responsible Person of the Tissue Establishment for further process-
figure 4. Flowchart of the production process of the SR1-expanded UCB-derived HSPC product including 
ancillary materials and excipients and in process controls.
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ing into an Advanced Therapy Medicinal Product (ATMP) on basis of predefined criteria, 
including viability, purity and number of CD34+ cells. 
The manufacturing process continues with a substantial manipulation (ex vivo expan-
sion) which falls under the GMP license for the production of an ATMP. All ancillary mate-
rials, e.g. media and cytokines, used in the production process are either manufactured 
in compliance with GMP guidelines or registered medicinal products. The selected CD34+ 
cells are cultured in serum-free CellGro SCGM expansion medium with hematopoietic 
cytokines (SCF, FLT3-L and TPO) and the aryl hydrocarbon receptor (AhR) antagonist SR1 
in a closed system using gas-permeable Vuelife™ culture bags for 10 days. Cultures are 
refreshed with expansion medium every 2-3 days to achieve the desired HSPC expansion. 
At several critical points during the production process, in process quality controls are 
performed (see figure 4). Quality controls include: bacterial and fungal contamination 
tests, White Blood Cell (WBC) count, overall viability and enumeration of viable CD34+ 
cells. The analytical procedures for the quality controls have been validated and are 
performed in accordance with the European Pharmacopeia. The criteria that have to be 
met are defined for each quality control at each time point.
At the end of the culture at day 10, cells are harvested, extensively washed to decrease 
ancillary material contamination in the final cell product below threshold levels. The final 
cell product is resuspended in 0,9% NaCl with 5% Human Serum Albumin. In addition 
to the standard in process quality controls, the final cell product is also analyzed for 
frequencies of phenotypic HSC, and mature T-, B- and NK-cells. The final UCB-derived ex 
vivo expanded HSPC product, when meeting the release criteria (see table 1), is released 
by the Qualified Person (QP) of the GMP facility. 
table 1. Validation of expansion protocol
Exp. 
nr.
Cell number at start of culture (x 106) Cell number at end of culture (x 106) fold expansion
WBC CD34+ cells WBC CD34+ cells WBC CD34+ cells
1 1,84 1,70 421 172 229 101
2 2,14 1,93 488 175 227 91
3 1,77 1,74 399 149 225 86
4 0,83 0,82 105 37 127 45
5 2,01 2,00 184 74 92 37
6 2,09 2,01 375 183 180 91
7 2,27 2,20 157 86 69 39
8 2,67 2,60 679 261 254 100
Exp. 1, 2 and 6 were started with selected CD34+ cells from a fresh UCB product and exp. 3, 4, 5, 7 and 8 were 
started with selected CD34+ cells from a cryopreserved UCB product.
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Validation of manufacturing process 
To demonstrate that the GMP-compliant manufacturing process is robust and reproduc-
ibly yield SR1-expanded UCB-derived HSPC products that meet the predefined release 
criteria, 8 validation runs were performed in which clinically relevant numbers of UCB-
derived CD34+ cells (i.e. > 0,5 x 106 CD34+ cells) were expanded in Vuelife® 290AC culture 
bags in SCGM medium with GMP-grade cytokines (SCF, Flt3L and TPO) and SR1. table 1 
summarizes the yields of WBC and CD34+ cells and the fold expansion of WBC and CD34+ 
cells in these validation procedures. The results of these 8 validation runs demonstrate 
that the end-product of the GMP-compliant manufacturing process always met the 
predetermined release criteria (see table 2). 
An investigational medicinal product dossier (IMPD) including summaries of informa-
tion on the development, quality, manufacturing process, controls and risk assessment 
of the SR1-expanded UCB-derived HSPC product has been developed. 
CLInICaL StUDy DESIGn 
Currently, double UCBT is generally applied in adult patients qualifying for cord blood 
transplantation in the Netherlands. Double UCBT was originally developed to improve 
engraftment by administering higher numbers of progenitor cells1. It has since been 
shown that sustained engraftment is observed in 85-100% of patients, both after my-
eloablative (MA) and after nonmyeloablative (NMA) conditioning regimens [1-5]. How-
ever, hematopoietic recovery generally originates from only a single unit and receovery 
times for neutrophils, platelets, and lymphocytes are still prolonged as compared to 
other alternative donor types.
table 2. Release criteria for UCB-derived ex vivo expanded HSPC product
In process test analysis method Criteria
Release of UCB-derived CD34+ cell fraction 
for ex vivo expansion by the Responsible 
Person of Tissue Establishment
- Present. 
Sterility (intermediate and end-products) Visual examination 
No signs of bacterial or fungal 
contamination. 
Sterility (end-product) Microbial culture: BacTec™ 
PEDS-culture bottle
No bacterial or fungal 
contamination. 
Viability (end-product) Trypan Blue exclusion ≥ 70 % trypan blue negative.
WBC count (end-product) Bürker counting chamber ≥ 50 x 106 nucleated cells.
CD34+ cell enumeration (end-product) Flow cytometry ≥ 20 x 106 viable CD34+ cells.
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Preceding studies: HoVon studies 106 and 115
Recently, results from the HOVON 106 study were published, showing the feasibility of 
double (dUCBT) preceded by a 4 Gy TBI containing reduced intensity conditioning (RIC) 
regimen in patients with poor-risk underlying hematological malignancies [6,7]. Data 
indicated that dUCBT following the above mentioned RIC regimen is feasible and may 
provide an important alternative source of hematopoietic stem cells in recipients lack-
ing a sibling or well matched unrelated donor (MUD). With a median follow-up of 35 
months, 2-year OS was 57%, 2 year TRM was 19%, and 2 year PFS was 42%. Thereafter, the 
HOVON-106 protocol has become the standard protocol for application of UCBT in adult 
patients in The 
Netherlands. Sustained hematopoiesis in dUCBT recipients was derived from a single 
donor in 90% of patients and early predominance was already discernible at days 7-14 
[6,7]. The mechanism of predominance was unclear, but subject of investigation in the 
succeeding HOVON 115 study. It was hypothesized that HLA class II specific CD4+ T cells 
of the ultimate engrafting UCB unit elicit an immediate and targeted alloreactive im-
mune response towards mismatched HLA class II molecules of the non-engrafting UCB 
cells, resulting in rapid rejection of the non-engrafting unit. The HOVON-115 trial was 
designed to test that hypothesis. It was shown that the majority of patients indeed de-
veloped an early expansion of CD4+ T-cells, including effector T-cells with specificity for 
mismatched class II alleles of the rejected cord. The majority of mismatched class II alleles 
between the 2 cords in each individual patient evoked an alloreactive response, which 
appeared most prominent early after transplantation [8]. These findings suggested that 
matching of the 2 cords at the allele level for class II is no longer obligatory and can be 
omitted, which expands the choices for dUCBT. Despite the low incidence of graft failure 
following dUCBT, hematopoietic recovery is usually slow with neutrophil recovery (>0.5 
x 10-9/L) around day 26 after transplantation and platelet recovery (>50) around day 50. 
Retarded hematopoietic recovery is mainly associated with the low number of HSPC in 
the graft. In order to increase these numbers, several investigators have initiated studies 
to expand HSPC ex vivo and improve hematopoietic recovery [9-21].
Expansion of hematopoietic stem cells
In this thesis, the history and current practice on the expansion of HSC are comprehen-
sively described. Currently, the hypothesis that ex vivo expansion of HSC requires a com-
bination of proliferative signals provided by hematopoietic growth factors with a factor 
that inhibits differentiation during culture has been studied extensively. Compounds 
including StemRegenin1 [20-21], copper chelation [14-15], mesenchymal stem cells [18-
19], Nicotinamide [12-13], and Notch ligand Delta-1 [16-17], were studied in order to test 
that hypothesis. Of these, especially SR1 was shown to be associated with inhibition of 
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differentiation and when used with early acting cytokines to result in strong expansion 
of HSPC (this thesis (Chapter 5); [20-21]). 
rationale of the study
Transplantation of SR1-expanded CD34+ cells in a clinical double cord blood setting ap-
peared safe and feasible and resulted in engraftment in all 17 transplanted patients [21]. 
The median time to neutrophil and platelet recovery was 15 and 49 days, respectively, 
which is faster compared to an historical control group receiving unmanipulated dUCBT. 
In 11/17 patients, hematopoiesis was primarily derived from the expanded unit and in 
those patients, neutrophil recovery was even more rapid with a median of 11 days versus 
23 days in the 6/17 patients engrafting with the unmanipulated unit [21]. These results 
have set the stage for clinical studies in a single UCBT setting, which is proposed here. 
Collectively, in view of 1. the rejection of one UCB graft in the majority of recipients of 
double UCBT, 2. the absent contribution of the rejected unit to hematopoietic recovery, 
and 3. the potency of SR1 to expand hematopoietic progenitor cells and thereby to 
improve engraftment and recovery, it is proposed to perform a feasibility study in 10-15 
patients evaluating single UCBT using one SR1 expanded unit. 
Study objectives
•	 To study the feasibility of single UCBT using one SR1-expanded unit
•	 To assess engraftment and engraftment kinetics; to evaluate immune reconstitution, 
acute and chronic Graft-Versus-Host Disease (GVHD), chimerism, toxicity, progres-
sion-free survival and overall survival after single unit UCBT, using with one ex vivo 
expanded unit. 
Study design
This is a prospective phase I-II feasibility study. Patients lacking a matched unrelated 
donor and patients for whom a matched unrelated donor cannot be identified within 2 
months and for whom an allogeneic transplant is urgently needed, are eligible for UCBT 
if a suitable UCB unit is available. Transplantation will be preceded by a reduced-intensity 
conditioning regimen, irrespective of patient age. Post grafting immunosuppression is 
performed by mycophenolate mofetil (30 days) and cyclosporine A (90 days, taper there-
after).
Study population
Eligibility for registration
All patients must be registered before start of treatment and must meet all of the follow-
ing eligibility criteria.
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Inclusion criteria
•	 Age 18-70 years inclusive
•	 Diagnosis of poor-risk hematological malignancy or (Very) Severe Anaplastic Anemia 
relapsing after or failing immunosuppressive therapy and meeting the criteria for a 
MUD allo-SCT 
•	 Lacking a sufficiently matched volunteer unrelated donor or lacking such a donor 
within the required time period of ≤ 2 months in case of urgently needed allo-SCT 
•	 Availability of 1 (≥5/6) matched UCB graft with a nuclear cell count > 2,7 x 107/kg (see 
paragraph 8.2). 
•	 Availability of a back-up autograft, harvested and frozen earlier in the course of treat-
ment, (harvest according to local apheresis policies)
•	 WHO performance status 0-2
•	 Written informed consent
Exclusion criteria
•	 Bilirubin and/or transaminases > 2.5 x normal value 
•	 Creatinine clearance < 40 ml/min
•	 Cardiac dysfunction as defined by:
- Reduced left ventricular function with an ejection fraction < 45% as measured by 
MUGA scan or echocardiogram (another method for measuring cardiac function is 
acceptable)
- Unstable angina
- Unstable cardiac arrhythmias
•	 Pulmonary function test with VC, FEV1 and/ or DCO < 50%
•	 Active, uncontrolled infection
•	 History of high dose (≥ 8 Gy) total body irradiation
•	 Pregnant or lactating females
•	 HIV positivity
UCB unit selection 
UCB units will be selected according to the following criteria: 
1. The total amount of total nucleated cells present in the UCB unit must be > 2.7 x 107/
kg recipient body weight.
2. HLA-matching is performed for HLA-A and HLA-B at the serological split resolution 
level and for HLA-DRB1 at the 4-digit resolution level. The minimal match grade 
required is a 5/6 match both between recipient and the UCB unit.
3. Absence of HLA-antibodies in the recipient directed against HLA class I and class II 
mismatches on the cord blood cells is required.
4. Preferably, RBC- and plasma reduced UCB units are selected.
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5. Preferably, ABO-compatible or minor ABO-mismatched UCB units are selected.
6. Preferably, UCB units are selected from NETCORD/FACT accredited UCB banks
Note: If recipient anti-A/anti-B titer >512, (NaCl gel card (Diamed, Switzerland)); incuba-
tion either at room temperature (IgM) or after treatment with 0.01M DTT at 37° C (IgG), 
major incompatible non-RBC reduced / non-plasma reduced CBUs are not administered.
treatment 
Conditioning regimen
A reduced-intensity conditioning regimen is used (table 3).
table 3. Reduced-intensity conditioning regimen used
agent Dose/day route of administration Days
Cyclophosphamide 60 mg/kg i.v. -7
Fludarabine 40 mg/m2 i.v. -6, -5, -4, -3
TBI 2 Gy -2, -1
Conditioning regimen and immunosuppression schedule
See table 4. 
table 4. Conditioning regimen and immunosuppression schedule
Day - 7 - 6 - 5 - 4 - 3 - 2 - 1 0 + 1
Cyclophosphamide X
Fludarabine X X X X
TBI X X
Infusion of ex vivo expanded HSPC product X
Infusion of UCB-CD34- fraction X
Cyclosporine A X X X X X X X→
MMF X X →
(Val)acyclovir X X →
Benzylpenicilline X X →
Cord blood processing, expansion and infusion
As outlined in the IMPD, the selected cord blood will be thawed, washed and CD34+ 
cells will be purified using immunomagnetic positive selection with a CliniMACS device 
according to Standard Operating Procedures (SOP’s) of the Transplantation Laboratory. 
The CD34 negative fraction that contains donor T-cells will be frozen again, according to 
SOP’s of the Transplantation Laboratory. The CD34 positive fraction will be released on 
basis of specific criteria, as described in the IMPD for further processing into an ATMP 
by the Responsible Person of the Tissue Establishment Transplantation Laboratory. 
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figure 5. Scheme of study
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Subsequently, CD34+ cells will be expanded in ex vivo cultures using a combination of 
cytokines and SR1, as detailed in the IMPD. The UCB-derived ex vivo expanded HSPC end 
product will be released by the QP of the GMP facility on basis of prespecified criteria 
(as outlined in detail in the IMPD). The manipulated UCB unit will contain after culture 
no red blood cells and will also be devoid of donor plasma, which obviates the need for 
additional precautions in case of major and minor ABO-incompatibility. The expanded 
graft will be infused on day 0, followed by thawing and infusion of the cryopreserved 
CD34 negative fraction on day +1.
The CD34 negative fraction contains RBC and residual donor plasma, which necessi-
tates the need for monitoring of hemolysis (haptoglobin, bilirubin, LDH, creatinine, CBC, 
DAT and plasma-Hb) in case of major- or minor AB0 blood group incompatibility. 
approval
As outlined above, a clinical study protocol and the IMPD have been submitted for ap-
proval to the competent authorities in the Netherlands, the Centrale Commissie Mensge-
bonden Onderzoek (CCMO).
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IntroDUCtIon
Umbilical cord blood (UCB) has emerged as an important alternative stem cell source 
for patients in need of an allogeneic hematopoietic stem cell transplantation (allo-
SCT) but lacking a HLA-matched related or unrelated donor. Compared to other donor 
sources, UCB is rapidly available because of the well-organized storage by public cord 
blood banks that are affiliated with international donor registries (1, 2) and require 
less stringent HLA-matching (3). However, the relatively low number of hematopoietic 
stem cells (HSC) in UCB units results in retarded hematopoietic recovery and a higher 
incidence of graft failure (4-6). Co-infusion of two UCB units, the so-called double UCB 
transplantation (dUCBT) to increase the number of HSC infused, results in sustained 
engraftment and less graft failure compared to single UCBT. However, hematopoietic 
recovery appeared still retarded and derived from a single unit with the other unit being 
rejected (7-10). Ex vivo expansion of HSC, as a means to increase the number of cells in 
the graft, has been studied extensively from bench to bedside (11-23). Other types of 
stem cells, such as embryonic stem cells and epithelial stem cells, can be expanded in 
cultures supplemented with a combination of growth factors to stimulate proliferation 
and a factor to inhibit differentiation. Based on this hypothesis, the combined effects 
of proliferation-inducing cytokines and a differentiation-inhibiting factor were studied 
with the aim to expand HSC. The studies described in this thesis were based on that 
hypothesis: two potential inhibitors of HSC differentiation, Wingless-related integration 
site protein 3a (Wnt3a) and the Aryl hydrocarbon Receptor (AhR) StemRegenin1 (SR1), 
were studied with the aim to develop a clinically applicable expansion protocol. While 
Wnt3a failed to inhibit hematopoietic differentiation in our in vitro culture system, SR1 
combined with early acting hematopoietic cytokines showed effective proliferation of 
hematopoietic progenitor cells accompanied with limited differentiation, resulting in the 
expansion of hematopoietic stem and progenitor cells (HSPC). Based on these studies, a 
clinical phase I study was developed. In the current chapter, we discuss the main findings 
of this thesis, the potential challenges and the future prospects of UCB transplantation 
using expanded HSPC. 
ImProVInG ex vIvo HSPC ExPanSIon StratEGIES
The ex vivo expansion of HSPC has progressed remarkably in the last decade but robust 
ex vivo expansion of the long term repopulating HSC remains a formidable challenge. 
The optimal HSPC expansion protocol should (1) generate a sufficient number of HSPC to 
perform a single unit UCBT, (2) shorten the time to hematopoietic and immune recovery, 
(3) achieve durable long-term engraftment and (4) be cost-effective. The currently used 
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expansion protocols for HSPC are based on extensive studies that have resulted in the 
identification of developmental regulators and chemical modulators that play a role in 
the regulation of self-renewal, differentiation and survival of HSC. Although fate decisions 
of HSC, balancing self-renewal, proliferation and differentiation, are controlled in vivo by 
a variety of factors (i.e. signaling molecules, direct cell-cell contact, circadian rhythm and 
oxygen level), most of the reported expansion protocols use, in addition to hematopoi-
etic cytokines, only a single differentiation-inhibiting or self-renewal promoting factor, 
including the protocols tested in chapters 4 and 5 of this thesis. Few studies investigated 
simultaneous activation or inhibition of multiple pathways known to be important in 
HSC fate decisions (21, 24, 25). In 2011, Perry et al.(25), studied the simultaneous activa-
tion of the PI3K pathway and the canonical Wnt pathway combined with hematopoietic 
growth factors in mouse HSPC expansion cultures. While neither pathway alone was 
sufficient to promote self-renewal, combined stimulation of both pathways resulted in 
robust expansion of immature HSPC which were capable of long-term engraftment in 
serial transplantations in immunodeficient mice. More recently, AhR antagonist SR1 was 
used in two studies, combining SR1 with Notch ligand Delta1 (24) and pyrimidoindole 
derivative UM171 (21). Combination of SR1 and Delta1 resulted in a threefold increased 
expansion of severe combined immune deficient mice (SCID) repopulating cells (SRC) 
compared to either agent alone. Delta1 increases the expression of the Notch target 
gene HES1, which is a transcriptional repressor that influences the differentiation of HSC. 
The authors hypothesized that the increase of HES1, which was not observed in cultures 
with SR1 alone, may be responsible, at least in part, for the delay in differentiation ob-
served in their culture system. Fares et al. discovered UM171, a pyrimidoindole derivative, 
working independently of AhR suppression. Their studies suggested that UM171 and SR1 
both affect very immature, but yet different, cell populations. Both compounds appeared 
to cooperate to enhance ex vivo expansion of progenitor cells and suppressed differen-
tiation. In this setting, interaction between the pathways is key, with each component 
making cooperative as well as unique contributions to HSC expansion. 
Expansion protocols using mesenchymal stem cells (MSC) as stromal layer are based 
on the same principle, since mesenchymal stem cell provide multiple signals for ex vivo 
expansion of HSPC (23). However, it is still unknown which MSC-derived signals are 
pivotal for ex vivo HSPC expansion. Moreover, co-culture of HSPC with MSC appears to 
preferentially expand committed progenitors at the expense of long-term repopulating 
HSC with self-renewal capacity.
Extracellular vesicles (EVs) are a newly uncovered means of intercellular communication 
that mediate cell-to-cell communication and regulate cell fate via the horizontal transfer 
of bioactive lipids, proteins and RNA. Recently, it has been described that MSC-derived 
EVs contain microRNAs (miRNAs) and Piwi-interacting RNAs (piRNAs) which were able 
to modify the gene expression profile of UCB-derived CD34+ cells, resulting in more vi-
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able, less differentiated cells (26). Furthermore, human osteoblast-derived EVs promoted 
proliferation and cell cycle progression of human UCB-derived HSPC and enhanced the 
ex vivo expansion of human UCB-derived HSPC, including the most immature subset in 
growth factor supported expansion cultures. EV-expanded HSPC retained their full differ-
entiation capacity in vitro and successfully engrafted in immune-deficient NSG mice (27). 
Interestingly, the expansion promoting effects of osteoblast-derived EVs on UCB-derived 
HSPC remained evident even in the presence of the differentiation inhibiting factor SR1. 
However, the molecular mechanisms underlying the EVs mediated expansion of HSPC 
still remain to be explored. 
Another strategy to improve engraftment and time to hematopoietic and immune 
recovery is to expose HSPC to factors that improve homing of HSPC towards the bone 
marrow niche. It is known that UCB-derived HSPC do not home as efficiently to the 
bone marrow as HSPC derived from adult bone marrow (28) and in addition, cytokine 
exposure of HSPC leads to a rapid loss of bone marrow homing capacity (29). Several 
strategies have been reported to enhance the homing capacity of HSPC and thereby 
enhance hematopoietic recovery post-transplantation, such as fucosylation of the HSPC 
ligands binding to P- and E-selectin adhesion molecules expressed on bone marrow 
endothelial cells (30, 31) or activation of ‘homing receptor’ CXCR4 on HSPC by treatment 
with 16,16-dimethyl prostaglandin E2 (dmPGE2) (32, 33). Practical advantage of these 
techniques is that they require minimal processing as the maximum incubation time is 
120 minutes. Strategies aiming to combine an optimized expansion protocol with an 
approach to improve the homing capacity of the expanded cells may result in a graft 
with optimal engraftment capacity and hematopoietic recovery potential.
ImmUnE rEConStItUtIon aftEr ExPanDED (D)UCBt
Of all the different expansion protocols, only few were tested clinically (14, 16, 18, 20, 
23). The studies by Horwitz et al. (14), Wagner et al. (20) and de Lima et al. (23), with lim-
ited patient numbers, showed significant enhanced hematopoietic recovery in terms of 
neutrophil and platelet recovery. Neutrophil recovery was accelerated by approximately 
10 days, while the time to platelet recovery (> 50 x 109/L) was reduced with 4 to 5 days. 
However, apart from protracted neutrophil and platelet recovery, especially retarded 
immune recovery is of concern, as non-relapse mortality (NRM) is especially associated 
with insufficient T cell recovery rather than protracted neutrophil recovery(34). T cell 
recovery after dUCBT was studied and described in chapter 2. A higher risk of severe 
infections in patients failing to recover thymopoiesis at 3 months post-transplantation 
was described, which compares well to our earlier observations in unrelated donor 
allo-SCT recipients (34).  Sofar, only one clinical study addressed the recovery of B and T 
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cells after expanded UCB transplantation (20), which failed to demonstrate improved T 
cell recovery upon engraftment of the expanded UCB unit compared to T cell recovery 
originating from the unmanipulated unit in a dUCBT setting. Of note, T cell recovery was 
even suggested to occur at a slower rate after transplantation using an expanded UCB 
unit (20). How to explain the latter findings? Different factors may be involved. First, it is 
still possible that expansion of true HSC was limited, while more committed progenitors 
were expanded at a greater degree, especially myeloid committed progenitors (35). The 
rapid neutrophil recovery rather than lymphoid recovery might support that explana-
tion. Secondly, T cell recovery not only depends on hematopoietic HSC engraftment but 
also depends on generation of lymphoid precursors, their entry into the thymus, and ef-
fective thymopoiesis. It is well known that thymopoiesis in adult patients can be severely 
compromised (36-38) despite efficient engraftment and early hematopoietic recovery. 
However, Wils et al. (36) showed that T cell recovery may be improved upon expansion of 
HSC and lymphoid progenitors in vivo by treatment with Flt3ligand of immunodeficient 
mice having received a bone marrow transplantation. Lastly, many transplant centers use 
G-SCF post-transplant to accelerate neutrophil recovery. That myeloid growth factor may 
skew hematopoietic recovery towards the myeloid lineage. Therefore, a slow rate of T cell 
recovery after UCBT with expanded HSC/HPC may be due to a combination of insufficient 
thymic function and insufficient generation and supply of lymphoid progenitors. Since T 
cell recovery is pivotal to reduce the toxic and potential lethal complications of allo-SCT, 
it is of the utmost importance to develop expansion strategies that also expand T cell 
precursors. Apart from the cytokines we applied in our expansion protocol (SCF, Flt3L 
and TPO), lymphopoietic cytokines including  IL-7 and  IL-15 might be considered. Both 
cytokines are acting as survival factors for (developing) T cells by the prevention of apop-
tosis through up- and downregulation of anti- and pro-apoptotic factors, respectively 
(39, 40). An alternative approach might the use of stromal cells, such as DL-1 expressing 
cells, in the expansion protocol. Interaction of HPC with DL-1 results in the generation of 
T cell progenitors, that may directly enter the thymus (41). Given the pivotal role of the 
thymic epithelium in T-cell recovery,  another strategy to improve T cell recovery might 
be the application of strategies that favorably affect the thymic epithelium. Possible 
strategies may include protection of the nursing stromal compartment by keratinocyte 
growth factor or by regeneration of the thymic epithelium (34). Altogether, it is clear that 
expansion of true hematopoietic stem cells is an important first step, but it might be nec-
essary to add strategies specially aiming to improve T cell recovery and thymic function. 
Therefore, in future clinical trials with ex vivo expanded stem cell grafts, endpoints should 
include improvement of T cell reconstitution and thymopoiesis, apart from neutrophil 
and platelet recovery. In addition, immune reconstitution data should be correlated to 
HSC and HPC numbers infused as well as to subsets of lymphoid and myeloid progenitors 
obtained after expansion.
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aLtErnatIVE DonorS
HLA-matched related and HLA 10/10 matched unrelated donors are currently considered 
as preferred donors for patients eligible for allo-SCT. However, many patients lack such 
a preferred donor and depend on alternative stem cell sources. Currently, alternative 
donors or stem cell sources include mismatched unrelated donors, haplo-identical 
family donors, and UCB. While the large retrospective registry study by Brunstein et al. 
suggested that disease free survival (DFS) in recipients of UCBT may come close to DFS 
following matched unrelated allo-SCT (51% versus 48%, respectively), NRM remains of 
concern (34% versus 14%, respectively)(42). The use of UCB as an alternative stem cell 
source for adult patients is hampered by the limited number of HSPC in most of the 
UCB grafts available, leading to susceptibility for infections and also NRM. In order to 
increase the number of HSPC, double UCBT was developed , which however insufficiently 
accelerated recovery and also appeared to be associated with high costs. Other alterna-
tive donor sources for patients lacking a matched related or unrelated donor include 
HLA-mismatched unrelated donors (MMUD, defined as 1 or 2 mismatches at class I and/
or class II) or haplo-identical family donors (haplo-SCT). Currently, no consensus has 
been reached as regards the hierarchy of alternative donors. Recently, several studies 
have been published discussing and comparing alternative transplant possibilities (43-
47). An important concern for the use of MMUD grafts is the higher risk of GVHD due 
to HLA-incompatibility. However, HLA-incompatibility may also be associated with a 
somewhat higher graft versus leukemia (GVL) effect, preventing disease relapse. A recent 
meta-analysis comparing overall survival after MUD and MMUD showed an increased 
mortality risk of 27% for patients receiving a MMUD (43). It indicates that the excess rate 
of NRM was insufficiently compensated by a lower risk of relapse, leading to significantly 
reduced OS. In the past, results obtained with haplo-SCT suggested a similar pattern of 
increased NRM associated with increased degree of HLA-incompatibility, which is insuf-
ficiently counteracted by a reduced relapse rate (48, 49). As a result of observed high 
NRM, also autologous transplantation has been brought forward as an alternative stem 
cell source (50, 51). While the latter stem cell source lacks allogenic T cells and thereby 
is devoid of the allogeneic GVL-effect, the very low rate of NRM may favor that mode of 
transplantation. Especially in leukemia patients, autografting may provide for an alter-
native stem cells source if no HLA-identical sibling or MUD is available (52). However, 
the last decade has witnessed an enormous surge in haplo-SCT, because of significant 
progress in the prevention of GVHD and thereby reduction of NRM. Especially the use of 
post-transplant cyclophosphamide, as explored by the Baltimore group (53, 54) appeared 
associated with effective prevention of GVHD and limited NRM. Of note, an accompany-
ing increase of relapse, as may be expected by inhibition and elimination of allogeneic 
haplo-identical T-cells, has sofar not been demonstrated. These results suggest that the 
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net result of low NRM and an acceptable risk of relapse may favor haplo-SCT. In addition, 
benefits of haplo-SCT include the rapid availability of the donor, the option for subse-
quent donor lymphocyte infusions and the relatively low costs. When compared to UCBT, 
clinical outcome after haplo-SCT was reported to be largely similar in terms of relapse 
incidence, NRM and relapse-free survival (RFS) in a retrospective study including patients 
with acute leukemia (46). However, higher rates of relapse and lower rates of NRM, result-
ing in similar OS, have been reported as well (47). Preliminary findings in a large group 
of high-risk AML patients showed a lower relapse rate and similar NRM upon haplo-SCT 
(using post-transplant cyclophosphamide) compared to UCBT, resulting in better OS and 
RFS at 2 years post-transplantation (55). Collectively, recent studies have shown a clear 
improvement in haplo-SCT, while NRM following UCB remains of concern. Future studies 
using expanded UCB will answer the question whether manipulation of UCB grafts may 
be associated with less NRM and to what extent that will compare to haplo-SCT. Until 
results of those studies become available, allo-SCT using sibling and MUD donors are 
still to be preferred, while haploidentical donors and UCB can be considered as preferred 
alternative donors and mismatched unrelated donors as third alternative, which then, 
however, should also be weighed versus autologous transplantation.
ConCLUSIon
The field of alternative donor transplantation is currently rapidly evolving. Although 
hampered by the small size of the grafts, UCB is an important stem cell source for patients 
in high need of an allogenic HSC donor. Ex vivo expansion protocols using a combination 
of signals to inhibit differentiation in combination with proliferation inducing growth 
factors are promising. Preclinical studies as described in this thesis and clinical studies in 
dUCBT settings have set the stage for a clinical feasibility study of expanded HSPC in a 
single unit setting. Results of that study as well as those addressing other approaches to 
expand HSC are eagerly awaited.
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The first allogeneic hematopoietic stem cell transplantation (allo-SCT) using umbilical 
cord blood (UCB) was performed in 1988 in a patient with Fanconi’s anemia. Over the 
past decades, UCB has emerged as an important alternative stem cell source in patients 
in need of an allo-SCT but lacking a matched related or unrelated donor. To date (2016), 
more than 35,000 UCB transplantations (UCBT) have been performed. Advantages 
of UCB as a stem cell source are its rapid availability and less stringent HLA-matching 
criteria. However, adult patients receiving UCBT show retracted hematopoietic recovery 
and a higher incidence of graft failure compared to recipients of other stem cell sources. 
An association between time to hematopoietic recovery and numbers of nucleated 
cells (NC) in the graft resulted in guidelines discouraging the use of UCB grafts with low 
numbers of NC. The total number of NC is generally used as a reflection of the number 
of hematopoietic stem cells (HSC) in the UCB graft. However, the NC threshold adhered 
to severely limits the number of grafts suitable for transplantation, especially for adult 
patients. Double UCBT (dUCBT) was developed in order to increase the number of HSC 
and thereby to improve engraftment and recovery.  Although less graft failure was ob-
served, hematopoietic recovery appeared still retarded and is generally accounted for 
by a single unit with the other unit being rejected.  In order to increase the number of 
HSC per UCB unit, the expansion of HSC and hematopoietic progenitor cells (HPC) in 
vitro has been studied extensively (Chapter 1). Studies in the eighties and nineties of 
the last century focused on the application of early acting hematopoietic growth factors, 
which exert proliferative, anti-apoptotic, and differentiation inducing effects in HSC. The 
latter phenomenon proved to be an overriding effect resulting in the generation of large 
numbers of differentiated cells accompanied by loss of HSC. Thereafter, the combined 
effects of proliferation inducing cytokines and a differentiation inhibiting factor was 
studied with the aim to expand HSC and prevent their differentiation and exhaustion. 
The underlying hypothesis was based on observations in embryonic and epithelial stem 
cells, which could effectively be expanded by a combination of early acting cytokines 
and a differentiation inhibiting factor (see figure 2, Chapter 1) The studies described 
in this thesis were based on exactly that hypothesis. Two potential inhibitors of HSC dif-
ferentiation were studied, namely Wnt3a and the Aryl hydrocarbon Receptor antagonist 
StemRegenin1 (SR1). Only studies with SR1 ultimately supported our hypothesis and, 
therefore, provided a basis for the development of a clinical study.
In Chapter 2 a retrospective study on hematopoietic and immune reconstitution in 
recipients of dUCBT is described. Clinical outcome, including infection rate and non-
relapse mortality (NRM), were correlated to immune reconstitution in a group of 55 high-
risk patients receiving dUCBT. While B and NK cell recovery was relatively rapid (values 
returned within the normal range at 6 and 2 months respectively), T cell recovery was 
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severely retarded. At 24 months post-transplantation, the median level of CD3+ T cells 
had not reached the lower normal range limit. Although T cell numbers were very low, 
newly formed sjTREC+ T cells were detectable in the majority of patients at 3, 6 and 12 
months post-transplantation. Median frequency of sjTREC+ T cells per 105 CD3+ T cells 
and median sjTREC+ T cell content per milliliter blood increased over time, but at 12 
months post-transplantation, both frequency and content had not recovered to normal 
values. The absence of sjTREC+ T cells at 3 months post-transplantation appeared associ-
ated with a higher risk for severe infections after that time point. These results show that 
a retarded T-cell recovery and subsequent susceptibility for infections are a pronounced 
feature of dUCBT. 
In Chapter 3 the protein Wingless-int3a (Wnt3a) in combination with the cytokines 
Stem Cell Factor (SCF) and Thrombopoietin (TPO) is studied using mouse HSPC. Wnt 
proteins have been implicated to play an important role in the regulation of stem cells, 
including embryonal stem cells and HSC. Based on the potential differentiating inhibi-
tory effects of Wnt3a, we investigated whether the combination of the tyrosine kinase 
receptor activating growth factors SCF, Flt3L, and TPO and Wnt3a would result in expan-
sion of HSC. Addition of Wnt3a to our culture system resulted in a reduced number of 
HSPC, as measured by flow cytometry. To increase the stability of Wnt3a and prolong 
its half-life, Wnt3a was tethered onto liposomes resulting in the formation of ‘liposomal 
Wnt3a’. Similar to purified Wnt3a, liposomal Wnt3a resulted in a reduced number of 
HSPC. Overexpression of the anti-apoptotic BCL2 protein failed to rescue the negative 
impact of Wnt signals on HSPC numbers, suggesting that the loss of HSPC was not due 
to apoptosis. An alternative explanation for the reduced number of HSPC is increased 
differentiation by the combination of the growth factors used and Wnt3a.
Chapter 4 describes the evaluation of the combined effects of Wnt3a and early act-
ing cytokines, SCF, TPO and FMS-like tyrosine kinase 3 ligand (Flt3L) with respect to the 
expansion of human UCB-derived HSPC. Similar to observations with murine HSPC, com-
bining Wnt3a with the hematopoietic growth factors SCF, Flt3L and TPO resulted in less 
expansion of CD34+ cells compared to these growth factors alone.  The reduced expan-
sion was also observed in cultures initiated with Lin-CD34+CD38lowCD45RAlowCD90+ cells, 
which are highly enriched for HSC. The effect was due to the activation of the canonical 
Wnt pathway by binding of Wnt3a to its receptor, as was shown by blockade of Wnt3a 
binding to its receptor using a Wnt antagonist. Stabilization of Wnt3a in liposomes effec-
tively increased its half-life, but failed to increase expansion of HSPC. In addition, Wnt3a 
reduced the frequency of multilineage CFU-GEMM and the long-term repopulation abil-
ity of the expanded cells in immuno-deficient mice. In conclusion, the results described 
in Chapters 3 and 4 show that, in contrast to our hypothesis, Wnt3a failed to inhibit 
the enormous differentiation induced by the growth factors. Rather, the combination of 
Wnt3a and the growth factors SCF, TPO and Flt3L resulted in increased differentiation. 
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Additional signals might be needed to inhibit growth factor induced proliferation and 
differentiation. 
In Chapter 5 the Aryl hydrocarbon Receptor (AhR) antagonist StemRegenin1 (SR1), a 
strong inhibitor of hematopoietic cell differentiation, is described. An earlier study by 
Boitano and coworkers suggested that SR1 combined with hematopoietic growth factors 
could result in expansion of HSPC. Here, we show that SR1 in combination with the early 
acting hematopoietic growth factors SCF, Flt3L and TPO induces a more than 25-fold 
expansion of the most primitive subset, as measured by flow cytometry. It is important 
to emphasize that flow cytometric techniques are still not able to identify true HSC, 
capable of self-renewal and multilineage differentiation. The expanded population of 
cells retained their functional properties as assessed in long-term culture systems (LTC-IC 
assays), which currently is the best in vitro surrogate assay for primitive HSC. Transplanta-
tion of SR1-expanded UCB cells into sublethally irradiated NSG mice resulted in long-term 
multilineage engraftment. Strikingly, human chimerism levels in blood were reduced as 
compared to levels obtained after the transplantation of non-expanded cells. Of note, 
the mouse model used, the NSG mouse, results in a preferable outgrowth of B cells. Ex-
pansion using a combination of cytokines and SR1 results in expansion of HPC, but with 
relative low numbers of B cell progenitors. A preferential increase of myeloid precursors 
at the expense of lymphoid precursors upon expansion cultures might explain reduced 
human chimerism levels as was observed in vivo. In addition, impaired homing of the 
expanded cells could play a part as well. Expansion may result in decreased homing 
capacity by the loss of essential homing (surface) proteins. 
To visualize the homing of transplanted HSPC to the bone marrow, a 19F-labeling pro-
tocol was designed. Chapter 6 describes the successful labeling of UCB-derived CD34+ 
cells using poly(lactic-co-glycolic acid) (PLGA) nanoparticles that contain 19F and can be 
detected by both flow cytometry and magnetic resonance spectroscopy. These intracel-
lularly labeled CD34+ cells maintained their capacity to proliferate and differentiate, 
characteristics pivotal for successful engraftment upon transplantation. These results set 
the stage for in vivo tracking experiments, studying the homing capacity of expanded 
and non-expanded cells. 
The research expansion protocol for HSPC described in Chapter 5 was translated 
into a Good Manufacturing Practice (GMP) expansion protocol, that can be used for 
the expansion of UCB-derived HSPC intended for transplantation in patients suffering 
from hematological malignancies. This process is described in Chapter 7. Using the GMP 
expansion protocol, similar levels of expansion of HSPC were obtained as compared to 
the expansion levels using the research grade protocol. The setup of a clinical study is 
described, aiming to assess the safety and feasibility of transplantation of SR1-expanded 
UCB-derived HSPC in a single graft setting in a total of 10 patients.
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Finally, the implications of the findings described in this thesis for the future are 
discussed in Chapter 8. The quest for the optimal protocol for ex vivo expansion and 
the study of its effects on subsequent in vivo engraftment will continue. In addition, 
early clinical studies are pivotal to address whether the current practice using double 
transplants can be abandoned and if transplantations using expanded single units 
result in similar, or better, clinical outcome. Finally, UCB should be compared with other 
alternative donor sources, such as adult mismatched unrelated donors and non-matched 
(haplo-identical) family donors. 
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De eerste allogene hematopoëtische stamceltransplantatie (allo-SCT) waarbij gebruik 
gemaakt werd van navelstrengbloed werd in 1988 uitgevoerd bij een patiënt met Fanconi 
Anemie. De afgelopen decennia heeft navelstrengbloed zich ontwikkeld tot een belang-
rijke alternatieve stamcelbron voor patiënten die een allo-SCT nodig hebben, maar waar-
bij geen passende verwante of niet-verwante donor beschikbaar is. Momenteel (2016) 
zijn er wereldwijd al meer dan 35.000 navelstrengbloedtransplantaties uitgevoerd. Bij 
volwassen patiënten, die een navelstrengbloedtransplantatie krijgen, duurt het herstel 
van witte bloedcellen en bloedplaatjes vaak lang en komt uitblijvend herstel ("graft 
failure") vaker voor in vergelijking tot andere stamcelbronnen voor allo-SCT. Dit bleek 
terug te voeren op het geringe aantal bloedstamcellen (verder 'stamcellen') in navel-
strengbloed en heeft geleid tot richtlijnen, waarin het gebruik van navelstrengbloedeen-
heden met een klein aantal stamcellen afgeraden wordt. Hierdoor vermindert het aantal 
eenheden dat geschikt is voor transplantatie, met name in volwassen patiënten, echter 
aanzienlijk. Teneinde het aantal stamcellen te verhogen werd de dubbele navelstreng-
bloedtransplantatie ontwikkeld. "Graft failure" werd minder vaak waargenomen, maar 
het hematopoëtisch herstel bleek niet verbeterd, mogelijk als gevolg van afstoting van 
een van de twee gegeven eenheden. Teneinde het aantal stamcellen per navelstreng-
bloed eenheid te doen toenemen, is internationaal veel onderzoek gedaan naar expansie 
van navelstrengbloedstamcellen in het laboratorium (hoofdstuk 1). In de jaren '80 en 
'90 werden expansieprotocollen ontwikkeld met daarin hematopoëtische groeifactoren, 
welke zorgden voor proliferatie en overleving, maar ook uitrijping van de stamcellen. Dit 
resulteerde in de productie van grote aantallen uitgerijpte voorlopercellen, terwijl de 
stamcellen niet meer aanwezig waren. Op basis hiervan, werd de combinatie proliferatie 
stimulerende groeifactoren met een factor die de uitrijping remt bestudeerd met als 
doel stamcellen te expanderen zonder dat zij uitrijpen of uitputten. De onderliggende 
hypothese was gebaseerd op observaties gedaan in studies met embryonale en epitheli-
ale stamcellen, welke geëxpandeerd konden worden door de combinatie van specifieke 
groeifactoren en een factor die de uitrijping remt (zie figuur 2, hoofdstuk 1)   De in dit 
proefschrift beschreven studies zijn gebaseerd op exact die hypothese. Twee potentiele 
remmers van stamcel uitrijping zijn onderzocht, namelijk Wnt3a en Aryl hydrocarbon 
Receptor antagonist StemRegenin1 (SR1). Alleen het onderzoek naar SR1 ondersteunde 
onze hypothese en heeft de basis gelegd voor de ontwikkeling van een protocol voor 
een klinische studie. 
In hoofdstuk 2 wordt een retrospectief onderzoek naar het hematopoëtisch en immu-
nologisch herstel na transplantatie met twee navelstrengbloedeenheden beschreven. 
Klinische uitkomstmaten, inclusief het aantal infecties, werden gerelateerd aan het im-
munologisch herstel in 55 ontvangers van een dubbele navelstrengbloedtransplantatie. 
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Terwijl herstel van B- en NK-cellen relatief vlot plaatsvond na transplantatie (respectievelijk 
na 6 en na 2 maanden), bleek het T-cel herstel erg traag. Na 24 maanden lag het mediane 
aantal T-cellen nog steeds onder de normaalwaarde. Hoewel de T-cel aantallen erg laag 
waren, werden bij de meeste patiënten op 3, 6 en 12 maanden na transplantatie nieuwe, 
in de thymus gevormde sjTREC+ T-cellen aangetroffen. De mediane sjTREC frequentie 
per 105 CD3+ T-cellen en het mediane aantal sjTREC+ T-cellen per millimeter bloed nam in 
de loop van de tijd toe, maar 12 maanden na transplantatie waren zowel de frequentie 
als het aantal nog niet terug op de normale waardes. Onderzocht werd of het herstel 
van de thymusfunctie, gemeten aan de aanwezigheid van sjTREC+ T-cellen, verband hield 
met ernstige infecties en sterfte als gevolg van complicaties. Met name uitblijven van 
herstel van nieuwgevormde T-cellen in de thymus op 3 maanden na transplantatie bleek 
voorspellend voor ernstige opportunistische infecties daarna. Hoe hoger het aantal 
sjTREC+ T-cellen in het bloed, hoe lager de kans op infectie. Deze resultaten tonen aan 
dat het trage hematopoëtische herstel na dubbele navelstrengbloedtransplantatie het 
meest uitgesproken is wat betreft het T-cel herstel. Naast het geven van meer stamcellen 
zouden ook interventies gericht op verbetering van thymusfunctie verder onderzocht 
moeten worden. 
In hoofdstuk 3 wordt effect van het eiwit Wingless-int3a (Wnt3a) op de proliferatie en 
differentiatie van muizen stam- en voorlopercellen onderzocht. Wnt eiwitten spelen een 
belangrijke rol bij de deling en rijping van stamcellen, waaronder embryonale stamcellen 
en bloedstamcellen. De hypothese was dat een combinatie van tyrosine kinase receptor 
activerende groeifactoren in combinatie met Wnt3a expansie van stamcellen zou kunnen 
geven, zoals eerder gezien met embryonale stamcellen, waarbij het Wnt-effect berustte 
op remming van de uitrijping. Toevoeging van Wnt3a aan ons kweeksysteem, (met daarin 
ook hematopoëtische groeifactoren die aangrijpen op tyrosine kinase receptoren) leidde 
echter tot een vermindering van het aantal stam- en voorlopercellen, zoals gemeten door 
middel van flowcytometrie. Teneinde de stabiliteit te verhogen en de halfwaardetijd te 
verlengen werd Wnt3a geladen op liposomen (liposomaal-Wnt3a), hetgeen echter op-
nieuw leidde tot een vermindering van het aantal stam- en voorlopercellen. Overexpres-
sie van het anti-apoptotische BCL2 proteïne in stam- en voorlopercellen had geen effect 
op de vermindering van het aantal stam- en voorlopercellen door Wnt3a. Dit suggereert 
dat de Wnt3a-geïnduceerde vermindering van het aantal stam- en voorlopercellen niet 
het gevolg is van apoptose. Een mogelijke verklaring voor het lagere aantal stam- en 
voorlopercellen is onvoldoende remming en zelfs toename van uitrijping onder invloed 
van de combinatie van groeifactoren en Wnt3a.
In hoofdstuk 4 wordt het effect van Wnt3a beschreven op expansie van humane CD34+ 
cellen, een populatie van cellen bestaande uit stam- en voorlopercellen. Gelijk aan de 
observatie bij muizen stam-en voorlopercellen, bleek te combinatie van groeifactoren en 
Wnt3a te leiden tot minder expansie van het aantal CD34-positieve cellen in vergelijking 
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met stimulatie d.m.v. groeifactoren alleen. Dit effect werd ook waargenomen in kweken 
met Lin-CD34+CD38lowCD45RA-CD90+ cellen, die in hoge mate verrijkt zijn voor stamcel-
len. Het waargenomen effect was te wijten aan de activering van de Wnt signaalroute, 
waarbij Wnt3a aan diens receptor bond en stabilisering van Wnt3a tot liposomaal Wnt3a 
leidde andermaal niet tot een verhoogde expansie van stam- en voorlopercellen. Wnt3a 
verminderde ook het aantal multilineage kolonies (CFU-GEMM) en het vermogen tot 
succesvolle transplantatie in immuun gecompromitteerde NSG muizen. Concluderend 
wordt gesteld dat de in de hoofdstukken 3 en 4 beschreven data, in tegenstelling tot 
onze hypothese, aantonen dat Wnt3a de uitrijping geïnduceerd door de groeifactoren 
niet kan remmen. Daarentegen zagen we juist iets meer uitrijping door de combinatie 
van groeifactoren en Wnt3a. De door hematopoëtische groeifactoren geïnduceerde 
celdeling en celrijping benodigen derhalve aanvullende signalen om de rijping te blok-
keren. 
In hoofdstuk 5 wordt een studie beschreven, waarin gebruik gemaakt werd van 
een sterke remmer van de celrijping, namelijk de Aryl hydrocarbon Receptor (AhR) 
antagonist StemRegenin1 (SR1). Een eerdere studie in een ander centrum suggereerde 
dat SR1 in combinatie met hematopoëtische groeifactoren wel zou kunnen leiden tot 
stamcelexpansie. Wij laten zien dat SR1 de expansie van humane stam- en voorlopercel-
len inderdaad bevordert. De celpopulatie die het meest verrijkt is voor echte stamcellen 
(Lin-CD34+CD38lowCD45RA-CD90+ cellen) expandeerde meer dan 25 maal in 2 weken. 
Overigens dient benadrukt te worden, dat de werkelijke bloedstamcel, die zichzelf kan 
vermeerderen en ook alle cellijnen als nakomelingen kan genereren, nog steeds niet 
met flowcytometrische technieken precies aangetoond kan worden. De geëxpandeerde 
stam- en voorlopercellen behielden hun functionele eigenschappen, zoals o.a. gemeten 
in lange termijn kweeksystemen (de zogenaamde LTC-IC testen), welke momenteel de 
beste in vitro surrogaattest voor primitieve stamcellen vertegenwoordigt.  Transplantatie 
van SR1-geëxpandeerde cellen in bestraalde NSG-muizen resulteerde in herstel van rijpe 
humane cellen in het perifere bloed. Opvallend genoeg bleek het percentage humaan 
chimerisme na transplantatie van SR1-geëxpandeerde humane stam- en voorlopercellen 
lager dan na transplantatie van niet-geëxpandeerde humane stam- en voorlopercellen. 
De meest waarschijnlijke verklaring hiervoor is het gekozen muizenmodel, waarin met 
name rijpe humane B-cellen ontstaan. Expansie met groeifactoren en SR1 leidt weliswaar 
tot stam- en voorlopercel expansie, maar met een relatief laag aantal voorloper B-cellen 
en juist een hoog aantal myeloïde voorlopercellen. Deze verdeling van voorlopercellen 
na expansie is een mogelijke verklaring van het lagere percentage humaan chimerisme. 
Daarnaast zou ook de nesteling ("homing") van de stam- en voorlopercellen een rol 
kunnen spelen. Expansie zou kunnen leiden tot een verminderde homing-capaciteit, als 
gevolg van verlies van daartoe benodigde (oppervlakte) eiwitten op de geëxpandeerde 
stam- en voorlopercellen. 
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Om homing van getransplanteerde stam- en voorlopercellen naar het beenmerg zicht-
baar te kunnen maken, werd een Fluor-19-labeling protocol voor stam- en voorlopercel-
len ontworpen. In hoofdstuk 6 wordt beschreven hoe stamcellen uit navelstrengbloed 
met succes gelabeld kunnen worden met poly(lactic-co-glycolic acid) (PLGA) nanodeel-
tjes die Fluor-19 bevatten. Fluor-19-gelabelde cellen kunnen worden opgespoord met 
behulp van zowel flowcytometrie als magnetische resonantie spectroscopie (MRS). Deze 
intracellulair gelabelde stamcellen behielden hun capaciteit om in vitro te prolifereren en 
differentiëren, eigenschappen die essentieel zijn voor een geslaagde uitkomst na trans-
plantatie. Deze studie heeft de weg vrijgemaakt voor toekomstige in vivo experimenten, 
waarbij de homing-capaciteit van geëxpandeerde en niet-geëxpandeerde cellen naar 
het beenmerg wordt onderzocht. 
In hoofdstuk 7 wordt beschreven hoe het in hoofdstuk 5 ontwikkelde laboratorium 
expansieprotocol voor het expanderen van stam- en voorlopercellen werd vertaald in 
een Good Manufacturing Practice (GMP)-expansieprotocol dat gebruikt kan worden 
voor transplantatie in patiënten met bloedkanker. Met het GMP-expansieprotocol werd 
een vergelijkbare expansie van stam- en voorlopercellen verkregen als het met labora-
torium expansieprotocol als beschreven in hoofdstuk 5. Daarnaast beschrijven we de 
opzet van een klinische studie waarvan het doel is om de veiligheid van transplantatie 
van SR1-geëxpandeerde van stam- en voorlopercellen afkomstig van één navelstreng-
bloedeenhied te evalueren. In deze studie zullen 10 patiënten geïncludeerd worden. 
Ten slotte worden in hoofdstuk 8 van dit proefschrift de implicaties van onze bevin-
dingen voor de toekomst beschreven. De zoektocht naar het optimale ex vivo expansie 
protocol gaat verder. Daarnaast zijn vroeg-klinische studies nodig om na te gaan of de 
huidige praktijk met dubbele navelstrengbloedtransplantaten verlaten kan worden in 
volwassen patiënten en transplantaties met enkele geëxpandeerde navelstrengbloed 
eenheden dezelfde, zo niet betere, klinische resultaten zullen geven. Tenslotte zal 
navelstrengbloed afgewogen dienen te worden tegen andere alternatieve stamcelbron-
nen zoals die van volwassen onverwante donoren of niet-passende (haplo-identieke) 
familiedonoren. 
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Lucia Duinhouwer werd op 18 april 1988 geboren in Rotterdam en bracht haar geluk-
kige jeugd door onder de rook van deze prachtige stad. In 2006 behaalde zij cum laude 
haar gymnasiumdiploma aan het Einstein Lyceum te Hoogvliet Rotterdam. In datzelfde 
jaar begon zij aan de studie Geneeskunde aan de Erasmus Universiteit Rotterdam. Zij 
behaalde haar doctoraal diploma in augustus 2010 en startte aansluitend met een pro-
motietraject op de afdeling Hematologie onder leiding van dr. E. Braakman en prof. dr. J.J. 
Cornelissen, waarvan de resultaten staan beschreven in dit proefschrift. In oktober 2013 
pakte zij haar studie Geneeskunde weer op en startte met haar coschappen. In november 
2015 behaalde zij cum laude haar artsexamen, waarop zij als ANIOS Chirurgie aan de slag 
ging in het IJsselland Ziekenhuis te Capelle aan den IJssel (dr. I. Dawson). Op 1 januari 
2017 start zij met haar opleiding tot chirurg in de regio Rotterdam (dr. B. Wijnhoven). 
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DanKWoorD
Eindelijk, na jaren werk, is het zover: het is af. Ik had dit proefschrift nooit kunnen schrijven 
zonder de hulp van velen en in dit laatste, meest gelezen, deel van mijn proefschrift pro-
beer ik iedereen te bedanken die mij de afgelopen jaren heeft geholpen en bijgestaan.
Prof.dr. Cornelissen, beste Jan, het is ondertussen alweer meer dan 8 jaar geleden dat 
ik als tweedejaars geneeskundestudent, in het kader van keuzeonderwijs, onder jouw 
hoede een review schreef over de rol van Imatinib in de behandeling van CML. Via wat 
databasewerk en mijn keuzeonderzoek over chimerisme na stamceltransplantaties kwa-
men we uiteindelijk bij dit promotietraject aan. Een fantastische kans die jij me bood en 
wat ben ik blij dat ik hem met beide handen heb aangegrepen. Er waren ups en uiteraard 
ook downs en we konden zeker van mening verschillen, maar uiteindelijk wist je mij 
altijd weer te motiveren verder te gaan. Ik waardeer zeer dat je tijdens de laatste loodjes 
zelfs op je vrije zondag naar het lab kwam om nog even wat laatste revisies met mij 
door te nemen. Ik kijk uit naar de eerste resultaten van de klinische fase van het project! 
Ook al ga ik in de kliniek een andere kant op, ik hoop je nog zeker tegen te komen in de 
toekomst en van je te mogen leren.
Dr. Braakman, beste Eric, waar moet ik beginnen jou te bedanken? Dankzij jouw dage-
lijkse begeleiding is dit proefschrift uiteindelijk geworden wat het is. Precies tot op de 
komma, en daar werd ik heus weleens gek van, maar uiteindelijk heeft het zijn vruchten 
afgeworpen. Jouw deur stond altijd open, zeker in de laatste fase, toen ik vaak onaange-
kondigd kwam binnenvallen. Ik heb ontzettend veel van je geleerd de afgelopen jaren 
en daar ben ik je heel dankbaar voor. Ik wens je ontzettend veel succes met het nieuwe 
project en hoop je nog zeker tegen te komen in de toekomst!
Ik wil graag prof.dr. Löwenberg, prof.dr. Van Leeuwen en prof.dr. Zwaginga bedan-
ken voor het plaatsnemen in de leescommissie en het kritisch lezen van mijn proefschrift. 
Beste Bob, ik wil u bedanken voor de fijne gesprekken toen we ‘kamergenoten’ waren in 
EE1300. Ondanks uw drukke schema nam u altijd even de tijd hiervoor en ik heb zeer veel 
gehad aan uw inzichten en adviezen.
De leden van de grote commissie, dr. ten Berge, dr. Bernsen en dr. Boelens, wil ik graag 
bedanken voor het plaatsnemen hierin.
Elwin, aan jou 6 jaar geleden de ondankbare taak om deze geneeskundestudent, die 
nog nooit een pipet had vastgehouden, alle kneepjes van het vak te leren. En dat heb je 
gedaan! Celisolaties, kweken, FACSen, bijna alle labtechnieken gebruikt in dit proefschrift 
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heb ik van jou geleerd. Daarnaast heb je zelf ook nog ontzettend veel werk verricht voor 
het project, zonder jou was dit proefschrift niet mogelijk geweest. Ik wil je hiervoor, en 
voor onze gezellige praatjes in de gang, ontzettend bedanken en ik wens jou en je gezin 
alle goeds voor de toekomst! mariëtte, wat was het een schot in de roos om jou aan te 
nemen als analist! Je hebt ontzettend veel werk verricht voor het project, en als ik je naar 
een bepaald experiment vroeg, wist je door je nauwkeurige manier van werken precies 
waar je de data kon vinden. Ik kan ook niemand bedenken die beter geschikt om de 
transplantaten in de clean room te bewerken voor de klinische fase van het project dan 
jij. Ik wens je veel geluk met je mooie gezin en hopelijk tot ziens! Oud-collega’s van de 
Braakman/Cornelissen groep, Eric, Irene en amiet wil ik bedanken voor hun hulp op het 
lab, input tijdens werkbesprekingen en gezelligheid tussen het werken door!
De collega’s van het transplantatielab wil ik bedanken voor het feit dat ik altijd gebruik 
mocht maken van hun apparatuur en de leuke gesprekken die we ondertussen hadden. 
Het was heel fijn samenwerken met jullie! Speciale dank gaat naar anita, bedankt voor 
al het werk dat je verzet hebt voor het IMRETREC project, zonder jouw kritische blik was 
het stuk niet zo geworden als het nu is!
The (old) members of the Cupedo Lab, natalie, rogier, ferry, Julien, Patricia, monica, 
Jurre and tom. I would like to thank you for the nice atmosphere in the lab, the moti-
vating conversations we had and your critical views and good ideas for my work in our 
work discussions. I wish you all many Nature publications and I hope we will meet again.
Twee kamers heb ik versleten, en daarmee ook vele kamergenoten. Davine, ik ben zeer 
onder de indruk van jouw motivatie voor het onderzoek en het prachtige project waar 
je je al zoveel jaar voor inzet. Ik wil je bedanken voor de vele gesprekken die we had-
den in EE1300, zowel over werk als over andere dingen en ik wens je alle goeds voor de 
toekomst. avinash, ik wens je veel succes bij de IKNL en wie weet zit er ooit nog een 
samenwerking in! Jurjen, het waren maar een aantal maanden, maar ik vond ze wel heel 
gezellig! Ik wens je ontzettend veel succes met de laatste loodjes van jouw proefschrift 
en wellicht kruisen onze paden nog in de kliniek! Kasia, how I loved your enthusiastic 
vibes in our room! Never a dull moment with you! Thank you for the nice time we had 
and I hope we will meet again! Good luck finishing your thesis! roberto, although you 
had so much lab work to do that you were not much around in EE1300, I always enjoyed 
your presence. I wish you all the best and good luck finishing your thesis! mark, af en aan 
kamergenoten de laatste jaren en dan vooral de laatste maanden, soms zelfs ’s avonds of 
in het weekend. Ik heb ontzettend met je gelachen en als er nieuws is over Sylvie, ben jij 
de eerste die het hoort! roel, van kamergenoten naar hele goede vrienden. We begon-
nen tegelijk aan dit avontuur en wat een avontuur was het. Eindeloze gesprekken over 
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geneeskunde, wetenschap en alle dingen die belangrijk zijn daarbuiten. Ik heb ontzet-
tend veel bewondering voor jouw werkethos, hoewel je daar soms wel wat in afgeremd 
mag worden. Je hebt het mooiste meisje van het lab geschaakt en wat een prachtig stel 
zijn jullie! Ook nog jullie heerlijke zoon erbij, wat een rijkdom. Ik ben ontzettend blij dat 
we elkaar nog zien (hoewel eigenlijk veel te weinig!) ook al zijn we allebei al een aantal 
jaar weg van de 13e. Succes met de laatste loodjes (oh, wat wegen ze zwaar!) en probeer 
niet alles ’s nachts te doen. En als je Roel zegt, zeg je merel. Ondanks dat we op het lab 
niet zoveel met elkaar te maken hadden, hadden we direct een klik. Liters koffie hebben 
we versleten, en de meeste eigenlijk nog nadat we allebei niet meer op de 13e rondlie-
pen. Het was altijd heerlijk om de onderzoeksfrustaties te kunnen delen met iemand die 
precies begrijpt wat je bedoelt! Je bent een hele goede vriendin geworden en daar ben ik 
ontzettend dankbaar voor, dat ik dat heb mogen overhouden aan mijn promotietraject. 
Ik wens jou met Roel en Max een prachtig leven! Gaan we trouwens nog een keer naar 
dat Cheesecake festival?
Alle overige promovendi van de Hematologie wil ik bedanken voor de gezelligheid en 
jullie input tijdens werkbesprekingen. Succes met het afronden van jullie proefschriften!
Verder wil ik prof.dr. Delwel, prof.dr. touw, prof.dr. Sonneveld, dr. raaijmakers en dr. 
Jongen-Lavrencic bedanken voor hun input en kritische blik tijdens de werkbesprekin-
gen op vrijdagochtend, die het onderzoek op onze afdeling altijd naar een hoger niveau 
brengt.
De dames van het secretariaat, ans, Leenke en annelies, wil ik bedanken voor hun 
ondersteuning! Zonder jullie zou de afdeling een stuk minder soepel functioneren! 
mariska, ontzettend bedankt voor jouw steun tijdens de laatste fase van mijn traject. Je 
hebt me heel veel werk uit handen genomen en er mede voor gezorgd dat alles op tijd 
af was. Dank je wel!
De basis van dit proefschrift ligt in de TI Pharma samenwerking met het Stem Cell Insti-
tute en de afdeling Radiologie. Derk and nesrin, thank you for all the work you put into 
the Wnt part of the project! I enjoyed our meetings and even though outcomes were 
not always as we hoped, I think we can be proud on what has been achieved! I wish 
you both all the best! monique, ramon, Gyula, Gaby, Sandra en Joost, bedankt voor 
de vruchtbare samenwerking met betrekking tot de 19F-labeling, het heeft een mooie 
publicatie en inspiratie voor de toekomst opgeleverd! Bernard, ik vond het ontzettend 
leuk om jou als student te begeleiden, het was een mooi project! Ik wens je veel succes 
als dokter!
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Het IMRETREC project was meer werk dan we gedacht hadden, nick, en ik wil je bedan-
ken voor alle tijd die je erin gestopt hebt! Wellicht tot ziens in de kliniek!
Het onderzoek uitgevoerd in dit proefschrift was absoluut onmogelijk geweest zonder 
alle moeders in de verschillende ziekenhuizen, die zo onbaatzuchtig hun navelstreng-
bloed hebben afgestaan. Mijn dank is ontzettend groot. Verder gaat mijn dank uit naar 
régine Steegers-theunissen, Hanneke de Graaf en Gretel van Hoecke voor hun hulp 
met het organiseren van de afnames in hun centra en aan alle medewerkers van de 
afdelingen Verloskunde van het albert Schweitzer Ziekenhuis en het Erasmus mC en 
van het Geboortecentum Sophia voor hun inzet ten aanzien van het verzamelen van 
navelstrengbloed. Tenslotte wil ik de Sanquin navelstrengbloedbank bedanken voor 
het ter beschikking stellen van navelstrengbloeddonaties, welke niet geschikt waren 
voor klinisch gebruik. Zonder de inzet van al deze mensen, had dit proefschrift niet kun-
nen bestaan.
Mijn fijne collega’s van de afdeling Chirurgie van het IJsselland Ziekenhuis wil ik bedanken 
voor de fantastische sfeer, veel te gezellige borrels en alle ruimte die jullie mij gegeven 
hebben om dit proefschrift onder werktijd te voltooien! Zonder jullie, had ik hier niet nu 
al kunnen staan.
Onderzoek doen is hard werken, en zeker de laatste jaren in combinatie met mijn 
klinische taken was het niet altijd een feestje. Gelukkig heb ik een heel palet aan fijne 
vrienden en vriendinnen die altijd klaar stonden om mijn verhalen aan te horen, maar 
ook mijn aandacht af te leiden met kopjes koffies, gezellige etentjes, weekendjes weg en 
al die andere dingen de het leven leuk maken. Dank jullie wel daarvoor!
Stephanie, lieve kip. Alweer 10 jaar zijn we vriendinnen, en samen zijn we geneeskun-
destudent, promovendus en coassistent geweest en nu zijn we ook nog samen dokter 
en doctor. Bij alle belangrijke momenten was je er en ik ben ontzettend dankbaar dat jij 
op deze dag naast me wilt staan. Het was heerlijk om alles te kunnen delen met iemand 
die in precies hetzelfde schuitje zat, maar om daarnaast ook met elkaar de dingen die er 
echt toe doen in het leven te delen. Ik wens je ontzettend veel succes met je opleiding tot 
KNO-arts, al weet ik nu al dat je dat ook weer op je sloffen gaat doen, en heel veel geluk 
samen met Lorenzo!
Sanne, we zaten al samen in de zandbak en sinds 6VWO zijn we echt onafscheidelijk. 
Jouw gedachten zijn mijn gedachten, dus natuurlijk moet jij als paranimf naast me staan. 
Lieve Sann, ik ben ontzettend dankbaar voor je vriendschap al die jaren, voor het feit 
dat je het altijd met me eens bent en dat we aan een half woord genoeg hebben. Ook 
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al woon je ondertussen helemaal in Gouda, dat heeft niks veranderd. Op naar nog heel 
veel sushi!
Jan, nettie en marlies, mijn favoriete schoonouders en schoonzus. Bedankt voor alle 
gezellige avonden en jullie steun tijdens al die jaren dat ik hier mee bezig was.
Lieve opa en oma, wat een rijkdom dat jullie dit nog meemaken! Dank jullie wel voor 
jullie onvoorwaardelijke trots en liefde! Op naar de 100!
Papa en mama, waar het allemaal begon. Jullie hebben me altijd gestimuleerd het beste 
uit mezelf te halen, met als basis jullie onvoorwaardelijke trots. Zonder jullie steun was 
ik nooit zover gekomen. Papa, hoe ouder, hoe gekker, maar je staat altijd klaar met wijze 
raad. mama, de stabiele factor, je begrijpt me altijd precies. Ik kan hier nog 1000 zinnen 
schrijven maar jullie weten het al. Dank jullie wel.
Edwin, het is af. Net toen je dacht dat het nooit meer ging gebeuren. Al die avonden en 
weekenden. Dank je wel voor je begrip en geduld, voor je grote liefde en voor je humor. 
Je bent het beste wat er is en ik kan niet wachten om samen oud, grijs en lelijk te worden.

